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ABSTRACT 
 
CHERYL N. MILLER: A Genetic and Biochemical Approach to Identify Function of 
Novel Proteins in Francisella tularensis 
(Under the direction of Tom Kawula) 
 
Francisella tularensis is a Gram-negative bacterial pathogen that can infect a 
broad range of hosts and is the etiologic agent of the human disease tularemia.  Members 
of the family Francisellaceae have few close relatives, and about 30% of the F. tularensis 
genome encodes hypothetical proteins, or proteins with unknown function. We used 
biochemical techniques and developed genetic tools to identify and characterize two 
proteins of unknown function in F. tularensis.  First we identified a conserved 
cytoplasmic membrane protein with unknown function, which we termed RipA. In F. 
tularensis, RipA is required for intracellular growth and virulence in the mouse model of 
tularemia. As a means to determine RipA function, we isolated and mapped independent 
extragenic suppressor mutants of a ∆ripA strain that restored growth in host cells.  Each 
suppressor mutation mapped to one of two essential genes, lpxA or glmU, which are 
involved in lipid A synthesis. We found that the ratio of C:18 to C:16 fatty acids in lipid 
A was greater in the presence of RipA. Furthermore, LpxA was more abundant in the 
presence of RipA. Induced expression of lpxA in the ΔripA strain stopped bacterial 
division. Together these data suggest RipA modulates the activity and abundance of 
LpxA in F. tularensis during adaptation to the host cell environment.  Furthermore, we 
characterized the function, and named a second conserved protein in F. tularensis, PanG, 
iv 
 
which was required for pantothenate (vitamin B5) synthesis. PanG is a novel ketopantoate 
reductase (KPR) that can convert 2-dehydropantoate to pantoate. Both the homologous 
gene from Enterococcus faecalis (EF1861) and the analogous gene, panE, from 
Escherichia coli functionally complemented the Francisella novicida KPR mutant. Using 
genetic and chemical complementation we confirmed the in silico predicted genes 
involved in pantothenate synthesis in Francisella novicida and tularensis and identified a 
novel KPR, PanG.  Together this work provided functional characterization of two F. 
tularensis proteins that were previously unknown.  However, there remain over 500 
genes in F. tularensis that are either annotated as hypothetical or unknown, which need to 
be characterized.  
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Chapter 1 	  
 
  Francisella tularensis Introduction:  
History, Epidemiology, Medical Relevance, Taxonomy, Microbiology and 
Pathogenesis 
 
 
 Francisella tularensis is an extremely small (0.2-0.7 µm), non-mobile, 
Gram-negative bacterial pathogen that infects a broad range of organisms, and grows 
efficiently in the cytoplasm of many different cell types (37, 81).  In humans, inhaling as 
few as 10 F. tularensis organisms can cause the lethal disease tularemia (73).  F. 
tularensis is found predominantly throughout the Northern Hemisphere, but recently 
tularemia infections have also been reported in areas as far south as Australia (42, 95).  
According to the CDC about 100 cases of tularemia are reported each year in the United 
States, which has declined significantly since its discovery in the early twentieth century 
(1).  
History 
 
F. tularensis was first identified by George McCoy in 1911 in Tulare County 
California during an outbreak in ground squirrels that was mistakenly thought to be 
plague (56). McCoy determined the outbreak was not due to Yersinia pestis the causative 
agent of plague, but was an unknown organism with plague like characteristics.  McCoy 
isolated and grew F. tularensis and developed both the agglutination test and the 
complement fixation test used to diagnose tularemia (44).  Shortly following the 
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identification of F. tularensis many human infections were identified.  The first 
diagnosed tularemia case was in 1913 when a butcher in Cincinnati developed an eye 
infection with severe conjunctivitis and yellow necrotic ulcers (76, 97).   
Dr. Edward Francis recorded over 14,000 cases of tularemia and determined the 
distribution of tularemia in the early part of the twentieth century (27).  Edward Francis 
was one of the many scientists to contract the disease during his research.  Laboratory 
acquired tularemia was common and frequently recurrent in the early twentieth century 
before containment facilities were built and safety protocols were developed. 
  The bacterium Francisella tularensis and the disease it causes, tularemia, were 
derived from the word Tulare based upon the location of the initial outbreaks in Tulare 
County, California.  Francisella was derived from Francis in recognition of Dr. Francis’ 
contributions to our understanding of tularemia epidemiology.  Other common names of 
the disease are listed in Table 1.  
While McCoy and Francis were researching tularemia, Dr. Hachiro Ohara, a 
scientist in Japan, was also studying the same disease in Tokyo.  He observed that human 
cases of the disease were associated with rabbit hunting and dressing (44).  Dr. Ohara 
used his wife, Mme Ohara, as a volunteer to demonstrate that the disease (tularemia) is 
transmittable by infected rabbits (44). 
F. tularensis is now considered a Category A Select Agent based on probability of 
use, distribution, availability, and risk assessment.  In particular, the CDC specified 6 
agents that have the highest risk: anthrax, plague, tularemia, botulinum toxin, smallpox, 
and viral hemorrhagic fever.  During WWII the US, Japan, and the former USSR 
developed weapons to aerosolize F. tularensis (61).  The US military stockpiled the 
 3 
 
weapon in the 1960s and destroyed the stockpile in 1973 (61).  The Soviet Union 
continued their weapon production of F. tularensis into the early 1990s.   
 
Epidemiology 
 
Francisella species can survive for weeks in Brackish-water (10), soil (11), moist 
straw (64), and animal carcasses (3).  The natural reservoir for F. tularensis is currently 
debated and under investigation, but is thought to be present in protozoa, and in arthropod 
vectors (38, 83).  The broad range of species F. tularensis can infect is numerous and 
diverse. In particular, F. tularensis commonly infects and kills many small mammals, 
such as rabbits, aquatic rodents, rats, muskrats, squirrels, lemmings, and mice within days 
of infection (58). Over 250 other species have been identified, including marsupials, 
birds, amphibians, and fish (58).  Transmission of tularemia to humans can occur by 
several routes including inhalation, entry through skin abrasions, insect bites, ingestion of 
contaminated food or water, and contact of infected material with mucus membranes 
(16). No human-to-human transmission has been reported. Vectors that are known to 
transmit the disease are ticks, mosquitoes, mites, fleas, and deer flies (25).     
Medical Relevance 
 
In an attempt to develop a vaccine for tularemia, Dr. Samuel Saslaw, conducted 
experiments on inmates of the Ohio State Penitentiary during the 1960s (73, 74). The 
prisoners were intranasally and intracutaneously infected with F. tularensis and were 
rigorously monitored during the course of the experiments; daily temperatures, 
symptoms, lesion size, blood cultures, complete blood counts, urinalysis, chest x-rays, 
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and agglutination experiments were performed and recorded.  These experiments on 
inmates, though an ethically contentious practice, have provided a substantial amount of 
data on human tularemia infections and prognosis.   
The incubation period for tularemia is about 1-14 days depending on route and 
dose (35).  Signs and symptoms generally start to develop between 3-5 days.  Symptoms 
consist of fever, headache, chills, rigors, sore throat, and can also include loss of energy, 
appetite and weight (73, 74).  
The disease manifestations depend on the route of infection, and there are seven 
clinical types of tularemia.  Ulceroglandular tularemia is the most common form of the 
disease (84) and is often caused by arthropod bites, or by contact with an infected animal.  
In this case an ulcer develops at the site of infection, and the draining lymph node 
becomes inflamed.  Glandular tularemia is similar to ulceroglandular, but the primary 
lesion is not evident while the regional or superficial lymph nodes are involved.  
Ingestion of contaminated food or water can lead to either oropharyngeal or typhoidal 
tularemia, where the ulcer is located in the throat, or gastrointestinal tract, respectively.  
Finally, pneumonic tularemia is caused by inhalation of aerosolized F. tularensis and is 
the most fatal form of the disease (24). F. tularensis can quickly become septic if left 
untreated and can spread to the lung, liver, and spleen (35). 
Before antibiotics were developed, a case of pneumonic tularemia had a 30 to 
60% mortality rate depending on the strain and dose (63, 77). With antibiotic therapy the 
potential of tularemia fatalities has dropped, however due to the rare prevalence of 
outbreaks, delayed diagnosis can lead to incorrect antibiotic treatments and potential 
death (39).  Antibiotics used to treat tularemia are Streptomycin and aminoglycoside 
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gentamicin, tetracycline and chloramphenicol quinolones (ciprofloxacin) doxycycline 
(70). 
In the United States, the most recent outbreak of tularemia occurred in Martha’s 
Vineyard in 2000 (11). Fifteen landscapers from Martha’s Vineyard contracted 
pneumonic tularemia, with one fatality.  The individuals infected were mowing and brush 
cutting, identifying new risk factors for contracting tularemia (24). Most cases occur in 
rural environments where hunting is common.  The number of reported cases of tularemia 
has declined recently and this is due to both the development of effective antibiotics and 
a decrease in hunting and trapping.   
Although there is no requirement to report tularemia cases in the United States, 
other countries are recording the number of sera positive individuals (65). In 2009, 2.3% 
of 2,416 people screened positive for antibodies against F tularensis in a Southern 
German urban population located in Leutkirch (78).  Although tularemia remains 
relatively rare, it is important to immediately diagnose and treat the disease with such a 
low infectious dose and a high mortality rate. 
Taxonomy 
 
To date, Francisella is the only genus belonging to the family Francisellaceae of 
the class gammaproteobacteria. Francisellaceae have few close relatives, and is only 
distantly related to two human pathogens, Coxiella burnetii, and Legionella pneumophila 
(83).  One of the closest relatives to Francisellaceae is a fish pathogen Piscirickettsia 
salmonis with 84% sequence identity.  Currently, the genus Francisella contains five 
groups F. novicida, F. noatunensis, F. philomiragia, F. piscicida and F. tularensis, which 
differ in virulence in humans and animals.  There has been considerable debate about the 
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classification of F. novicida (46), and throughout this dissertation it will be considered its 
own species distinct from F. tularensis. The human tularemia cases are caused 
predominantly by F. tularensis (61).  There are three subspecies of Francisella 
tularensis, each having distinct geographical distribution and disease severity (17). 
The most widespread subspecies, F. tularensis subsp. holarctica (type B), is 
found in Europe, Asia, North America, and Australia and is responsible for the mild cases 
of human tularemia.  F. tularensis subsp. tularensis (type A) has been found almost 
exclusively in North America, although cases have also been reported in Europe and is 
responsible for the majority of human fatalities.  F. tularensis subsp. mediasiatica has 
been identified in limited portions of Central Asia and has not been associated with 
human disease (95).  
 The whole genome of the most virulent strain Francisella tularensis subspecies 
tularensis was sequenced in 2005, and consists of a 1,892,819 bp circular chromosome 
with G+C content of 32.9% (52). Now with the available affordable sequencing 
technology there are 18 complete genomes sequenced within Francisellaceae, and 18 
whole genome sequencing reads available online (32).  Table 1.2 lists the available 
genome sequences on the Pathosystems Resource Integration Center (PATRIC) (32). In 
this dissertation, the focus of research is on F. tularensis, but the other species can be 
helpful tools for understanding the evolutionary differences between highly virulent and 
less virulent species.  Our laboratory conducts research using two subspecies of F. 
tularensis and one species of F. novicida.  F. tularensis subspecies tularensis Schu S4 is 
the most virulent subspecies we work with, which was isolated from a human infection in 
1941 from Ohio, USA and is a strictly regulated BSL-3 select agent (69). F. tularensis 
subspecies holarctica live vaccine strain (LVS) is an attenuated strain of holarctica that 
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was developed in Russia in the 1930s as a vaccine and is a BSL-2 agent (22).  The source 
of the attenuation of the LVS strain is in part due to the loss of pilA, encoding a putative 
type IV pilin, and FTT0918, encoding an outer membrane protein required for iron 
acquisition (71). F. novicida is a BSL-2 organism that is rarely associated with human 
infections and was isolated from water in Utah, USA in the 1950s (69). 
 
Microbiology 
 
The expansive host range and geographic distribution of F. tularensis is indicative 
of its evolutionary success.  There have been a number of animal models developed for 
studying Francisella pathogenesis, including non-human primates, mice, rabbits, guinea 
pigs, rats, zebrafish, amoebae, and Drosophila melanogaster (2, 8, 87, 88, 96, 98).   In 
addition to the diverse host range, Francisella tularensis can infect an array of host cell 
types: including macrophages, dendritic cells, polymorphonuclear neutrophils, 
hepatocytes, endothelial cells, type II alveolar lung epithelial cells, and even red blood 
cells (16, 21, 37, 41).  The success of Francisella as a pathogen is intimately associated 
with its ability to enter host cells and replicate in the cytosol (Figure 1.4).  A number of 
receptors have been identified to be important for Francisella uptake, and the receptor 
and uptake mechanism profoundly impacts the outcome of infection. Normally, 
phagocytic cells and the complement complex bind an invading pathogen and either 
engulf the pathogen or mark it for destruction.  F. tularensis can avoid complement lysis 
by cleaving C3 to prevent the formation of the membrane attack complex (9). The exact 
mechanism of this process is not fully understood, and the bacterial factors likely 
involved in this process are O-antigen and capsule, which are discussed in more detail 
below (47). The mannose receptor (MR) plays an important role in nonopsonic uptake of 
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F. tularensis into macrophage cells (31).  However, during opsonizing conditions F. 
tularensis has markedly enhanced uptake by looping phagocytosis through interaction 
with actin microfilaments and the complement receptor 3 (CR3) (20). The Fcγ receptors, 
surfactant protein A, class A scavenger receptors and nucleolin have all been identified as 
important for Francisella uptake (6, 31).  It is likely that more receptors have yet to be 
identified that are important for infection considering the vast array of cell types that can 
be infected with F. tularensis. 
Following uptake, Francisella tularensis resides in a phagosome that sequentially 
acquires markers of early and late endosomes.  F. tularensis can escape the phagosome 
before lysosome fusion, which is a hallmark of the Francisella intracellular life cycle 
(16). The key aspect of Francisella pathogenesis is the ability to survive and replicate 
efficiently in the cytoplasm of the host cell (93). To date only a few Francisella factors 
have been identified to be required for cytosolic replication including, the purine 
biosynthesis genes (62) and several genes of unknown function, FTT0369 (dipA) (19), 
FTT0989 (13), and FTT0181 (ripA) (28). F. tularensis has been shown to grow 
extracellularly in mice as well, demonstrating the versatility of this organism (26). 
F. tularensis Virulence Factors 
Considering the versatility of F. tularensis pathogenesis, there is much left to 
understand about the unique mechanisms employed by F. tularensis to cause disease. 
Interestingly, F. tularensis does not express virulence factors commonly associated with 
Gram-negative bacterial pathogens, including Type III, IV, and V secretion systems, 
flagella, or secreted toxins (52).  Furthermore, genetic tools have only recently been 
created to develop transposon mutant libraries to screen for genes required for 
intracellular survival and virulence (7, 14, 30, 49, 53, 55).  Several genome-wide screens 
 9 
 
have identified F. tularensis virulence factors including the capsule, Type IV pilus, 
several proteases, iron acquisition systems, and the most interesting Francisella 
Pathogenicity Island (FPI) (63, 66, 75, 79, 94).  Depending on the subspecies, the 
comprehensive collection of transposon mutant screens have revealed that 4% to 16% of 
the genome encodes proteins involved in Francisella virulence and 20% to 49% of these 
genes are either annotated as hypothetical or encode proteins with unknown function that 
remain uncharacterized (63). 
F. tularensis Pathogenicity Island 
The Francisella Pathogenicity Island (FPI) is a conserved 30kb genetic element 
that contains about 17 open reading frames that are required for F. tularensis 
pathogenesis and are highly expressed during infection, but the function of these genes 
are still under investigation (59, 93).  The FPI has a low G+C content (27.5%) compared 
to the rest of the genome, and it is flanked by a rRNA operon and an insertion element 
(ISFtu1), suggestive of being acquired by horizontal transfer. The FPI is duplicated in the 
most virulent strains: F. tularensis subsp. tularensis and F. tularensis subsp. holarctica, 
while F. novicida contains only one copy.  Although, F. tularensis subsp. mediasiatica 
has not been associated with any human infections it also contains two copies of the FPI. 
A lot of the initial studies conducted on the FPI were in F. novicida because of the 
difficulties generating double deletions in the more clinically relevant strains.  One 
putative operon within the FPI contains genes encoding the intracellular growth locus 
(iglABCD), and mutations within these genes attenuated growth of Francisella in 
macrophages, and mice (33, 34, 48). A number of the proteins encoded in the FPI share 
distant homology to type six secretion proteins in Vibrio cholerae, and Pseudomonas 
aeruginosa. The most highly induced gene during F. tularensis internalization is iglC, 
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and it is essential for growth in macrophages and virulence in mice; however the specific 
function encoded by iglC is unknown (33).   
Genome Decay 
Acquiring virulence factors by horizontal transfer is one mechanism emerging 
pathogenic bacteria use to exploit novel intracellular niches. As mentioned above, an 
example of this was demonstrated with the pathogenicity island in Francisella tularensis. 
Gene loss can be just as critical to microbial survival as gene acquisition (12). More than 
10% of the CDSs in the Schu S4 genome are pseudogenes or gene fragments (52).  The 
F. tularensis genome is in an advanced state of decay and is likely a result from adapting 
to a more specific niche inside host cells.  The loss of pepO is one of many examples of 
gene loss in Francisella tularensis that has enhanced pathogenesis.  The inactivation of 
pepO in F. tularensis prevents host vasoconstriction and permits the spread of the 
bacteria to systemic sites (36). In addition, numerous restriction / modification systems 
have been lost in the evolution of the human pathogenic subspecies, which may allow for 
increase horizontal gene transfer (29).   
One mechanism that has contributed to accelerated loss of genes in Francisella 
species is the activity of insertion sequence elements (IS elements), which encode 
transposable elements that move within a genome (81). Five IS elements have been 
identified in the genome of Francisella species and the number of each IS element varies 
greatly between species (TABLE 1.3) (52, 69).  
The most common IS elements in F. tularensis are ISFtu1 that belongs to the 
IS630 Tc-1 mariner family and ISFtu2, an IS5 family element.  When performing 
genomic comparisons between different subspecies of F. tularensis, IS elements appear 
to play a prominent role in rearrangement events in F. tularensis because 82% of 
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breakpoints found between F. tularensis subsp. tularensis and subsp. holarctica are 
bordered by IS elements (69).  The ubiquitous polyamines spermine and spermidine are 
environmental signals that activate transcription of IS elements in addition to nearby 
genes, which is a novel gene regulation mechanism that has been shown to be important 
during infection to prevent proinflammatory cytokine production (15). 
Cell Envelope: Lipid A, LPS, and Capsule 
The defining characteristic of Gram-negative bacteria is their cell envelope, which 
is composed of two membranes—the inner and outer membranes separated by the 
periplasm that contains a thin peptidoglycan layer.  Both the inner and outer membranes 
are lipid bilayers but have dramatic differences in their structure and composition. The 
lipid composition in F. tularensis is high relative to other Gram-negative bacteria 
consisting of 21% lipid relative to total dry weight (4). F. tularensis phospholipids 
consist mainly of long chain phophadidylethanolamine, phosphatidylglycerol, 
phosphatidylcholine, and free lipid A (92), while cardiolipin and phosphatidylserine are 
not present (4).  
The outer membrane separates the bacterium from the external environment and 
is a selective barrier that is critical for bacterial survival inside host cells.  F. tularensis is 
unique in all aspects of its cell envelope.  Modifications to the F. tularensis membrane 
components, such as lipid A, the O-antigen, and the capsule are essential for the 
successful establishment of infection.   
LPS is the major glycolipid molecule present on the outer membrane of most 
Gram-negative bacteria that is in direct contact with the external environment.  LPS is 
made up of three domains, the first domain is lipid A (endotoxin) the hydrophobic 
domain that anchors LPS to the outer membrane.  The second domain is a non-repeating 
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core oligosaccharide (KDO), and the third domain is a distal polysaccharide (O-antigen) 
that varies greatly even between subspecies of F. tularensis (86). Lipid A is referred to as 
endotoxin in most Gram-negative bacteria because it typically induces a massive 
cytokine response when recognized by host cell TLR4/MD2 receptors (67).  However F. 
tularensis Lipid A does not induce a cytokine response and is not recognized by 
TLR4/MD2, because lipid A is modified to avoid host detection.  The 4’ phosphate and 
the 3’ hydroxyacyl are removed to make a tetra-acylated disaccharide of glucosamine 
with a 1’ phosphate (90, 91).  NaxD is a deacetylase that removes the 1’ galactosamine 
on lipid A in F. tularensis and is critical for growth inside cells (54).  Another unique 
property of F. tularensis lipid A is the majority of lipid A is free of the O-antigen sugars 
(60, 80, 92). What role free lipid A plays in the pathogenesis of F. tularensis is not fully 
understood, but could change the host receptors used for adherence and uptake, dictating 
the fate of the infection (43). In addition to immune evasion, LPS also plays an important 
positive role in the assembly of many outer membrane proteins and free lipid A may 
influence the composition of proteins on the surface of the bacteria (51).  
The O-antigen sugars help bacteria resist antibiotics, the complement pathway, 
and other environmental stresses (68).  The wbt gene cluster of F. tularensis is involved 
in O-antigen biosynthesis and contains 15 ORFs (82).  In contrast, the gene cluster in F. 
novicida contained only 12 ORFs. The LPS O-antigens of F. novicida and F. tularensis 
have been shown to be structurally and immunologically distinct due in part to the 
differences in the wbt genes.  The core two carbohydrate residues are the same in both 
species consisting of two α-D-GalNacAN sugars, but the anchor and distal residues differ 
and are composed of α-D-GalNAcAN and β-DQui2NAc4NAc in F. novicida and β-D-
Qui4NFn and β-D-QuiNAc in F. tularensis (85, 86, 89).  F. novicida LPS has greater 
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immunobiological activity in mice when compared to F. tularensis, which can be 
explained by the difference in the O-antigen sugars composition (50). 
In addition to the LPS sugars, the capsule is another barrier that protects many 
pathogenic bacteria from host detection and destruction.  A F. tularensis capsule was 
identified to be an important virulence factor (40).  Mutants lacking the capsule structure 
have increased sensitivity to serum and are attenuated in mouse models of tularemia (40, 
72).  The composition and expression of the capsule can change depending on the growth 
conditions (18).  The F. tularensis capBCD locus has partial homology to the locus in B. 
anthracis that encode proteins needed to synthesize poly-D-glutamic acid capsules, 
however no poly-D-glutamic acid capsule has been identified in F. tularensis (57).  The 
F. tularensis capBCD locus is required for intracellular growth and in a mouse model of 
tularemia (45).  Recent composition analysis and mass spectrometry determined that the 
capsule is at least in part composed of O-antigen sugars similar the composition of LPS 
(5).  Although the O-antigen sugars have been characterized as part of the composition of 
the capsule, it will be interesting to identify what molecule the cap locus synthesizes in F. 
tularensis that are required for virulence.  
I have highlighted only a few of the key pathogenic mechanisms used by F. 
tularensis to cause disease, and recently a substantial amount of progress has been made 
on identifying factors important for F. tularensis virulence (63). What is now critical for 
future progress is defining function to the proteins used by Francisella tularensis to 
survival and replication within host cells, which will be the key for developing effective 
drug targets to prevent tularemia. 
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Function	  of	  Two	  Novel	  Proteins	  in	  Francisella	  tularensis	  
 
With the continued advancement and availability of whole genome sequencing, 
the list of hypothetical proteins keeps growing. It is important to characterize the function 
of hypothetical proteins so we can identify better drug targets and develop new strategies 
to fight disease at the same time we can develop new tools to advance future research in 
microbiology. 
Francisellaceae is only distantly related to all other known gammaproteobacteria 
(Figure 1).  About thirty percent of the F. tularensis genome encodes hypothetical 
proteins or proteins with unknown function, and many of the unique virulence 
mechanisms used by F. tularensis to cause disease remain unknown (61).  We therefore 
have focused on identifying and characterizing proteins with unknown function in order 
to better understand F. tularensis pathogenesis. We characterized the function of two 
proteins that were initially annotated as hypothetical.  We recently elucidated the function 
of a hypothetical protein, FTL_1914, which we named RipA (28).  Through the use of 
extragenic suppressor mutations we discovered that RipA modulates LpxA stability and 
activity in F. tularensis (Chapter 4). We also identified the function of a second protein, 
FTL_1351, which we named PanG (Chapter 5). PanG is novel ketopantoate reductase 
required for vitamin B5 synthesis in F. tularensis and homologs of panG are found in 
other bacterial pathogens: Clostridium difficile, Coxiella burnetii, and Enterococcus 
faecalis (Chapter 5). Both RipA and PanG are conserved in all sequenced species of F. 
tularensis and are highly expressed during intracellular growth (93). We also developed 
the first anhydrotetracycline inducible and repressible system for F. tularensis to control 
gene expression, and using this tool we determined the induced expression of lpxA was 
detrimental for growth of F. tularensis lacking the ripA locus, while the wild type strain 
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containing ripA was unaffected by the production of lpxA. We therefore have focused on 
identifying and characterizing proteins with unknown function in F. tularensis.  We 
identified a novel modulator of lipid A synthesis, and a new ketopantoate reductase 
involved in vitamin B5 synthesis. 
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Figures 
 
 
Figure 1.1. Scanning Electron Microscopy of F. tularensis subspecies tularensis  
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Figure 1.2. Phylogeny of Francisellaceae 
Phylogenetic tree of Francisellaceae by analysis of ribosomal RNA SNP variations.  The 
evolutionary history of Francisellaceae was inferred from analysis of SNP sequences 
located within the ribosomal RNA gene locus.  The tree is drawn to scale with branch 
lengths calculated using the standard methods in Geneious Pro 5.5.6 (23).   
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Figure 1.3. Geographical distribution of Francisellaceae 
Geographical distribution of F. novicida, F. noatunensis, F. piscicida, F. philomiragia, 
and the three F. tularensis subspecies. The regions where the strains of Francisella and 
subspecies of F. tularensis have been isolated are shown in red. 
 
 
 
 
 
 19 
 
 
 
Figure 1.4. Fluorescence microscopy image from infected cell 
Mouse embryonic fibroblast 24 hours post infection with wild type F. tularensis. GFP F. 
tularensis bacteria are depicted in green, DAPI in blue, and wheat germ agglutinin in red. 
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Tables 
 
Table 1.1. Francisella tularensis common and historical names 
Name Location or Dates 
Deer-fly fever Utah 
Rabbit fever  Central States 
Glandular tick fever Idaho and Montana 
Lemming fever Norway 
Market men’s disease Washington D.C. 
Hunter’s disease Central States 
Ohara’s disease Japan 
Bacterium tularense 1950s and earlier 
Pasteurella tularense 1966 and earlier 
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Table 1.2. Whole genome sequencing of Francisellaceae 
Genome Name NCBI Taxon Id 
Genome 
Status 
Completion 
Date 
Francisella cf. novicida 3523 676032 Complete 2011-04-08 
Francisella cf. novicida Fx1 984129 Complete 2011-04-08 
Francisella noatunensis subsp. orientalis str. Toba 04 1163389 Complete 2012-05-10 
Francisella novicida FTE 545422 WGS 2008-07-18 
Francisella novicida FTG 563990 WGS 2008-10-06 
Francisella novicida GA99-3548 442346 WGS 2007-05-31 
Francisella novicida GA99-3549 430558 WGS 2007-05-14 
Francisella novicida U112 401614 Complete 2006-11-28 
Francisella philomiragia subsp. philomiragia ATCC 25015 539329 WGS 2008-12-22 
Francisella philomiragia subsp. philomiragia ATCC 25017 484022 Complete 2008-02-11 
Francisella sp. TX077308 573569 Complete 2011-06-20 
Francisella tularensis subsp. holarctica 119857 Complete 2006-03-02 
Francisella tularensis subsp. holarctica 257 412422 WGS 2006-12-18 
Francisella tularensis subsp. holarctica F92 1232394 Complete 2012-11-19 
Francisella tularensis subsp. holarctica FSC022 430556 WGS 2007-05-14 
Francisella tularensis subsp. holarctica FSC200 351581 WGS 2006-11-21 
Francisella tularensis subsp. holarctica FTNF002-00 458234 Complete 2007-08-23 
Francisella tularensis subsp. holarctica OSU18 393011 Complete 2006-09-20 
Francisella tularensis subsp. holarctica OSU18 (Prj:32025) 393011 Complete  
Francisella tularensis subsp. holarctica URFT1 445226 WGS 2009-09-03 
Francisella tularensis subsp. mediasiatica FSC147 441952 Complete 2008-05-07 
Francisella tularensis subsp. tularensis 3571 1292388 WGS 2013-03-14 
Francisella tularensis subsp. tularensis 70001275 1208319 WGS 2012-11-15 
Francisella tularensis subsp. tularensis 70102010 1210518 WGS 2012-10-16 
Francisella tularensis subsp. tularensis 80700075 1210520 WGS 2012-10-16 
Francisella tularensis subsp. tularensis 80700103 1210519 WGS 2012-10-16 
Francisella tularensis subsp. tularensis 831 1210521 WGS 2012-10-16 
Francisella tularensis subsp. tularensis AS_713 1210522 WGS 2012-10-16 
Francisella tularensis subsp. tularensis FSC033 430557 WGS 2007-05-14 
Francisella tularensis subsp. tularensis FSC198 393115 Complete 2006-07-12 
Francisella tularensis subsp. tularensis MA00-2987 543737 WGS 2008-08-26 
Francisella tularensis subsp. tularensis NE061598 510831 Complete 2009-12-28 
Francisella tularensis subsp. tularensis SCHU S4 177416 Complete 2004-12-17 
Francisella tularensis subsp. tularensis TI0902 1001534 Complete 2012-02-23 
Francisella tularensis subsp. tularensis TIGB03 1001542 Complete 2012-02-23 
Francisella tularensis subsp. tularensis WY96-3418 418136 Complete 2007-03-24 
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Table 1.3. Genome comparison of laboratory strains 
Property Strain (subspecies) 
 U112 (novicida) LVS (holarctica) Schu S4 (tularensis) 
Genome size (bp) 1,910,031 1,895,998 1,892,819 
Pseudogenes 14 303 254 
ISFtu1 1 59 53 
ISFtu2 18 43 18 
Other IS elements 7 7 8 
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Chapter 2 	  
 
Effects of the putative transcriptional regulator IclR on Francisella tularensis 
pathogenesis12 
 
 
Overview 
 
 Francisella tularensis is a highly virulent Gram-negative bacterium and is the 
etiological agent of the disease tularemia. IclR, a presumed transcriptional regulator, is 
required for full virulence of the animal pathogen, F. novicida U112 (46). In this study, 
we investigated the contribution of IclR to the intracellular growth, virulence and gene 
regulation of human pathogenic F. tularensis subspecies. Deletion of iclR from the Live 
Vaccine and SchuS4 strains of F. tularensis subspecies holarctica and tularensis, 
respectively, did not affect their ability to replicate within macrophages or epithelial cells. 
In contrast to F. novicida iclR mutants, LVS and SchuS4 ∆iclR strains were equally 
virulent as their wild type parental strains in intranasal inoculation mouse models of 
                                                
1 Adapted for this dissertation from Mortensen BL, Fuller JR, Taft-Benz S, Kijek TM, 
Miller CN, Huang MT, and Kawula TH. Effects of the putative transcriptional 
regulator IclR on Francisella tularensis pathogenesis. 2010. Infection and 
Immunity. 78:5022-5032. 
 
2 Attributions: Brittany Mortensen performed all the experiments in this chapter with the 
following exceptions. Cheryl Miller and Sharon Taft-Benz performed the mouse 
infections, organ collections, and organ burdens for Figure 3.  Cheryl Miller, Sharon 
Taft-Benz, and Todd Kijek assisted with the mouse infections, organ collections, and 
organ burdens for Figures 2 and 5.  
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tularemia. Furthermore, wild type LVS and LVS∆iclR were equally cytotoxic and 
induced equivalent levels of IL-1β expression by infected bone marrow-derived 
macrophages. Microarray analysis revealed that the relative expression of a limited 
number of genes differed significantly between LVS wild type and iclR strains. 
Interestingly, many of the identified genes were disrupted in LVS and SchuS4 but not in 
their corresponding F. novicida U112 homologs. Thus, in spite of the impact of iclR 
deletion on gene expression, and in contrast to the effects of iclR deletion on F. novicida 
virulence, IclR does not contribute significantly to the virulence or pathogenesis of F. 
tularensis. 
Introduction 
 
 Francisella tularensis is a Gram-negative bacterium and the etiological agent of 
tularemia or “rabbit fever”. While zoonotic hosts include small mammals such as rabbits 
and voles, F. tularensis is also found in ticks, mosquitoes, and flies, and can replicate 
within amoebae as well (24). Human infection with F. tularensis can occur by several 
routes including bites by arthropod vectors (1, 2, 28), contact with contaminated tissues, 
ingestion of contaminated food or water (23, 37), or inhalation of aerosolized bacteria 
(15, 41). F. tularensis is considered a Select Agent by the Centers for Disease Control 
due to its low infectious dose (as few as 10 organisms) via the pulmonary route and its 
potential as a biological threat agent (12, 39). 
 There are two F. tularensis subspecies most commonly associated with disease in 
humans: F. tularensis subspecies tularensis (Type A) and F. tularensis subsp. holarctica 
(Type B). The Live Vaccine Strain (LVS) of subsp. holarctica is a useful model for 
studying the virulent F. tularensis subspecies, because it causes disease in mice, is 
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attenuated in humans (16), and shares genomic and proteomic similarity with F. 
tularensis subsp. holarctica and tularensis (44).  F. novicida, which does not cause 
disease in healthy humans, has significant similarity with F. tularensis subsp. holarctica 
and tularensis and is also used as model organism for studying F. tularensis 
pathogenesis. Although there are reports of F. novicida causing disease, these cases are 
commonly associated with immunocompromised individuals (3, 8) However, F. novicida 
does cause a severe disease in in vivo mouse models (34). 
 Francisella is known to predominately infect and replicate within macrophages 
but also infects and replicates within neutrophils (31), dendritic cells (4) and Type II 
alveolar epithelial cells (19). After phagocytosis, F. tularensis escapes the phagosome 
and replicates within the cytoplasm of host cells (9).  Numerous in vitro and in vivo 
screens have identified virulence factors required for this intracellular life cycle (11, 22, 
25, 29, 35, 40, 42, 46); however, many of the identified virulence factors have little or no 
similarity to known proteins of other bacteria and their functions remain, for the most 
part, unknown. 
 Weiss et al. recently identified a locus (FTN_0720) in F. novicida U112 that is 
important for virulence in mice as determined by an in vivo competition assay between a 
FTN_0720 deletion mutant and wild type U112 (46). FTN_0720 encodes a protein with 
homology to the IclR family of transcriptional regulators. IclR family members activate 
and repress genes in a wide range of bacteria including genes involved in sporulation, 
metabolism, drug-efflux pumps and organic solvent tolerance, and phytopathogenicity 
(33). Given the close genetic relationship among F. tularensis and F. novicida, the 
phenotype of the F. novicida iclR deletion strain suggests that IclR may be involved in 
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the pathogenicity of the F. tularensis subspecies holarctica and tularensis. We 
investigated the contribution of IclR homologs in the pathogenicity of F. tularensis 
subsp. holarctica and tularensis by evaluating the role of IclR in gene expression, host 
cell interactions and virulence of F. tularensis subsp. holarctica LVS (FTL_1364) and 
subsp. tularensis SchuS4 (FTT_0748) strains. 
 
Materials And Methods 
Bacterial strains  
 
F. tularensis subsp. holarctica LVS was obtained from the CDC, Atlanta, GA. F. 
tularensis subsp. tularensis SchuS4 was obtained from BEI Resources. F. novicida U112 
was obtained from the American Type Culture 88 Collection (ATCC). An iclR 
transposon mutant was one of two mutants from the transposon mutant library (21) and 
was received as a gift from Colin Manoil. All strains were maintained on chocolate agar 
supplemented with 1% IsoVitaleX (Becton-Dickson), brain heart infusion (BHI) broth 
supplemented with 1% IsoVitaleX or Chamberlain’s defined medium (CDM) (5). 
Escherichia coli TOP10 (Invitrogen) were used for cloning purposes. E. coli was 
propagated in Luria broth supplemented with hygromycin at 200 µg/ml or kanamycin at 
20 µg/ml as necessary for antibiotic selection. All cultures were grown at 37°C. 
Cell Culture  
 
J774A.1 (ATCC TIB-67) cells are a macrophage-like cell line derived from 
mouse sarcoma reticulum cells and were cultured in Dulbecco’s minimal essential 
medium with 4.5 g/L glucose, 10% fetal bovine serum, and 2 mM L-glutamine. TC-1 
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(ATCC CRL-2785) cells are a tumor cell line derived from mouse primary lung epithelial 
cells and were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES and 0.1 mM nonessential 
amino acids. Bone marrow-derived macrophages were generated by flushing bone 
marrow cells from C57BL/6 mouse femurs and recovered cells were incubated for 6 days 
on 15 cm2 non-tissue culture-treated dishes in L929 cell-conditioned DMEM. 
Nonadherent cells were removed by washing with phosphate-buffered saline (PBS) and 
bone marrow-derived macrophages were recovered from the dish using 1 mM EDTA in 
PBS. 
Molecular techniques and allelic exchange  
 
For both LVS and SchuS4 the iclR deletion was generated by splice overlap 
extension (SOE) PCR using primers designed to amplify the 5’ and 3’ regions of the iclR 
locus, which were then annealed to their complementary, homologous genomic DNA 
tags (17, 20). The subsequent deletion left only the first six amino acids and the stop 
codon of iclR. Each construct was cloned into the pCR-Blunt II TOPO vector 
(Invitrogen), verified by DNA sequence analysis, and subsequently cloned into pMP590 
(sacB Kanr) using BamHI and NotI restriction sites (17, 27). For allelic exchange, 
plasmids were electroporated into LVS or SchuS4 and integrants were selected on 
chocolate agar containing kanamycin (10 µg/ml). Kanr strains were grown overnight and 
plated on 10% sucrose for counterselection (loss of plasmid) (17, 27).  Both the LVS and 
SchuS4 iclR deletion strains were confirmed for loss of iclR by PCR. For 
complementation of the iclR deletion in LVS, iclR and its predicted promoter were PCR-
amplified and subcloned into the pCR-Blunt II TOPO vector (Invitrogen). After a 
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MluI/EcoRV restriction digest, the construct was ligated into the pMP633 low-copy 
Francisella shuttle vector (17) and electroporated into LVSΔiclR. Complementation was 
determined by detection of iclR in the complementation strain via PCR as well as 
demonstration of increased iclR transcript levels via microarray analysis (data not 
shown). 
Gentamicin protection assays  
 
Gentamicin protection assays were performed as described (17, 19). Briefly, 
J774A.1 murine macrophages, TC-1 murine lung epithelial cells, or bone marrow-derived 
macrophages were infected with LVS or SchuS4 at an MOI of 100. Cells were incubated 
with the bacterial inoculum for 2 hr (J774A.1 and bone marrow-derived macrophages) or 
4 hr (TC-1) and then incubated with media containing 25 µg/ml gentamicin for an 
additional 2 hr to kill extracellular bacteria. At time points of 4 hr (or 6 hr for TC-1) and 
24 hr, medium was removed, cells were washed with PBS and then scraped from the 
dish, and the bacteria serially diluted and plated to determine the number of viable 
bacteria. 
Mouse infections 
 
6- to 8-week-old C57BL/6 mice were anesthetized intraperitoneally (i.p) with 
avertin and then inoculated intranasally (i.n.) with bacteria suspended in 50 µl PBS by 
application to the nares of each mouse or inoculated intradermally (i.d.) by injection into 
the tail using the same volume. Concentrations of LVS and U112 were determined by 
klett and concentrations of SchuS4 by spectrophotometer (OD600), and inocula were 
serially diluted and plated on chocolate agar to confirm the CFU administered. At the 
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designated time points, mice were euthanized and the lungs, liver and spleen of each 
mouse were removed and homogenized. Serial dilutions of the homogenates were plated 
on chocolate agar to enumerate the bacterial organ burdens. Statistical significance 
between strains in each organ and at each time point was determined by the Mann-
Whitney nonparametric test using GraphPad Prism v.5 software. All animal experiments 
were performed according to the animal care and use guidelines as established by 
IACUC-approved protocols. 
IL-1β ELISAs and cytotoxicity assays  
 
Bone marrow-derived macrophages were seeded in 12-well dishes at 1x106  cells 
per well, and infected with bacteria at an MOI of 500 in a final volume of 1 ml medium 
per well and incubated at 37°C. After 24 hr, the supernatants from each well were 
collected, centrifuged to pellet cellular debris, and stored at -20°C. The IL-1β ELISA was 
performed using the BD OptEIA mouse IL-1β ELISA kit (BD Biosciences) according to 
the manufacturer’s protocol. The OD450 was read using a TECAN Infinite M200 and 
analyzed using Magellan v6 software. Cytotoxicity assays were performed using the 
ToxiLight® BioAssay kit (Lonza) following the manufacturer’s protocol for cytokine 
detection from supernatants, and the luminescence was read using a TECAN Infinite 
M200 and analyzed using Magellan v6 software. Statistical significance between each 
strain was determined by the student’s t-test using GraphPad Prism v.5 software. 
Microarrays  
 
RNA was obtained using the RiboPure-Bacteria kit (Ambion) according to the 
manufacturer’s protocol. Briefly, bacteria were grown to early mid-log phase in CDM 
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and pelleted. Cells were disrupted by suspension in Trizol and vortexing with 0.1 mm 
glass beads. Purified RNA was recovered by chloroform extraction followed by treatment 
with DNase I to remove DNA. Microarray analysis was performed following the 
guidelines provided by the Venter Institute for Genomic Research (SOP#M007, M008). 
Briefly, aminoallyl labeled cDNA was generated from 2 µg total RNA using SuperScript 
III reverse transcriptase (Invitrogen), random hexamers, and dNTPs containing aa-UTP. 
After removal of unincorporated aa-dUTP and free amines, labeled cDNA was coupled to 
Cy3 or Cy5 mono-reactive dye (GE Healthcare). The Francisella microarray slides 
(Pathogen Functional Genomics Resource Center; PFGRC) contained 2331 70mer 
oligonucleotides in quadruplicates of the F. tularensis SchuS4 genome and several LVS 
genes as well as quadruplicates of 70mer oligonucleotides for 500 Arabidopsis thaliana 
as controls. Slides were prehybridized in 5x SSC, 10% SDS and 1% BSA, washed and 
then hybridized with cDNA probes at 42°C. After post-hybridization washes, the slides 
were scanned using the GenePix 4000B scanner and GenePix Pro v6.0 software. The 
microarray data were normalized using the TIGR MIDAS v2.22 and analyzed using the 
TIGR Multiexperiment Viewer v 4.2.1 (MeV) as part of the TM4 Suite software (45). In 
MeV, pooled, normalized Cy5/Cy3 intensities from wild type LVS control arrays were 
compared to pooled, normalized Cy5/Cy3 intensities from LVS∆iclR arrays. This list was 
filtered by statistical significance using Significance Analysis for Microarrays (SAM) 
provided on MeV after 179 an 80% cut-off filter and using a false discovery rate of 5%. 
Quantitative RT-PCR 
 
Quantitative RT-PCR was performed in a 96-well format using the SensiMix™ 
SYBR & Fluorescein One-Step kit (Bioline) following the manufacturer’s protocol. 
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Briefly, 50 ng of RNA isolated from wild type or iclR mutant strains was mixed with 
SensiMix™ SYBR & Fluorescein, RNase inhibitors, and designated primers in a 20 µl 
volume. A genomic DNA ladder and a no reverse transcriptase control were analyzed 
using the SensiMix™ SYBR & Fluorescein kit following the manufacturer’s protocol 
with primers to gyrA. Thermocycling and detection was performed using the iCycler 
Thermal Cycler (Bio-Rad). All starting quantity (SQ) values were normalized to the 
mean SQ value for gyrA. 
Antibiotic sensitivity assays  
 
F. tularensis LVS was grown to mid-log phase in BHI broth supplemented with 
1% IsoVitaleX, the bacterial suspension was spread onto chocolate agar plates, and 
antibiotic-containing filter paper discs were placed in the center of each plate. The 
rafampin (5µg), tetracycline (30µg), and colistin (10µg) were purchased pre-loaded from 
Becton Dickinson. The ampicillin and polymyxin B discs were self-prepared by adding a 
10 µl or 20 µl volume of antibiotic per disc at 10 µg ampicillin or 20 µg polymyxin B. 
Bacteria were grown for 36 hr and the diameter of the zone of inhibition was measured. 
Microarray data accession numbers  
 
The raw and normalized microarray 199 data is available on the GEO database 
under the following accession numbers: GSM574374, GSM574375, GSM574376, 
GSM574377, GSM574379, GSM574380, and GSE23454. 
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Results 
Comparison of iclR alleles among F. tularensis subspecies and construction of iclR 
deletion mutants 
 
The locus FTL_1364 is annotated as a hypothetical protein in NCBI; however, 
some of its homologs in other Francisella species are annotated as proteins belonging to 
the IclR family of transcriptional regulators. A search for conserved domains found 
within FTL_1364 resulted in several related hits including a helix-turn-helix (HTH) 
domain conserved among IclR family members. Additionally, Francisella IclR has a C-
terminal domain with high similarity to the IclR family profile Pfam01614. A recent 
publication describes a highly specific IclR family member profile that lies outside the 
HTH domain and covers less than 100 amino acids in the central region towards the C-
terminal end (26). These authors classify current Pfam01614 members as belonging to 
the IclR family based on the new profile. Furthermore, BLASTp analysis of F. tularensis 
LVS or SchuS4 IclR reveals high similarity to IclR family proteins found across many 
bacterial species. F. tularensis IclR proteins share considerable amino acid identity (30-
40%) and amino acid similarity (60%) with non-Francisella IclR family proteins. 
Overall, the bioinformatic analysis strongly suggests that Francisella FTL_1364 and its 
homologous loci in other Francisella species encode a protein belonging 220 to the IclR 
family of transcriptional regulators. 
 Using NCBI and the Francisella genome browser (www.francisella.org) for 
annotations and synteny analysis, we found that the iclR locus has shared characteristics 
among F. novicida U112, F. tularensis subsp. holarctica LVS, and F. tularensis subsp. 
tularensis SchuS4 strains (FTN_0720, FTL_1364 and FTT_0748, respectively), (Figure 
1A). On one side of iclR in each strain is a gene encoding a predicted protein with 
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similarity to an esterase lipase (FTL_1363, FTN_0721, and FTT_0749). On the other side 
of iclR is a gene encoding a predicted protein with similarity to the multidrug efflux 
protein EmrA (FTL_1365-66, FTN_0718, and FTT_0747). One difference is that EmrA 
is divided into two ORFs in LVS. There are other differences in the length and coding 
sequences of this genetic region, including an additional open reading frame in U112 that 
encodes a predicted protein of unknown function FTN_0719. Nevertheless, in each strain, 
iclR is located in a similar region of the genome. 
 Additionally, iclR itself is highly conserved among the three F. tularensis strains 
U112, LVS and SchuS4. SchuS4 iclR has three nucleotide differences compared to iclR 
from LVS that translate into two amino acid differences, S22G and H78Y, between LVS 
and SchuS4 IclR. U112 iclR has 95 nucleotide differences compared to LVS iclR and 94 
nucleotide changes compared to SchuS4 iclR. Although this results in a three nucleotide 
truncation of U112 iclR, there is 80% amino acid identity between U112 IclR and SchuS4 
and LVS IclR proteins (Figure 1B). While these similarities suggest that IclR is 
conserved among the U112, LVS, and SchuS4, there are a sufficient number of 
differences to account for possible functional deviations between these strains as well. 
Due to genetic similarity and the contribution of IclR to the virulence for F. tularensis 
subsp. novicida, we investigated the potential contribution of IclR to the virulence of F. 
tularensis subspecies holarctica and tularensis. To do this, we made a clean deletion of 
the iclR gene in the F. tularensis subspecies holarctica LVS (LVSΔiclR) and SchuS4 
(SchuS4ΔiclR) using SOE PCR and allelic exchange in LVS (FTL_1364). We also 
generated an iclR complementation strain by expression of iclR on a low-copy shuttle 
vector. 
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LVS and SchuS4 iclR deletion mutants are competent for intracellular replication 
 
 One method to assess the contribution of IclR to F. tularensis virulence is to 
determine what role IclR plays in intracellular replication. We used gentamicin protection 
assays in the J774A.1 murine macrophage-like cell line and the TC-1 murine lung 
epithelial cell-like cell line to assess intracellular replication by iclR deletion mutant 
strains. Both LVSΔiclR and wild type LVS replicated approximately two logs by 24 hr in 
both J774A.1 and TC-1 cells (Figure 2A-B). We also performed these assays in bone 
marrow-derived macrophages, and both wild type LVS and LVSΔiclR replicated 
intracellularly in these cells (Figure 2C). Similarly, the intracellular replication of 
SchuS4ΔiclR was similar to wild type SchuS4 in J774A.1 cells (Figure 2D). These results 
demonstrate that IclR is not required for intracellular replication of LVS or SchuS4 in 
these cell types. 
LVSΔiclR is not attenuated following intranasal or intradermal inoculation of mice 
 
 Properties other than intracellular replication contribute to F. tularensis 
pathogenesis. We therefore determined whether IclR was required for LVS virulence in 
vivo. To test this, we used a mouse model of pulmonary tularemia in which we inoculated 
C57BL/6 mice i.n. with a lethal dose (1x105 CFU) of LVS or LVSΔiclR. At 1, 3, 7 and 8 
days post inoculation the lungs, liver and spleen were harvested to enumerate the 
bacterial organ burdens (Figure 3A). These initial experiments revealed that there were 
no differences in the organ burdens at 1 or 3 days post inoculation. At day 7, there 
appeared to be slight differences in the organ burdens in the liver and spleen, and by day 
8 the organ burdens in the liver and spleen had not increased. These initial experiments 
suggested that LVSΔiclR may demonstrate enhanced clearance in the mouse. This would 
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correlate with previously published data demonstrating a decrease in competitive index in 
the spleen at 48 hr for the F. novicida U112 iclR deletion mutant compared to wild type 
F. novicida U112 (46). 
 To further investigate the possibility of a subtle phenotype of enhanced clearance, 
we used a low dose (1x103 CFU) i.n. inoculation of groups of six wild type C57BL/6 
mice with LVS or LVSΔiclR. At days 1, 3, 7 and 10 post inoculation, we again harvested 
the lungs, liver and spleen to calculate the bacterial organ burdens. There were no 
significant differences between the bacterial organ burdens of LVSΔiclR or wild type 
LVS at any time point (Figure 3B). This suggests that LVSΔiclR is not attenuated in a 
mouse model of pulmonary tularemia. 
 Since the experiments with F. novicida U112 iclR deletion mutant were 
performed using subcutaneous (s.c.) and i.p. inoculation, we investigated whether a role 
for iclR in pathogenesis may be route-specific. Groups of 6 to 7 wild type C57BL/6 mice 
were infected i.d. with 3x105 CFU of LVS or LVSΔiclR. The i.d. route has a comparable 
LD50 dose and is similar in nature to the s.c. route (14). At 1, 3, and 7 days post 
inoculation, we again harvested the lungs, liver and spleen and determined bacterial 
organ burdens. At each time point and in each organ, there was no significant difference 
in the bacterial burdens comparing LVS and LVSΔiclR (Figure 3C). These data indicate 
that in LVS, iclR is not required for pathogenesis in the mouse via the i.n. or i.d. route. 
SchuS4ΔiclR is not attenuated following intranasal inoculation of mice 
 
 Although iclR does not appear to be required for LVS pathogenesis, it is possible 
that iclR plays a role in SchuS4 pathogenesis. We inoculated groups of four wild type 
C57BL/6 mice i.n. with a lethal dose (100 CFU) of wild type SchuS4 or SchuS4ΔiclR. At 
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1 and 3 days post inoculation, the lungs, liver and spleen were harvested to enumerate the 
bacterial organ burdens of infected mice (Figure 4). At both time points and in each 
organ, there were no differences in bacterial burden between wild type SchuS4 and 
SchuS4ΔiclR. These data suggest that IclR does not play a role in the in vivo virulence of 
SchuS4 when assessed by the mouse model of pulmonary tularemia. 
F. novicida U112 iclR transposon mutant is attenuated following intranasal 
inoculation of mice 
 
 As noted above, an iclR deletion mutant in F. novicida U112 displays decreased 
competitive index in the spleen following s.c. and i.p inoculation of mice (53). Therefore, 
we wanted to determine whether iclR is required for F. novicida U112 pathogenesis in a 
pulmonary mouse model. We inoculated groups of six wild type C57BL/6 mice i.n. with 
a dose of approximately 10 CFU of wild type U112 or a U112 iclR transposon mutant. At 
1 and 5 days post inoculation, the lungs, liver and spleen were harvested and the bacterial 
organ burdens were enumerated. Each organ had reduced burdens of the iclR transposon 
mutant compared to wild type U112, and at day 5 these differences were statistically 
significant in the liver and spleen (Figure 5). These data suggest that iclR is required for 
U112 pathogenesis via the i.n. route and correlates with the previously published data 
using the s.c. and i.p. routes. 
Deletion of iclR does not affect IL-1β expression or cytotoxicity of infected cells 
 
 To determine if there is an altered cellular response to LVSΔiclR compared to 
wild type LVS, we measured the production of pro-inflammatory cytokines by infected 
cells. Bone marrow-derived macrophages were infected at an MOI of 500 with LVS or 
LVSΔiclR and the supernatants were analyzed for IL-1β at 24 hr post infection (Figure 
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6A). The levels of IL-1β measured in the supernatants of LVSΔiclR-infected cells was 
similar to that of cells infected with wild type LVS, and no differences between strains 
were statistically significant. 
 F. tularensis is also reported to induce cytotoxicity of infected macrophages. To 
determine whether there was a change in cytotoxicity induced by LVSΔiclR, we infected 
murine bone marrow-derived macrophages with LVS or LVSΔiclR at an MOI of 500 and 
performed cytotoxicity assays on supernatants collected at 24 hr post infection. As shown 
in Figure 6B, LVSΔiclR induces cytotoxicity in infected cells to a level similar to that of 
wild type LVS, and no differences between strains were statistically significant. 
The effects of IclR on gene expression 
 
 Due to its homology to transcriptional regulators, we used microarray analysis to 
determine what genes in LVS were affected by IclR by comparing gene expression 
between the LVSΔiclR mutant and wild type LVS. We grew LVS and LVSΔiclR to mid-
log phase to harvest RNA for reverse transcription and amino-allyl labeling of cDNA, 
and the labeled cDNA was hybridized to microarray slides. The slides are printed for 
every annotated ORF for SchuS4, plus LVS alleles that are either not present or are 
variant in SchuS4, but they are not tailored to F. novicida. Three separate microarrays 
from independent RNA samples were pooled and statistically significant gene expression 
differences between LVSΔiclR and wild type LVS were determined by SAM (Table 1). 
Genes exhibiting significant changes in expression are listed by the provided locus 
annotations, LVS or SchuS4, as printed on the slides. 
 Using the above criteria, we identified 13 downregulated and 4 upregulated genes 
in LVSΔiclR. The list of genes identified comprises diverse functional groups suggesting 
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that IclR does not impact expression of one specific functional group of proteins. There 
were several IclR-affected genes annotated as encoding hypothetical proteins. To get a 
better idea of what types of proteins these genes may be encoding and possibly obtain 
insight on IclR function, we performed BLASTp analyses. Many of the proteins were 
only conserved in Francisella with no similarity to proteins or conserved domains in 
other bacteria. However, there were several with similarity to known proteins in other 
bacteria and these are described in Table 1. Although most of the genes were represented 
exclusively by the SchuS4 allele, there were two cases where the SchuS4 and LVS 
homologs were both printed on the microarray slide and also appeared on the gene list as 
having significant expression changes in the absence of IclR. FTT_0741c and its 
FTL_1373 homolog were both upregulated in LVSΔiclR, and both FTL_0388 and its 
homolog FTT_0885 were downregulated in LVSΔiclR. Overall, although further studies 
need to be performed to demonstrate a function of IclR, both bioinformatic and 
microarray data suggest that Francisella IclR could function as a transcriptional 
regulator. 
Comparison of IclR-regulated genes between LVS, SchuS4 and U112 
 
 One explanation for the phenotypic differences observed for iclR mutants among 
the F. novicida U112, F. tularensis, LVS and SchuS4 strains could be due to differences 
in the genes affected by IclR among the strains. To address this we performed a more 
detailed examination of the genes on our microarray list. First, we performed synteny 
analysis using the genome synteny tool at www.francisella.org to determine whether each 
gene was annotated in SchuS4, LVS and U112. We observed that there were a few genes 
that were not annotated or not present in all three strains, as shown in Table 1. Secondly, 
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we generated alignments and protein translations of the genes using Vector NTI software 
based on the NCBI annotation or the putative loci of non-annotated genes from the 
synteny analysis, if they were found. For example, sequence alignments revealed that in 
LVS there is an unannotated ORF between FTL_1120 and FTL_1121 bearing homology 
to FTT_1082. Nearly half of the genes were similarly annotated and encoded one intact 
open reading frame (ORF) in SchuS4, LVS and U112. However, a significant percentage 
of genes displayed considerable sequence differences between strains as described in 
Table 1. 
 Of these genes, many were not intact in the virulent strains LVS and/or SchuS4, 
whereas the homologous genes in U112 were intact. For example, FTL_1506 and 
FTL_1507 are pseudogenes because they encode two ORFs while their SchuS4 
(FTT_0723c) and U112 (FTN_0634) encode only one ORF. One special case is 
FTT0715, which along with its LVS homolog FTL_1521, has two large deletions, 131bp 
(119bp in LVS) and 197bp, when compared to the U112 homolog FTN_0627. The 
significance of these deletions cannot be inferred, and though these genes are not 
pseudogenes, the fact that these large deletions are present only in SchuS4 and LVS is 
noteworthy. This also highlights the fact that many of the intact genes on the microarray 
list have greater overall sequence differences between U112 and LVS or SchuS4 when 
compared to that of the differences between LVS and SchuS4. 
  We next wanted to determine whether the set of genes that were changed in 
expression in LVSΔiclR were also changed in the absence of IclR in U112. First, we 
performed quantitative RT-PCR on six genes that were differentially-regulated in the 
microarray for LVS versus LVSΔiclR (Figure 7A) and normalized to the housekeeping 
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gene gyrA. We also included iclR. As expected, we detected a dramatic decrease in iclR 
transcript in LVSΔiclR and negligible change in gyrA. Of the six genes analyzed, four 
repeated the trend seen in the microarray analysis. For the two genes that did not, the 
primers appeared to amplify with similar efficiencies to other primers (data not shown). 
Overall, the qRT-PCR data supports the fact that the genes identified in our microarray 
are changed in expression in the absence of IclR using a different method. We then tested 
the same set of gene homologs on RNA isolated from wild type U112 and the U112 iclR 
transposon mutant (Figure 7B). Quantitative RT-PCR first verified that iclR transcripts 
were substantially lower in the transposon mutant. Overall, the six selected genes appear 
to be changed similarly to their LVS homologs, suggesting a similar set of genes affected 
by IclR in U112. These analyses do not account for any additional genes affected by 
U112 IclR that were not affected by LVS IclR as detected by microarray. Furthermore, 
these analyses alone are not sufficient to extrapolate any correlations in terms of IclR 
function or which of the IclR-affected genes are likewise impacted at the protein level or 
functional. 
 
The effects of IclR on antibiotic resistance 
 
  Other IclR family proteins are known to be involved in the regulation of multi-
drug efflux pumps (33). In F. novicida and F. tularensis subspecies, iclR is located near 
ORFs encoding hypothetical proteins that have homology to the EmrA multidrug efflux 
pump. In LVS, the two ORFs encoding proteins with EmrA homology that are found 
upstream of iclR were not changed in expression as determined by our microarray 
analysis. Nevertheless, the microarray data for LVSΔiclR showed increased expression of 
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a gene encoding a protein with homology to organic solvent tolerance proteins, 
suggesting that IclR may be involved in repression of some genes involved in drug 
efflux. Organic solvent tolerance is often associated with multi-drug efflux pumps, most 
notably in Escherichia coli and Pseudomonas putida (36). Furthermore, our BLASTp 
analyses of hypothetical genes that appear in the LVSΔiclR microarray gene list also 
reveal proteins with homology to other transporter proteins. To determine whether iclR is 
involved with drug efflux, we performed disc diffusion assays using a panel of 
antibiotics. Antibiotics selected for analysis were chosen as representatives from several 
classes of antibiotics targeting cell wall synthesis, protein synthesis, nucleic acid 
synthesis, and cell membrane integrity. There was no difference in antibiotic sensitivity 
between wild type LVS and LVSΔiclR using this method (Figure 8). 
 
Discussion 
 
 Herein we investigated the contribution of the putative transcriptional regulator 
IclR to F. tularensis pathogenicity. In this study, we found that the LVSΔiclR was not 
attenuated for intracellular replication in J774A.1 macrophage-like cells, TC-1 epithelial 
cells, or bone marrow-derived macrophages. Similarly, SchuS4ΔiclR was not attenuated 
for replication in J774A.1 cells. These data are consistent with published data by Weiss et 
al. for the F. novicida U112 iclR deletion mutant strain in bone-marrow derived 
macrophages (46). 
  When compared to wild type LVS, LVSΔiclR did not impact IL-1β induction or 
cytotoxicity of infected cells, which is different from that of the published F. novicida 
studies (46). It is important to note that the methods used for these analyses were 
 52 
 
different between the two studies. The levels of IL-1β that we reported in this study are 
near but not below the limit of detection for the ELISA. The fact that the levels of IL-1β 
induced are low is consistent with other studies evidencing that LVS suppresses the 
inflammatory response (21, 43). Furthermore, Weiss et al. used pre-stimulated bone 
marrow-derived macrophages, whereas we used naïve bone marrow-derived 
macrophages. Macrophages pre-treated with LPS or heat-killed F. novicida as well as 
thioglycolate-elicited macrophages produce higher levels of IL-1β in response to 
infection (9, 10, 30, 45). Another possibility is that there are strain-specific differences in 
the role of IclR, as evidenced by the results of the in vivo studies discussed below. 
  Unlike the F. novicida iclR deletion mutant, neither LVSΔiclR nor SchuS4ΔiclR 
were attenuated in mice following i.n. inoculation. There were differences in the 
experimental design between our studies and the novicida study. We initially inoculated 
mice i.n. and monitored lung, liver, and spleen over several days post infection. Weiss et 
al. used s.c. and i.p. inoculations in competition assays examining the spleen at 2 days 
post infection. It is possible that inoculation route may have an impact on the importance 
of IclR on establishing infection. To address the possibility that the phenotype is route-
specific, we performed a reciprocal analysis by evaluating the virulence of LVS and 
U112 iclR mutants in i.d. and i.n. infection models, respectively. The results confirmed 
that the Francisella virulence-specific properties of IclR are restricted to F. novicida. 
  It is not clear why IclR is required for virulence in U112 but not LVS and 
SchuS4. Based on our microarray analysis, the species-specific sequence differences 
among IclR-affected genes could contribute to the functional differences we observe for 
IclR between species. Many of the genes are intact in U112, but in LVS and/or SchuS4, 
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the homologous genes are pseudogenes or displayed significant sequence variation (e.g. 
two large deletions in FTT0715/FTL_1521). The virulent subspecies of F. tularensis are 
noted for their genome decay as characterized by smaller genomes as well as increased 
numbers of pseudogenes, transposases and gene rearrangements (44). Genome-wide 
analyses of Francisella strains support this idea and many of the genes changed in 
LVSΔiclR that we identified to be pseudogenes correlate with those found in other 
studies (6, 38). It is possible that IclR in F. novicida exerts its effects on genes that are 
intact whereas in LVS and SchuS4, IclR affects genes that are similar to those in F. 
novicida but because of disruptions or changes to the ORFs, many of these genes are 
transcribed but do not encode functional proteins. We must also consider that there are 
two genes in the list that are absent in U112 that are present in LVS and SchuS4, and the 
absence of a gene affected by IclR in novicida could also contribute to the different 
phenotypes. Overall, analysis of the genes identified in our microarray suggest that the 
majority of genes affected by IclR have differences in sequence between the three species 
and that this variation could contribute to the phenotypic disparities observed. 
  Taken together, our data suggest that IclR contributes to the virulence of U112 
but not to that of LVS or SchuS4, highlighting the fact that there are significant 
differences among these strains. Another example of differences among strains is seen in 
the conserved acid phosphatases AcpA, AcpB, and AcpC. These proteins were shown to 
be required for the virulence of F. novicida, but not for the virulence of SchuS4 (7, 32). 
Even though IclR may not play a major role in SchuS4 or LVS virulence, there are other 
potential roles that IclR could be have as a functional transcriptional regulator. Quite a 
few of the microarray-identified genes encode hypothetical proteins, but there are others 
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that encode proteins with known functions or are homologous to proteins with known 
functions. Investigation into these proteins may provide an additional understanding of 
the function of IclR in F. tularensis. For example, in Pseudomonas putida, the IclR 
family proteins TtgT and TtgV regulate operons encoding genes that form efflux pumps 
for organic solvent extrusion (13, 18). Although our antibiotic sensitivity assays showed 
no role for IclR in drug efflux by LVS, we cannot rule out the involvement of IclR in the 
regulation of a system specific for organic solvent efflux or the role of IclR in drug efflux 
in other Francisella species. Finally, direct comparison of the complete transcriptional 
profiles of F. novicida, and F. tularensis iclR deletion strains might reveal some clues to 
the properties that are responsible for the phenotypic differences. Unfortunately, the 
currently available microarrays do not contain targets for genes found exclusively in F. 
novicida. 
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Figures 
 
 
Figure 2.1. Comparison of iclR in three Francisella strains 
(A) Synteny diagram of the genomic organization of the iclR locus in F. novicida U112 
(FTN_0720), F. tularensis subspecies holarctica LVS (FTL_1364), and F. tularensis subspecies 
tularensis SchuS4 (FTT_0748). (B) Amino acid sequence alignment of F. novicida U112, F. 
tularensis subspecies holarctica LVS, and F. tularensis subspecies tularensis SchuS4 IclR. 
Alignment was created using VectorNTI software and iclR sequences uploaded from NCBI 
annotated genomes of each strain and translated using VectorNTI. Red letters highlight residues 
conserved between all three strains. Blue letters highlight the residues conserved between two 
strains. 
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Figure 2.2. Intracellular replication of LVS∆iclR and SchuS4∆iclR  
Gentamicin protection assays were performed by infecting (A) J774A.1 murine 
macrophages, (B) TC-1 murine lung epithelial cells, and (C) bone marrow-derived 
macrophages with wild type LVS or LVS∆iclR at an MOI of 100. (D) Gentamicin 
protection assay was performed using J774A.1 cells infected with wild type SchuS4 or 
SchuS4∆iclR. Bars represent the standard deviation of three replicate wells and each 
graph is representative of two separate experiments. 
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Figure 2.3. Recovery of LVS∆iclR mutant in mice following i.n. or i.d. inoculation 
C57BL/6 mice were inoculated with either wild type LVS (circles) or LVS∆iclR 
(triangles) i.n. at (A) a lethal dose of ~1x105 CFU or (B) a low dose of ~1x103 CFU. (C) 
C57BL/6 mice were inoculated with either wild type LVS (circles) or LVS∆iclR 
(triangles) i.d. at a dose of ~3x105 CFU. Each symbol represents data from a single 
mouse. There were no significant differences in recovery of mutant versus wild type 
organisms from any organ at any time point as determined by the Mann-Whitney 
nonparametric test in the low dose (B) and i.d. (C) experiments. 
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Figure 2.4. Recovery of SchuS4∆iclR mutant in mice following i.n. inoculation 
C57BL/6 mice were inoculated with either wild type SchuS4 (circles) or SchuS4∆iclR 
(triangles) i.n. at a dose of ~100 CFU. No differences in recovery of mutant versus wild 
type organisms from any organ at any time point were significant using the Mann-
Whitney nonparametric test. 
 59 
 
 
Figure 2.5. Recovery of U112 iclR transposon mutant in mice following i.n. 
inoculation 
C57BL/6 mice were inoculated with either wild type U112 (circles) or U112 iclR mutant 
(triangles) i.n. at a dose of ~10 CFU. Differences in recovery of mutant versus wild type 
organisms at day 5 for the liver and spleen were significant using the Mann-Whitney 
nonparametric test. 
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Figure 2.6. IL-1β release and cytotoxicity in macrophages infection with LVS∆iclR 
Infections were carried out at an MOI of 500 for wild type LVS, LVS∆iclR, and 
LVS∆iclR + IclR (complementation). (A) IL-1β was quantified via ELISA and (B) 
cytotoxicity was quantified via ToxiLight bioassay (Lonza), both at 24 hr post infection. 
Graphs are representative of at least three separate experiments, with duplicate or 
triplicate wells for each strain per experiment. No differences were significant by any 
strain comparison using the student’s t-test. 
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Figure 2.7. Differences in transcript levels of genes in LVS versus LVSΔiclR 
RNA was isolated from (A) wild type F. tularensis subsp. holarctica LVS and LVSΔiclR 
or (B) wild type F. novicida U112 and a U112 iclR transposon mutant and used in qRT-
PCR analysis for several genes that were significantly changed in the microarray. Data is 
presented as relative expression of log change in wild type over the respective iclR 
mutant after normalization to gyrA. Graph is representative of two or three experiments. 
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Figure 2.8. Antibiotic sensitivity of LVS∆iclR 
 
Wild type LVS and LVS∆iclR were grown to mid-log phase, bacteria spread on chocolate 
agar, and an antibiotic-containing paper disc was added to the center. Bacteria were 
grown for 36 hr and the diameter of the zone of inhibition was measured. Experiment was 
performed in triplicate and the averages and standard deviations were calculated. 
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Table 2.1. Microarray gene expression in LVS∆iclR 
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Chapter 3 	  
 
TetR-based Gene Regulation Systems for Francisella tularensis12 
 
 
Overview 
 
There are a number of genetic tools available for Francisella tularensis, the 
etiological agent of tularemia, however there is not an effective inducible or repressible 
gene expression system.  Herein we describe inducible and repressible gene expression 
systems for F. tularensis based on the Tet repressor, TetR.  For the inducible system a tet 
operator sequence was cloned into a modified F. tularensis groESL promoter sequence 
and carried in a plasmid that constitutively expressed TetR. To monitor regulation the 
luminescence operon, luxCDABE was cloned under the hybrid Francisella Tetracycline 
Regulated promoter (FTRp) and transcription was initiated with addition of 
anhydrotetracycline (ATc), which binds TetR and alleviates TetR association with tetAo.  
Expression levels measured by luminescence correlated with ATc inducer concentrations 
ranging from 20 – 250 ng ml-1.  In the absence of ATc luminescence was below the level 
                                                
1 Adapted for this dissertation from Eric D. LoVullo, Cheryl N. Miller, Martin S. 
Pavelka, Jr. and Thomas H. Kawula. TetR-based Gene Regulation Systems for 
Francisella tularensis. Appl. Environ. Microbiol. 2012, 78(19):6883-6889. 
 
2 Attributions: Eric LoVullo performed all the experiments in this chapter with the 
following exceptions. Cheryl Miller helped design and performed the TetR intracellular 
growth rescue experiment with LVSΔripA (Figure 4).  Cheryl also helped design and 
perform the essentiality test with SecA using the TetR and revTetR systems. 
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of detection.  The inducible system was also functional during the infection of J774A.1 
macrophages as determined by both luminescence and rescue of a mutant strain with an 
intracellular growth defect.  The repressible system consists of FTRp regulated by the 
revTetR, TetR r1.7.  Using this system with the lux reporter addition of ATc resulted in 
decreased luminescence, while in the absence of ATc the level of luminescence was not 
significantly different than a construct lacking TetR r1.7.  Utilizing both systems the 
essentiality of SecA, the protein translocase ATPase, was confirmed establishing that 
they can effectively regulate gene expression.  These two systems will be invaluable in 
exploring F. tularensis protein function. 
Introduction 
 
Regulated expression systems are important tools for the manipulation of gene 
transcription for the study of organismal biology.  Currently, there are no suitable genetic 
control systems for Francisella tularensis, a Gram-negative bacterium which is the 
etiological agent of tularemia (13).  A conditional expression system was developed for 
F. tularensis that relies on the F. tularensis glucose repressible promoter, FGRp (26).  
However, this system relies on a ubiquitous carbon source and is not flexible.  Hence, we 
developed regulated gene expression systems for F. tularensis based upon tetracycline 
that can be used for both induction and repression. 
 Tetracycline-regulated systems have become an useful tool in analyzing gene 
function in prokaryotes (6).  Such systems, derived from Tn10, involve a constitutively 
expressed tetracycline repressor, TetR, which binds the tetracycline operator, tetAo, of 
the tetracycline promoter, tetAp, blocking transcription.  TetR is released from tetAo in 
the presence of tetracycline allowing transcription from tetAp.  The tetracycline analog 
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anhydrotetacyline (ATc) is significantly less toxic and binds more avidly to TetR making 
it a useful chemical for modulating TetR mediated gene expression in bacteria (21).  The 
TetR system has been used with a diverse group of bacteria including other respiratory 
pathogens such as Yersinia pestis, Brucella abortus, Coxiella burnetii, and 
Mycobacterium tuberculosis (4, 14, 27, 37).  In addition, a mutant derivative, revTetR, 
acts as a corepressor binding tetAo only when associated with ATc and can thus function 
to silence gene expression (34).  Herein we describe TetR and revTetR plasmid systems 
for the regulation of target gene(s) in Francisella tularensis. 
 
Materials And Methods 
Bacterial strains, transformation and cell culture 
 
Escherichia coli strains (Table 1) were grown in Luria-Bertani (LB) broth (BD 
Biosciences) or on LB agar.  F. tularensis strains (Table 1) were grown at 37°C on 
chocolate agar (25 g BHI l-1, 10 µg hemoglobin ml-1, 15 g agarose l-1) supplemented with 
1% IsoVitaleX (Becton-Dickson) or in Chamberlain’s Defined Medium (CDM) (10)  
When necessary kanamycin (Km; Sigma-Aldrich) was used at 50 µg ml-1 for E. coli, 10 
µg ml-1 for F. tularensis and Hygromycin B (Hyg; Roche Applied Science) was used at 
200 µg ml-1 for both species.  Sucrose was used at a final concentration of 10% (w/v).  
Anhydrotetracycline (ATc; Sigma-Aldrich) was used at the concentrations stated. 
E. coli – F. tularensis shuttle vectors were introduced into F. tularensis strains via 
electroporation as described (30). Transformants were selected on chocolate agar 
supplemented with the appropriate antibiotics.   
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J774A.1 (ATCC# TIB-67) is a mouse macrophage-like cell line that was cultured 
in Dulbecco's minimal essential medium with 4.5 g l-1 glucose, 2 mM L-glutamine, and 
10% heat-inactivated fetal bovine serum. Cell lines were maintained at 37°C in 5% CO2. 
secA mutagenesis and allelic exchange  
 
A DNA fragment containing secA was obtained from LVS genomic DNA (GenBank 
accession no. AM233362.1) using PCR and cloned into the SacB/oriT vector pEDL50, 
which was used as a template for PCR to generate an in-frame deletion of 2703 bp within 
secA.  There is 761 bp of DNA upstream and 836 bp downstream of the ΔsecA1 allele in 
the deletion construct, pEDL55. 
Conjugation and allelic exchange was performed similar to the previous described 
method (24) except pEDL55 was mobilized into F. tularensis using E. coli S17-1 λpir 
and primary recombinants were selected on chocolate plates supplemented with 
polymyxin B at 200 µg ml-1 and kanamycin at 10 µg ml-1.   
DNA manipulation 
 Recombinant DNA methods were performed essentially as described (2).  DNA 
fragments were isolated using agarose gel electrophoresis and QIAquick spin columns 
(Qiagen Inc.).  Oligonucleotides were synthesized by Invitrogen Life Technologies.  All 
restriction endonucleases were from New England Biolabs (NEB).  DNA ligations were 
performed with the Fast-Link DNA ligation kit (Epicentre).  PCR reactions were 
performed with Phusion High-Fidelity DNA Polymerase (NEB) according to the 
manufacturer’s recommendations.   
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Plasmid construction 
 
 Plasmids pertinent to this study are listed in Table 1.  Detailed descriptions of the 
construction of the plasmids can be obtained from the corresponding author.   
Broth culture luminescence assay and SecA depletion assay 
 
Bacteria were grown shaking at 37°C in 96 well flat clear bottom black polystyrene 
plates (Corning) in CDM in an Infinite 200 microplate reader (TECAN) with 
luminescence and absorbance (OD600) monitored every fifteen minutes.  The SecA 
depletion assay was performed similarly except growth was in 96 well flat clear 
polystyrene plates (Corning) and only the absorbance (OD600) monitored.   
Intracellular induction and ripA growth rescue  
 
To determine the rate of intracellular induction by ATc F. tularensis LVS strains 
harboring luminescent FTRp constructs were cultured to mid-exponential phase in CDM 
and then added to J774A.1 cells at a multiplicity of infection (MOI) of 100.  Wells were 
washed 2 hours post infection and 50 µg ml-1 gentamicin was added to inhibit any 
remaining extracellular bacteria.  As peak luminescence of a LVS J774A.1 gentamicin 
protection assay is ~24-30 hours post infection, the strains were induced with ATc at 23 
hours and placed in an Infinite 200 Pro microplate reader (Tecan) equipped with a gas 
control module set at 5% CO2 and luminescence was monitored every fifteen minutes.   
We used the gentamicin protection assay described above for the ripA 
intracellular growth rescue experiments, except that ATc was added at 12 hours post 
infection and CFU’s were enumerated at 12 hours and 36 hours post infection.   Assays 
were performed in sextuplicate and statistical significance was determined using unpaired 
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t tests on the fold change of recovered CFU to compare the difference in growth between 
rescued strains and the ripA deletion strains. 
 
Results 
 
As Francisella tularensis does not recognize the Tn10 tetA promoter (data not 
shown) we chose to modify the well characterized Francisella groESL promoter (15, 22), 
which drives strong gene expression in vitro and in vivo (7, 30).  The groESLp was 
modified by inserting a tetAo sequence immediately downstream of the predicted 
transcriptional start site creating the Francisella Tetracycline Regulated promoter (FTRp) 
(Fig. 1).   A MluI restriction site was added to facilitate cloning open reading frames and 
also to allow for changing the 5’ UTR or start codon (e.g. a GTG start has been found to  
decrease expression in F. tularensis (3)).  The tetR gene encoding the repressor TetR was 
placed under the constitutively active Francisella rpsL promoter and cloned divergent to 
FTRp (28).   
We used the bacterial luminescence operon luxCDABE from Photorhabdus 
luminescens,  which has been shown to function in F. tularensis (7), to assess our ability 
to regulate transcription of the hybrid promoter.  We created two separate constructs; 
pEDL40 (Fig. 2A), an E. coli – F. tularensis shuttle vector bearing FTRp driving the lux 
operon and a rpsLp-tetR cassette, and pEDL41 (Fig. 2B), which is pEDL40 with tetR 
deleted allowing for constitutive FTRp-luxCDABE expression.  As the groESL promoter 
is strong we specifically chose the low copy hygromycin resistant vector platform (29).  
The plasmids were introduced into F. tularensis LVS and growth curves in 
Chamberlain’s defined medium (CDM) were performed in the presence of ATc at 0, 100 
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or 250 ng ml-1 while monitoring luminescence and absorbance (OD600) (Fig. 3A).  The 
constitutive ∆tetR strain was not supplemented; however we found ATc had no effect on 
luminescence except at high levels (> 250 ng ml-1 ATc) becoming increasingly 
bacteriostatic causing an overall reduction in RLU/OD600 (data not shown).  No 
luminescence was detected at 0 ng ml-1 suggesting the system is effectively silenced by 
TetR, while the 100 and 250 ng ml-1 concentrations were similar to the constitutive 
promoter suggesting that at these levels the system was fully induced.  LVS exhibits 
diauxie in CDM, which leads to the two peak luminescence curve. The system was 
titrated with concentrations of 20 to 50 ng ml-1 ATc and as the concentration increased so 
did the luminescence, although concentrations less than 20 ng ml-1 were below the level 
of luminescence detection (Fig. 3B).  Thus by luminescence the TetR system has a 
useable range of 20 – 250 ng ml-1 ATc in broth culture.  To determine the speed of 
induction, a midlog culture was induced with 250 ng ml-1 ATc and measured over time 
(Fig. 3C).  Luminescence exceeded the limit of detection within 18 minutes showing that 
induction of transcription and subsequent translation is rapid.   
 These results confirm that the system is useful in broth culture; however as F. 
tularensis is a facultative intracellular bacterium we wanted to determine if induction of 
the TetR system was possible in cell culture.  A J774A.1 mouse macrophage-like cell line 
was infected with LVS bearing pEDL40 or pEDL41.  Since peak luminescence in a 
J774A.1 infection is ~24-30 hours post infection (Data not shown) ATc was added at 23 
hours post infection at 0, 100 or 250 ng ml-1.  With addition of ATc at 100 or 250 ng ml-1 
the luminescence was above background within 45 minutes and reached the level of the 
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constitutive promoter within 3 hours (Fig. 3D).  The bacteriostatic concentration of ATc 
in cell culture was found to be greater than 500 ng ml-1.   
We wanted to establish if the TetR system was suitable for rescuing a mutant 
defective for intracellular replication.  RipA is a cytoplasmic transmembrane protein 
essential for Francisella tularensis intracellular growth in host macrophage cells and for 
growth at the neutral pH found in the host cell’s cytoplasmic environment (19, 38).  The 
F. tularensis ∆ripA mutant can infect host macrophages and escape the phagosome at the 
same frequency as wild type, but fails to replicate inside host cells and is impaired in its 
ability to colonize and disseminate in a mouse model of tularemia (18). A gentamicin 
protection assay was performed with LVS bearing the TetR control plasmid pEDL17 in 
which FTRp drives production of a RFP, mOrange2 (36), LVS∆ripA bearing pEDL17, 
and LVS∆ripA containing the plasmid pEDL20 with ripA under the control of FTRp.  
J774A.1 macrophages were infected and 100 ng ml-1 ATc was added at 12 hours post 
infection, to determine if the LVS∆ripA strain could be rescued after such a long period 
of stasis.  As expected, the control strains LVS/pEDL17 replicated inside host 
macrophages, increasing in numbers by 3 to 5 fold between 12 and 36 hours post 
infection, while the ripA/pEDL17 failed to replicate inside macrophages.  Furthermore 
the addition of 100 ng ml-1 ATc did not change the intracellular growth of LVS or the 
ripA deletion mutant (Fig. 4).  In contrast, the ∆ripA/pEDL20 strain was rescued for 
growth when 100 ng ml-1 of ATc was added to the cells, increasing in viable counts by 50 
fold in the subsequent 24 hours (P<0.0001) (Fig. 4).  The rescue of ∆ripA/pEDL20 by 
addition of ATc confirmed that the system works intracellularly and suggests that 
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although the ripA deletion strain is unable to replicate, it is still viable at 12 hours post 
infection.     
To create a repressible TetR system in Francisella we chose a highly efficient 
revTetR, TetR r1.7 (23, 34).  We replaced the tetR gene in pEDL40 with tetR r1.7 to 
create pEDL47 (Fig. 2C).  The plasmid pEDL47 was introduced into LVS and growth 
curves were performed in the presence of ATc at 0, 100 or 250 ng ml-1 (Fig. 5).  There 
was no significant difference between 0 ng ml-1 ATc and the constitutive ∆tetR strain, 
which suggests that there is no binding of TetR r1.7 to tetAo in the absence of ATc.  Both 
the 100 and 250 ng ml-1 ATc levels tested inhibited transcription of the operon and while 
it took over 20 hours to reach baseline it was significantly different than 0 ng ml-1 ATc.  
This slow decline in luminescence is likely due to the time it takes for depletion of the 
Lux proteins after transcriptional silencing by TetR r1.7. 
 To determine if the TetR and revTetR systems were suitable for silencing gene 
expression an essentiality test was performed on SecA, the protein translocase ATPase.  
SecA is a component of the general secretory pathway (Sec).  The Sec pathway consists 
of three integral membrane proteins SecY, SecE, and SecG and two cytosolic proteins 
SecA and SecB.  The SecYEG complex forms a heterotrimeric channel in the 
cytoplasmic membrane where the unfolded substrates pass through (32).  SecB is a 
cytosolic chaperone that specifically targets preproteins to SecA (39).   SecA is central to 
the pathway as it is the ATPase that energizes the transport through SecYEG, as well as 
recognizing and delivering preproteins to the SecYEG channel (8, 11).  In a transposon 
screen in the closely related Francisella novicida there are two hits in the 3’ end of the 
secA gene (20) and a study by Margolis et al 2009 found that these secA mutants were 
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defective in biofilm formation, suggesting a defect in protein secretion, however they 
were unable to delete the full length F. novicida secA (31) as SecA is likely essential in 
all prokaryotes (1, 5, 9, 16, 17, 23).  To silence expression of SecA in LVS we deleted the 
chromosomal copy of secA in strains bearing either plasmid pEDL54 (FTRp-secA, TetR) 
or pEDL58 (FTRp-secA, revTetR) which will be referred to as the TetOn and TetOff 
strains, respectively.  We streaked LVS, TetOn, and TetOff on plates containing 0 or 500 
ng ml-1 ATc.  The LVS control grew normally in both conditions, and as expected TetOn 
grew only in the presence of ATc and TetOff in the absence of ATc (Fig. 6A).  There 
were a few colonies in the primary streak of the silenced strains, suggesting the selection 
of suppressors.  To resolve the nature of the suppression three overnight cultures of the 
TetOn strain, grown in 50 ng ml-1 ATc, were plated onto chocolate agar lacking ATc and 
15 colonies were chosen for further analysis.  Each strain that grew without ATc was 
found to harbor a mutation in tetR or tetAo allowing constitutive production of SecA.  
These results established SecA as essential; however the growth kinetics of the two 
strains on depletion of SecA in CDM might explain whether depletion was bacteriostatic 
or bactericidal.  As expected TetOn grew without ATc until SecA was depleted but grew 
to WT levels with ATc present (P<0.01) and TetOff followed the opposite pattern 
(P<0.01) (Fig. 6B).  Even though it has been suggested that lack of SecA or inhibition of 
SecA is bactericidal (35) these results suggest that depletion was bacteriostatic in LVS, 
however at late time points suppression of the secA deletion did occur in both strains 
which obfuscates the results.  As it was difficult to maintain a clean population of the 
TetOn strain, because of constant selective pressure, the revTetR system would likely be 
a better system to use when studying a potentially essential gene.  
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Discussion 
 
In this study, we developed TetR-based gene regulation systems for Francisella 
tularensis that allow for inducible or repressible gene expression with addition of ATc 
and demonstrated that the systems are useful in both broth and cell culture.  We further 
established that the systems can be used effectively for gene silencing.  We anticipate 
these systems will be useful for studies investigating gene dosage, gene timing, 
essentiality testing, as well as for expression of toxic proteins.  Thus these systems will 
be invaluable in addressing protein function in Francisella tularensis.   
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Figures 
 
Figure 3.1. Francisella Tetracycline Regulated Promoter 
FTRp has both sigma 32 and sigma 70 recognition delineated by the underlined -35 and -
10 sequences.  The asterisk* signifies the transcriptional start.  Following in the 5’ UTR 
is the tet operator, tetAo, as well as a MluI site to facilitate cloning.  The ATG represents 
the translational start. 
 
σ32 
    __-35                   -10         *       tetAo        MluI 
ATTTCTTGAAAATTTTTTTTTTGACTCAATATCTAGACTTGTCCCTATCAGTGATAGAGAACGCGTACAAAGGAGTAACTGCAGTATG 
      -35                     -10                                                    MET… 
σ70 
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Figure 3.2. Maps of the FTRp-luxCDABE vectors 
(A) The inducible vector, pEDL40, is a stable HygR E. coli – F. tularensis shuttle vector 
that contains the hybrid Francisella FTR promoter driving the luminescence operon, 
luxCDABE.  Divergently transcribed is the tetR gene constitutively expressed from the 
Francisella rpsL promoter.  (B)  The vector, pEDL41, is pEDL40 with the tetR gene 
deleted.  This allows constitutive expression of the lux operon from FTRp.  (C)  The 
repressible vector, pEDL47, is a HygR stable E. coli – F. tularensis shuttle vector that 
contains FTRp-luxCDABE.  Divergently transcribed is the revTetR tetR r1.7 gene 
constitutively expressed from the Francisella rpsL promoter.    
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Figure 3.3. The TetR system 
(A)  Growth curves were performed in Chamberlain’s Defined Medium (CDM) with 
LVS bearing plasmid pEDL40 in the presence of ATc concentrations of 0, 100 and 250 
ng ml-1 and LVS bearing pEDL41 ∆tetR as the constitutive control.  The absorbance at 
OD600 and luminescence were monitored every fifteen minutes for 36 hours.  To 
determine the relative light produced per bacterium the luminescence was divided by the 
absorbance and represented as RLU/OD600.  (B)  Growth curves were performed in CDM 
utilizing ATc concentrations from 0 - 50 ng ml-1 in 10 ng ml-1 increments and 
luminescence per bacterium was followed as above.  (C)  A midlog culture of 
LVS/pEDL40 was induced with 250 ng ml-1 ATc to test induction time.  Luminescence 
was monitored every fifteen minutes to ascertain the time it took to increase above 50 
RLU, which represents the limit of detection. (D) A gentamicin protection assay was 
A. 
C. D. 
B. 
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performed with LVS bearing plasmid pEDL40 LVS bearing pEDL41 ∆tetR as the 
constitutive control.  Induction was at 23 hours post infection with ATc concentrations of 
0, 100 and 250 ng ml-1.  Luminescence was measured every fifteen minutes for 5 hours 
after induction.   
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Figure 3.4. The TetR system rescues LVSΔripA intracellular growth in J774A.1 
macrophages 
Fold change in growth was measured after 24 hours during a gentamicin protection assay 
with LVS bearing the TetR control plasmid pEDL17, LVS∆ripA bearing pEDL17, and 
LVS∆ripA containing pEDL20 with Pgrotet-ripA.  All strains were added to J774A.1 
cells at a multiplicity of infection of 100.  Gentamicin was added at 2 hours post 
infection.  At 12 hours 100 ng ml-1 ATc was added to wells.  CFU’s were enumerated at 
12 hours and 36 hours post infection.  Data are represented as average fold change in 
growth (n=6) between 12 and 36 hours post infection.  Error bars represent standard 
deviation.  **** P< 0.0001. 
**** **** **** 
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Figure 3.5. The revTetR system 
Growth curves were performed with LVS bearing plasmid pEDL47 in the presence of 
ATc concentrations of 0, 100 and 250 ng ml-1 and LVS bearing pEDL41 ∆tetR as the 
constitutive control.  The absorbance at OD600 and luminescence were monitored every 
fifteen minutes for 36 hours.  To determine the relative light produced per bacterium the 
luminescence was divided by the absorbance.   
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Figure 3.6. SecA is essential 
(A)  The strains LVS, TetOn (FTRp-secA, TetR), and TetOff (FTRp-secA, revTetR) were 
streaked onto chocolate agar plates that either contain 0 or 500 ng ml-1 ATc.  The plates 
were allowed to incubate for 72 hours at 37 °C.  (B)  Growth curves of either TetOn or 
TetOff were performed in media containing 0 or 100 ng ml-1 ATc.  The absorbance at 
OD600 was measured every 15 minutes for 50 hours.  The growth curves were plotted 
onto a log10 scale.  There was a significant difference in final growth as measured by 
absorbance at OD600 with TetON unable to reach WT levels without ATc P<0.01 and 
TetOff unable to reach WT levels of growth with ATc P<0.01.   
B. 
A. 
TetOn 
TetOn Te
tO
ff 
Te
tO
ff 
LVS LVS 
ATc 0 ATc 500 
TetOn TetOff 
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Tables	  
 
 Table 3.1. Bacterial strains and plasmids 
 
Strains or Plasmids Description Reference or 
Source 
Strains   
E. coli   
  DH10B F- mcrA Δ(mcrBC-hsdRMS-mrr) 
[φ80dΔlacZΔM15] ΔlacX74 deoR 
recA1 endA1 araD139 Δ(ara,leu)7697 galU 
galK λ- rpsL nupG 
Invitrogen 
  S17-1 λpir Tpr Smr hsdR pro recARP4-2-Tc::Mu-
Km::Tn7 λ pir 
(12) 
  NK7402  trpC83::Tn10, IN(rrnD-rrnE)1 source of 
tetR 
CGSC Strain #6688 
F. tularensis   
  LVS F. tularensis subsp. holarctica live vaccine 
strain 
CDC 
  LVS∆ripA LVS∆ripA (18) 
  LE149/TetOn LVS∆secA pEDL54 in trans This work 
  LE150/TetOff LVS∆secA pEDL58 in trans This work 
Plasmids   
pcDNA3-mOrange2 ApR, NeoR source of mOrange2 (36) 
pJH1 HygR, source of oriT (25) 
pMP812 KmR, SacB suicide vector (28) 
pNR55 KmR, source of the revTetR, tetR r1.7 (33) 
pXB173-lux KmR, E. coli-F.tularensis shuttle vector 
containing the luxCDABE operon 
(7) 
pEDL17 HygR, FTRp-mOrange2, rpsLp-tetR This work 
pEDL20 HygR, FTRp-ripA, rpsLp-tetR This work 
pEDL40 HygR, FTRp-luxCDABE, rpsLp-tetR This work 
pEDL41 HygR, FTRp-luxCDABE with deletion of 
tetR 
This work 
pEDL47 HygR, FTRp-luxCDABE, rpsLp- tetR r1.7 This work 
pEDL50 KmR, pMP812 SacB suicide vector with 
oriT from pJH1 
This work 
pEDL54 HygR, FTRp-secA, rpsLp-tetR This work 
pEDL55 pEDL50 with LVS ∆secA region This work 
pEDL58 HygR, FTRp-secA, rpsLp-tetR r1.7 This work 
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Chapter 4 	  
 
RipA modulates the acyl chain specificity and stability of LpxA in Francisella 
tularensis.1 
 
Overview 
 
Francisella tularensis is a Gram-negative bacterium that infects hundreds of species 
including humans, and has evolved unique mechanisms to grow efficiently within a 
plethora of cell types. Using transposon mutagenesis we identified RipA, a conserved 
cytoplasmic membrane protein with unknown function. RipA is dispensable for growth in 
defined media, but is required for growth inside host cells. As a means to determine RipA 
function, we isolated and mapped independent extragenic suppressor mutants in ∆ripA 
that restored growth in host cells.  Each suppressor mutation mapped to one of two 
essential genes, lpxA or glmU, which are both involved in lipid A synthesis.  We repaired 
one of the suppressor mutations in lpxA (S102) and demonstrated that the mutation was 
responsible for the suppressor phenotype. We hypothesize that the mutation in S102 
alters the stability of LpxA, which compensated for the absence of RipA function.  LpxA 
is an essential protein, which uses the precursors UDP-N-acetylglucosamine (UDP-
                                                
1 Attributions: 
Cheryl Miller performed all the experiments in this chapter. Eric LoVullo designed the 
inducible gene expression system for lpxA (Figure 10).  Artur Romanchuk and Corbin 
Jones aligned the sequenced genome of S102 and identified the polymorphisms (Table 
1).  Ronald Jenkins and Garry Dotson developed the continuous fluorescent enzyme 
assay for LpxA and made the hydroxypalmytic-ACP necessary for the experiments with 
F. tularensis LpxA (Figure 12).  
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GlcNAc), and acyl-ACP to begin lipid A synthesis.  We found that the ratio of C:18 to 
C:16 fatty acids in lipid A was greater in the presence of RipA. Furthermore, LpxA was 
more abundant in the presence of RipA.  Induced expression of lpxA in the ΔripA strain 
stopped bacterial division. We also found that the LpxA S102 protein was less stable and 
therefore less abundant than wild type LpxA protein. These data suggest RipA modulates 
the activity and abundance of LpxA in F. tularensis as a way to adapt to the host cell 
environment.   
Introduction 
 
Francisella tularensis is a highly virulent Gram-negative bacterial pathogen that 
causes systemic infections in hundreds of animal species, including humans.  Key 
pathogenic properties of F. tularensis are its ability to invade and replicate within many 
different host cell types and to suppress the initial host inflammatory response by innate 
immune cells.  We previously identified a protein termed RipA, which is conserved 
among all sequenced Francisella species (9). RipA is dispensable for growth in minimal 
media, but is required for F. tularensis virulence in mouse models of infection (9).  RipA 
is a homooligomeric cytoplasmic membrane protein that contains two cytoplasmic 
domains that are essential for RipA function (25).  The ∆ripA strain infects host cells and 
escapes the phagosome entering the cytoplasm similar to wild type F. tularensis, but fails 
to replicate within the cytosol (9).  Both transcription and translation of ripA are elevated 
at neutral pH coinciding with F. tularensis leaving the acidified vacuole and entering the 
neutral cytoplasm (10).  The F. tularensis ∆ripA strain stimulates a robust host 
inflammatory response activating the inflammasome and MAPK pathways, a response 
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which is not seen with wild type F. tularensis (12). In Francisella novicida, ∆ripA 
activates increased levels of AIM2-dependent pyroptosis, suggesting the bacterial 
membrane is compromised (27). Determining RipA function would provide an important 
insight into the specific mechanisms used by F. tularensis to grow within eukaryotic 
cells.  Given the scant information obtained from bioinformatics analysis of RipA, and 
the eclectic group of organisms that express RipA-like proteins (25), we took genetic and 
biochemical approaches to determine RipA function.  We isolated five independent 
extragenic suppressor mutations of ∆ripA that restored intracellular growth, and all 
suppressor mutations mapped to either lpxA or glmU.  Both lpxA and glmU encode 
essential enzymes involved in lipid A synthesis (1, 24).  Repairing one of the mutations 
in lpxA abrogated the suppressor phenotype supporting that the mutation in lpxA was 
responsible for the suppressor phenotype.  LpxA is a UDP-N-acetylglucosamine 
acyltransferase that catalyzes the transfer of an acyl chain from acyl carrier protein (ACP) 
to UDP-N-acetylglucosamine (UDP-GlcNAc) to make lipid A, which is the hydrophobic 
anchor of lipopolysaccharide (LPS) (6).  The active site and substrate binding pocket of 
LpxA is well characterized in Escherichia coli (39).  LpxA forms a trimer composed of 
three identical subunits with each subunit composed of two domains (30). The N- 
terminal domain forms a left-handed helix of short parallel β-sheets and the C-terminal 
domain is composed of four α-helices.  The active site in LpxA is located in a cleft 
between the two subunits, and the amino acids essential for LpxA function in E. coli are 
K76, H122, H125, H144, M156, A158, H160, V171, G173, and R204 (39, 40).  E.coli 
LpxA has a strict preference for C:14 (hydroxymyristoyl) fatty acids, and this preference 
is referred to as a hydrocarbon ruler (39). LpxA from F. tularensis shares 44% identity 
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and 66% similarity with E. coli LpxA, but does not share the same hydrocarbon ruler 
(28).  Instead, F. tularensis LpxA has evolved a relaxed acyl chain specificity and can 
attach longer fatty acids onto the 3’ hydroxyl acyl of UDP-GlcNAc: incorporating either 
stearoyl (3-OH C18:0), or palmitoyl (3-OH C16:0) fatty acids.  
Herein we describe the isolation and characterization of an extragenic suppressor 
mutation of ∆ripA in F. tularensis subspecies holarctica live vaccine strain (LVS) that 
mapped to lpxA and restored intracellular growth. We show that RipA and LpxA co-
immunoprecipitate, and RipA is involved in modulating the ratio of C:18 to C:16 acyl 
chain specificity of LpxA in F. tularensis. Induced expression of lpxA in the absence of 
ripA is detrimental to bacterial growth, and the suppressor mutation T36N in LpxA 
renders the protein less stable. In summary, F. tularensis uses RipA to modulate LpxA 
activity. 
Materials And Methods 
 
Bacterial Strains 
 
All bacterial strains, plasmids, and primers used in this study are listed in Table 3.  F. 
tularensis subsp. holarctica LVS was obtained from Ft. Collins, CO.  Francisella strains 
were maintained on chocolate agar supplemented with 1% IsoVitalex (BD), 
Chamberlains defined media (CDM) (4), or in BHI supplemented with 1% IsoVitalex at 
37°C.  
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Whole Genome Sequencing and PCR Verification 
 
Genomic DNA was purified from 10 ml cultures of F. tularensis grown in CDM using 
the MasterPure DNA purification kit (Epicentre). DNA was dissolved in 200 µl of EB 
buffer at 50 ng µl-1 and submitted for whole genome sequencing at the High-Throughput 
Sequencing Facility at the University of North Carolina at Chapel Hill.  Using the 
Genome Analyzer IIx (Illumina) we produced 36 bp single-end reads that were mapped 
the to the annotated genome on NCBI (NC_007880). By aligning the reads from the 
suppressor mutant strain to this reference we could identify the suppressor mutation.  
Alignments were made using SOAP with default parameters. Average sequence coverage 
was over 50 for the 1.89 Mb genome (19). Single nucleotide polymorphisms, deletions 
and insertions were located using SOAP and BLAT (16). A total of 4 mutations and 55 
zero coverage regions identified. Mutations also present in our wild type laboratory strain 
and the ΔripA strain were discarded as background mutations, leaving one unique 
mutation present in S102. To verify all polymorphisms detected by Illumina sequencing 
we PCR amplified the regions of interest and sequenced all strains including wild type F. 
tularensis, ΔripA, and all suppressors (Genewiz, Inc.).  Following further confirmatory 
sequencing all but one mutation were eliminated as background mutations. 
Gentamicin Protection Assay 
 
J774A.1 macrophage-like cells and TC-1 epithelial cells were inoculated with LVS at a 
multiplicity of infection (MOI) of 100.  All LVS strains were grown overnight in CDM 
prior to inoculation.  The cells were incubated with the bacterial inoculum for 2 hours 
(J774A.1) or 4 hours (TC-1) and then incubated with media containing 25 µg ml-1 
gentamicin to kill extracellular bacteria.  At 4 hours (J774A.1) or 6 hours (TC-1), and at 
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24 hours post infection medium was removed, cells were scraped from the plate, serially 
diluted in PBS, and plated to determine the number of viable bacteria.  To enrich for 
extragenic suppressor mutations in ΔripA the infection was extended to 36 hours before 
bacteria were enumerated.  
Extragenic Suppressor Repair Using Allelic Exchange 
 
The lpxA (FTL_0539) allele plus 100bp of flanking DNA was PCR amplified from F. 
tularensis LVS genomic DNA.  The amplified fragment was cut with BamHI and NotI 
and ligated into the SacB suicide vector, pMP812 (21).  Allelic exchange was achieved 
by transformation, selection for plasmid co-integration, and counter selection on media 
containing 10% sucrose. DNA sequencing confirmed replacement of the mutant allele 
with the wild type (23).   
Co-immunoprecipitation of LpxA and RipA 
 
LpxA-HA was immunoprecipitated from mid-exponential phase F. tularensis LVS 
expressing lpxA-HA on a plasmid grown in CDM and pelleted by centrifugation at 13,000 
xg for 5 minutes.  Bacterial pellets were lysed using 150 mM NaCl, 1% Triton X-100, 50 
mM Tris HCl (pH 8.0) and incubated for 30 minutes while shaking.  Cell debris was 
removed by centrifugation for 5 minutes at 13,000 xg.  Protein lysates were then 
incubated with 80 µl of µMACSTM Anti-HA MicroBeads (Miltenyi Biotec) for 30 
minutes at 4°C.  Following the manufacturers protocol, the proteins bound to the 
µMACSTM Anti-HA MicroBeads (Miltenyi Biotec) were loaded onto the µ column in the 
magnetic field of the µMACS separator.  The column was washed with 5 column 
volumes of 150 mM NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
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and 50mM Tris HCl (pH 8.0) and the protein bound to LpxA-HA were eluted using hot 
50mM Tris HCL (pH 6.8), 50 mM DTT, 1% SDS, 1 mM EDTA, 0.005% bromphenol 
blue, and 10% glycerol.  All samples were analyzed by SDS-PAGE and western blot.  
Immunoprecipitation was performed on lysates of the strain with ripA-HA integrated in 
the chromosome and lpxA-V5 on a plasmid (Table S1, SKI22) as described above 
following the manufacturer’s protocol for µMACSTM Epitope Tag Protein Isolation Kit 
(Miltenyi Biotec). 
Membrane Fractionation 
 
Membranes were fractionated as described previously by ultracentrifugation and Sarkosyl 
extraction (9).  Briefly, mid-exponential phase bacteria were lysed by bead beating two 
times for 45 seconds using Lysing Matrix Tubes (MP Biomedicals). The lysates were 
clarified at max speed in a microcentrifuge for 5 minutes and crude membranes pelleted 
by ultracentrifugation for 2 hours at 100,000 xg. To enrich for cytoplasmic membranes 
from the pelleted crude membrane fraction 0.5% Sarkosyl was added overnight to 
selectively solubilize the inner membrane.  The outer membrane was separated from the 
inner membrane by ultracentrifugation for 1 hour at 100,000 xg.  
Membrane Purification and Thin Layer Chromatography 
 
F. tularensis 100 ml cultures were grown to optical density of 1.0 (OD600) or a T225 flask 
of J774A.1 cells were infected with F. tularensis at an MOI of 500.  The bacteria were 
harvested by centrifugation and washed twice with PBS.  The pellet was suspended in 8 
ml of PBS. To the cell suspension 10 ml of chloroform and 20 ml of methanol were 
added to form a single phase (chloroform, methanol, and aqueous ratio of 1:2:0.8, v/v/v) 
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as previously described (42). After one hour of incubation at room temperature, the 
insoluble debris was removed by centrifugation at 3000 xg for 30 minutes.  The 
supernatants were transferred to clean solvent-resistant bottles, and 10 ml of chloroform 
and 10 ml of PBS were added to generate a two-phase system.  After mixing, the samples 
were centrifuged at 3000 xg for 15 minutes, and the lower phase and interface was 
collected.  Samples were dried under a stream of nitrogen or in a speed vac. Thin layer 
chromatography was performed on purified membrane fractions dissolved in a total of 10 
µl of chloroform and methanol (4:1) and spotted onto a silica gel 60 Å chromatography 
plate (Whatman). The plate was developed in the solvent chloroform, methanol, water, 
and acetic acid (25:15:4:2, v/v/v/v) and sprayed with 10% sulfuric acid in ethanol and 
charred at 100°C for 20 minutes. 
Western Blots 
 
Mini-Protean® TGXTM 4-20% precast gels (BioRad) were loaded with equal amounts of 
total protein from indicated samples and run at 250V using Tris-glycine SDS running 
buffer. For western blot assays, gels were transferred to nitrocellulose membranes and 
then blocked overnight with 1% bovine serum albumin in PBS-Tween 20. All antibodies 
were incubated at room temperature for 2 hours then washed with 3 volumes of PBS-
Tween 20.  The primary antibodies used were anti-RipAaa1-19, mouse anti-HA 
monoclonal antibody (Sigma), mouse anti-V5 monoclonal antibody (Sigma), mouse anti-
F.tularensis LPS (US Biologicals F6070-C2), monoclonal anti-IglC (BEIresources NR-
3196), monoclonal anti-IglB (BEIresources NR-3195).   The secondary antibodies used 
were goat anti-rabbit IgG IRDye 680CW and 800CW or goat anti-mouse IgG IRDye 
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680CW and 800CW.  Proteins were detected using near infrared fluorescence at 700 nm 
or 800 nm with the Odyssey Infrared Imaging System (LI-COR Biosciences). 
Lipid A Purification  
 
F. tularensis 100 ml cultures were grown to OD600 of 1.0.  The cells were harvested by 
centrifugation at 10,000 xg for 10 minutes in a RC5C centrifuge with the GSA rotor 
(Sorvall Instruments). Cells were resuspended in 10 ml of TE buffer with 50 µg ml-1 
proteinase K and incubated for one hour at 65°C. LPS was precipitated with 0.3 M 
sodium acetate and three volumes of 100% ethanol after incubation at -20◦C for 2 hours, 
the LPS was centrifuged for 10 minutes at 10,000 xg as previously described (28). The 
pellet was suspended in 5 ml of water and LPS was precipitated with ethanol and sodium 
acetate a second time. The LPS pellet was suspended in 5 ml of water with 20 µg ml-1 
each of DNase and RNase and incubated for 2 hours at 37°C.  Both 5 ml of LPS and 5 ml 
of phenol were warmed separately to 65°C then combined, mixed by vortexing, and 
incubated at 65°C for 30 minutes. LPS was then cooled on ice and centrifuged at 2000 xg 
for 10 minutes in an Allegra 6R centrifuge (Beckman Coulter). The aqueous layer and 
interface were collected. LPS was then ethanol precipitated 3X as above with 0.3 M 
sodium acetate and 100% ethanol. The LPS pellet was then suspended in 5 ml of 1% 
acetic acid and incubated at 100°C for three hours to separate the O-antigen from lipid A.  
Samples were then centrifuged at 14,000 xg for 30 minutes in a 5424 centrifuge 
(Eppendorf).  The lipid A pellet was washed in water and centrifuged again for 30 
minutes at 14,000 xg.  The lipid A pellet was suspended in 60 µl of water. Then 50 µl of 
 101 
 
methanol, and 100 µl of chloroform was added to the lipid A pellet and centrifuged at 
8,000 xg for 10 minutes.  The bottom organic layer and the interface were collected.  
Positive Ion Mode Mass Spectrometry on Lipid A 
 
Purified Lipid A samples were analyzed using a matrix-assisted laser desorption 
ionization Fourier transform mass spectrometer (MALDI-FTMS).  Spectra were obtained 
in a positive-ion mode using 1:1 matrix of methanol to 2,-5 dihydrozybenzoic acid 
(DHB). Lipid A samples were dissolved into (3:1, v/v) chloroform and methanol.   
Negative Ion Mode Mass Spectrometry on Purified Membrane Samples 
 
Purified membrane samples were analyzed in negative ion mode using electrospray 
ionization ESI/MS via direct infusion (42).  Samples were dissolved in (2:1, v/v) 
chloroform and methanol containing 1% piperidine.  Mass spectra were collected on a 
QSTAR XL quadrupole time-of-flight tandem mass spectrometer (ABI/MDS-Sciex). 
Quantitative RT-PCR 
 
Total RNA was isolated from mid exponential phase cultures using RiboPure-Bacteria kit 
(Ambion) adding TRIzol, bead beating, then adding chloroform to separate the aqueous 
phase containing the RNA. DNA was removed using DNase (Promega) for 30 minutes at 
37°C.  Quantitative reverse transcriptase PCR (qRT-PCR) was performed in a 96-well 
format using the SensiFAST SYBR One-Step Kit (Bioline) following the manufacturer’s 
protocol.  Thermocycling and detection were performed using the iCycler thermal cycler 
(Bio-Rad).  Both a positive control using a genomic DNA ladder and a negative control 
with no reverse transcriptase was analyzed for each run.  All lpxA starting quantity (SQ) 
values were normalized to the mean SQ values for gyrA.  Data represent three 
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independent experiments performed in triplicate.  Significance was determined using an 
unpaired two-tailed t-test with unequal variance.   
Anhydrotetracycline Inducible Gene Expression System for lpxA and ripA 
 
The E. coli-F. tularensis shuttle vector was created with lpxA under the control of the 
rpsLp-tetR as previously described (20). The E. coli-F. tularensis shuttle vector 
containing ripA or lpxA was introduced into wild type LVS and the ∆ripA strain via 
electroporation as described previously (23).  Transformants were selected on chocolate 
agar supplemented with 1% IsoVitalex and 200 µg ml-1 Hygromycin B (Hyg; Roche 
Applied Sciences). In F. tularensis, 100 ng ml-1 of anhydrotetracycline (ATc; Sigma-
Aldrich) was used to induce expression of lpxA or ripA as previously described (20).   
Circular Dichroism 
 
Spectra from a Chirascan Plus: steady state Circular Dichroism/Fluorescence 
spectrometer with titration and automated temperature ramping capabilities were 
recorded at 25°C using 0.1 cm water-jacketed cell.  LpxA samples were diluted to 3-10 
µM in 10 mM potassium phosphate, pH 8.0. Spectra were measured from 260 to 190 nm. 
Molar ellipticity was calculated: 
𝜃 =    𝛥𝐴𝐶 ∗ 𝐼 
ΔA is the change is CD spectra obtained from 260 to 190 nm, C is the molar 
concentration of LpxA, and I the cell path length.  Following polarimetric conversions 
molar ellipticity was reported in degrees cm2 dmol-1.  
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LpxA-His6 Purification for Enzyme Assay 
 
Strains of interest were inoculated into 500 ml of Luria-Bertani (LB) medium containing 
100 µg ml-1 of Ampicillin and were incubated while shaking at 37°C until an OD600 of 
1.0 was reached.  The cultures were induced with 1 mM IPTG followed by incubation at 
25°C for four hours.  Cells were harvested by centrifugation at 10,000 xg for 10 minutes 
at 4°C, and processed immediately or frozen at -80°C.  Cells were resuspended in 6 ml of 
20 mM Hepes, 100 mM NaCl at pH 8.0.  Cell suspensions were disrupted by French 
press at 20,000 psi.  Cellular debris was removed by centrifugation at 14,000 xg for 5 
minutes at 4°C in a 5424 centrifuge (Eppendorf).  Soluble crude cytosol was loaded onto 
3 ml of nickel-nitriol-triacetic acid (Ni-NTA) resin (Qiagen).  The resin was washed with 
10 column volumes of loading buffer containing 500 mM NaCl and then eluted with 20 
mM Hepes and 500 mM imidazole (pH 8.0).  Purified F. tularensis LpxA-His6 was 
desalted using Slide-A-Lyzer Dialysis Cassette (Thermo Scientific) and dialyzed against 
20 mM Hepes pH 8.0.  Protein concentrations were determined by BCA assay. The 
purification, and acylation of holo-ACP was carried out as described previously, except 
hydroxypalmitic acid (C16:0) was used in place of hydroxymyrstic acid (C14:0) (14).  
Fluorescent Enzyme Assay for LpxA-His6 
 
Following the procedure developed by Dotson and Jenkins, the assay was performed at 
25°C in 20 mM Hepes (pH 8.0) at a final volume of 100 µl monitoring the conversion of 
ThioGlo 1 (methyl10(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-9-methoxy-3-oxo-3H-benzo 
[f] chromene-2-carboxylate) to ThioGlo-ACP produced in the LpxA acyltransferase-
catalyzed reaction (14). To the appropriate well 40 µM of acyl-ACP, 4 mM UDP-
GlcNAc, and 10 µM ThioGlo were added.  To initiate the reaction, 10 nM LpxA-His6 
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was added directly to the well and mixed gently. The SpectraMax M2e plate reader 
(Molecular Devices) was used to continuously monitored at λex = 379 nm and λem = 513 
nm for 10 minutes at 15 second intervals. Control reactions lacking individual substrate 
or enzyme components were performed to demonstrate that an increase in fluorescence 
was both enzyme and substrate dependent. To calculate initial rates linear regression 
plots were generated for the first two minutes of the reaction. 
 
Results 
 
Extragenic Suppressor Mutation Enrichment in the ∆ripA Background 
 
As shown previously (9), following infection of host cells, wild type F. tularensis 
grew two logs in 24 hours, while typically there was no detectable growth of the ∆ripA 
strain (Fig. 1).  However, we routinely recovered colonies of the ∆ripA strain from the 
host cell cytoplasm 24 hours post invasion.  We therefore wanted to determine if any of 
the recovered ∆ripA strains had spontaneous extragenic suppressor mutations that 
restored intracellular growth. To enrich for extragenic suppressor mutations in the ∆ripA 
strain we performed several rounds of infections lasting 36 hours each in J774A.1 cells 
whereby the bacteria isolated from the first round of infections were then used to 
inoculate a new flask of J774A.1 cells (Fig. 1). Using the repeated rounds of infections in 
host cells, five independently derived extragenic suppressors of the ∆ripA strain were 
isolated.  Using whole genome sequencing with the Genome Analyzer IIx (Illumina) we 
mapped the suppressor mutations in one of the suppressors we obtained during 
enrichments in Figure 1, named S102, by conducting comparative analysis aligning the 
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sequencing reads from the suppressor mutant strain to the annotated genome on NCBI 
(NC_007880) (Table 1).  The sequencing results were remarkably similar to the 
published annotated genome, with only 4 polymorphisms detected and 55 zero coverage 
regions detected (Table 1).  Of the 55 zero coverage regions, 54 mapped to insertion 
sequence (IS) elements.  IS elements have small inverted repeats, where the short 
sequence reads cannot span the entire length of the conserved repeated sequence, 
allowing the reads to align to incorrect IS elements in the genome (Table 4).  The LVS 
genome contains 59 ISFtu1 elements and 43 ISFtu2 elements that range in size from 
about 100bp to about 900bp. The remaining zero coverage region was the ripA 
(FTL_1914) locus, confirming that the extragenic suppressor mutation was in a ΔripA 
background.   
To determine if the mutations identified by whole genome sequencing were 
unique to S102 and not just variations present in our laboratory strain, the regions of 
interest were PCR amplified and analyzed using wild type F. tularensis, ΔripA and ΔripA 
suppressor genomic DNA. All the strains tested had two polymorphisms, confirming that 
the laboratory strain is similar but not identical in sequence to the annotated genome 
online (NC_007880) (Table 1). The first polymorphism was a base pair change in 
FTL_0146, an ABC transporter ATP-binding protein that caused an R341L missense 
mutation.  The second polymorphism was a point mutation in FTL_1388, a L-aspartate 
oxidase, leading to the missense A93T mutation. The ΔripA strain contained an 
additional missense mutation in FTL_0717, ribonuclease E, K38T likely acquired during 
the deletion process of ripA.  
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The only unique mutation found in the suppressor strain, S102, was located within 
FTL_0539, which encodes LpxA (Table 1).  lpxA is located in an essential operon 
containing five genes involved in membrane synthesis.  LpxA is an acyltransferase that 
catalyzes the first step in lipid A biosynthesis, using UDP-N-acetylglucosamine (UDP-
GlcNAc) and acyl-ACP to synthesize the core component of lipopolysaccharide.  The 
polymorphism within lpxA was a point mutation leading to the substitution T36N. The 
amino acid substitution is located within the hexapeptide transferase domain close to the 
N-terminus, and not within the active pocket. Thus, the location of the mutation is 
unlikely to alter the active pocket but could alter protein stability. 
Four of the five independently derived extragenic suppressor mutations mapped to 
lpxA and the mutations resulted in amino acid substitutions located primarily along the 
left-handed helix of the short parallel β-sheet of LpxA (Fig. 2).  The fifth extragenic 
suppressor mutation mapped to a gene encoding GlmU, which is also involved in the 
synthesis of lipid A. GlmU is an essential bifunctional acetyltransferase and an 
uridyltransferase that performs the last two sequential steps in the synthesis of UDP-
GlcNAc. UDP-GlcNAc is an important component of both lipid A—the anchor of LPS, 
and peptidoglycan (Fig. 3).  S103 contained a missense mutation within the 
uridyltransferase domain of glmU resulting in a substitution E57D (Table 1).  
 
LpxA T36N Rescued Growth of ∆ripA in Eukaryotic Cells 
 
To determine if the unique mutation found in lpxA was responsible for the 
suppressor phenotype, we repaired S102 lpxA base pair mutation, changing adenine 107 
back to wild type cytosine, resulting in the reversion of T36N to N36T. S102 proliferated 
 107 
 
in 24 hours in both J774A.1 and TC-1 cells (Fig. 4A and B). The repaired lpxA abrogated 
the suppressor growth phenotype in both J774A.1 and TC-1 cells demonstrating that the 
single point mutation in lpxA was responsible for the suppressor phenotype (Fig. 4A and 
B). Given the exceptional difficulty manipulating the essential operon containing lpxA in 
F. tularensis we were unable to repair the other suppressor mutations.  
 
LpxA and RipA Co-immunoprecipitate  
 
RipA is a cytoplasmic membrane protein containing two domains that are 
essential for function and are accessible to the cytoplasm (25).  LpxA is a soluble protein 
that interacts with acyl-ACP on the cytoplasmic membrane.  To evaluate interactions 
between RipA and LpxA we performed immune precipitation reactions using F. 
tularensis lysates.  The first precipitation reaction was performed with a F. tularensis 
strain containing the wild type copy of ripA in the chromosome and lpxA-HA expressed 
from a plasmid. LpxA-HA bound to an anti-HA agarose column immunoprecipitated 
with RipA (Fig. 5). The reciprocal co-immunoprecipitation was performed with ripA-HA 
integrated into the chromosome and lpxA-V5 expressed from a plasmid. In both 
conditions LpxA and RipA co-precipitated, but the interaction was weak (Fig. 5).  The 
two proteins are likely only involved in transient binding or their interaction may be 
facilitated by another protein. Given the possibility that RipA and LpxA likely interact, 
we next wanted to determine if the localization of LpxA was altered in the ΔripA strain.  
Membrane fractions were separated using ultracentrifugation and Sarkosyl extraction for 
the strain containing lpxA-HA on a plasmid.  The soluble, inner membrane, and outer 
membrane fractions were normalized to equivalent total protein and analyzed by Western 
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blot.  LpxA-HA was present in the inner membrane fraction in both the wild type F. 
tularensis stain and the ΔripA strain, suggesting localization of LpxA was not influenced 
by the presence or absence of RipA (Fig. 6). Based on these results we conclude that 
RipA and LpxA interact in the inner membrane, but RipA does not impact the subcellular 
localization of LpxA. 
 
Membrane Composition and LPS are not Altered by the Extragenic Suppressor 
Mutation in lpxA  
 
There is substantial diversity among bacterial fatty acids profiles and F. tularensis 
is unique for its relative abundance of long chain saturated and monoenoic acids (13). F. 
tularensis LVS has a lipid content of 21% by dry weight, and the two major phospholipid 
components are phosphatidylethanolamine (PE; 76%) and phosphatidylglycerol (PG; 
24%) (2). In F. tularensis PE contains a high proportion of 24:0 fatty acids, while PG 
contains mainly C18:0 and C22:0 fatty acids. Another unique property of the membrane 
composition of F. tularensis is the abundant amount of free lipid A present on the outer 
membrane of the bacteria that is not attached to O-antigen sugars (37). In F. novicida two 
forms of free lipid A were identified: one containing a galactosamine sugar attached to 
the 1’ phosphate position (compound A1), and the other containing a glucose sugar 
attached to the 6’ OH group on glucosamine (compound A2) (37).  We analyzed the lipid 
profile of purified membrane fractions from wild type F. tularensis, ΔripA and S102 in 
order to identify any differences in the membrane composition between the strains.  As 
reported previously, the most abundant components of the purified membrane fractions 
were PE, PG, phosphatidylcholine (PC), and lipid A (Fig. 7A) (37). We also observed 
 109 
 
similar quantities of free lipid A in F. tularensis LVS as seen in F. novicida, however no 
compound A2 was detected corresponding with a glucose sugar linked to the 6’ position 
of lipid A, confirming previous findings (32, 37). In all broth grown strains analyzed, 
there was a similar composition of lipids as determined by thin layer chromatography 
(TLC) (Fig. 7A). Others have shown that F. tularensis membrane profiles changed during 
intracellular growth (3).  To determine if RipA is involved in modifying the membrane 
during host infection, we purified bacterial membrane fractions from J774A.1 cells 
infected with either wild type F. tularensis LVS or ΔripA and subsequently analyzed the 
lipid profiles by TLC.  We observed changes in the membrane composition of 
F.tularensis inside J774A.1 cells as compared to broth grown organisms, but the changes 
were not influenced by the absence of ripA (Fig. 7B).  In addition, there were no 
consistent changes among the LPS banding pattern of wild type F. tularensis, ΔripA, and 
S102 observed by western blot (Fig. 7C). 
 
Mass Spectrometry Lipid A Profiles for Wild Type F. tularensis, ΔripA, and ΔripA 
Suppressor S102 are Similar  
 
Lipid A is an essential component of the outer membrane of most Gram-negative 
bacteria (33). No deletions or transposon insertions in lpxA have been isolated in F. 
tularensis and we were not successful at making a ∆lpxA strain (unpublished results). 
Thus, it is likely that lpxA is essential in F. tularensis (11).  To determine if the 
suppressor mutation in S102 lpxA disrupted LpxA function we assessed the structure and 
quantity of lipid A produced in wild type F. tularensis LVS, ∆ripA, and S102. Purified 
lipid A was analyzed using matrix-assisted laser desorption ionization Fourier transform 
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mass spectrometer (MALDI-FTMS) in positive ion mode (Fig. 8A-C).  Each of the three 
samples contained a peak at 1549 m/z corresponding with an intact lipid A molecule with 
a 1’ phosphate and 3’ stearoyl acyl chain (3-OH C18:0).  Another peak was present in 
each sample at 1521 m/z that corresponded with lipid A containing a shorter palmitoyl 
acyl chain on the 3’ position of glucosamine (3-OH C16:0).  Confirmatory fragment ions 
that are naturally generated by neutral loss of acyl chains from the parent ion were 
observed at 683 m/z and 655 m/z corresponding with the palmitoyl and stearoyl acyl 
chains located on the 3-OH of glucosamine. These data are consistent with the previously 
published F. tularensis lipid A structures (28, 32, 37).  Similar results were obtained 
using electrospray ionization mass spectrometry ESI/MS in negative ion mode (Fig. 8D-
F).  All samples contained lipid A with the 1’ phosphate and the 3’ stearoyl acyl chain (3-
OH C18:0) at 1504 m/z.  The 1476 m/z corresponded with lipid A with the shorter 
palmitoyl chain on the 3’ position of glucosamine (3-OH C16:0). There were no unique 
structures present in the lipid A samples from the suppressor when compared to wild type 
and all strains contained detectable amounts of lipid A. However the ratio of the 18/16 
carbon chains for the ΔripA strain was consistently lower than wild type suggesting a 
preference for longer acyl chain lengths by LpxA in the presence of RipA (Fig. 8G).  
 
LpxA Protein Levels are Significantly Lower in the ΔripA Strain Compared to Wild 
Type 
 
A potential consequence of RipA-LpxA interaction is that RipA may stabilize 
LpxA.  To determine if RipA influences the stability of LpxA we first quantified the 
amount of LpxA protein present in wild type F. tularensis and the ∆ripA strain.  At one 
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hour post chloramphenicol treatment LpxA protein levels were 2-fold higher in wild type 
F. tularensis than in ∆ripA, when normalized to the loading control IglB (Fig. 9A and B). 
The LpxA-HA T36N protein levels were low in both wild type and ∆ripA, suggesting 
that the suppressor mutation in LpxA may reduce protein stability (Fig. 9A and B).  To 
further analyze whether the observed difference in LpxA protein levels were due to 
protein stability or changes in transcription, we quantified lpxA mRNA in wild type and 
∆ripA strains. We performed quantitative real time PCR on lpxA and normalized 
transcript levels to the housekeeping gene gyrA.  The relative transcript levels of lpxA 
were not significantly different between wild type F. tularensis and ∆ripA indicating that 
the regulation of lpxA is posttranscriptional (Fig. 9C).  
 
Inducing Expression of lpxA Negatively Affects the ∆ripA Strain 
 
Given that LpxA and RipA physically interact, and the protein concentration of 
LpxA in wild type F. tularensis was significantly higher than ∆ripA, we hypothesize that 
elevated levels of LpxA protein in the absence of RipA could be detrimental for growth 
and therefore responsible for the failure of ΔripA to grow in vivo. To test if LpxA activity 
and the flux of UDP-GlcNAc and acyl-ACP are important for bacterial cell viability we 
created an anhydrotetracycline (ATc) inducible expression system for lpxA to control the 
amount of LpxA present in both wild type F. tularensis and ∆ripA (20).  When lpxA 
expression was induced in the ∆ripA strain the bacteria stopped growing (Fig. 10A and 
B), whereas, growth of wild type F. tularensis was barely affected by the increased 
expression of lpxA. These results suggest that activity and amount of LpxA is very tightly 
regulated in the cell and is dependent on RipA.  Conversely, when ripA expression was 
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induced in the suppressor mutant strain containing LpxA T36N, growth of F. tularensis 
was only slightly reduced (Figure 10C and D). These results suggest that the activity or 
amount of LpxA is modulated in a RipA dependent manner.   
 
LpxA T36N is Less Stable than Wild Type LpxA and has Reduced Enzyme Activity  
 
The coils of the β-helix of LpxA are specified by hexapeptide repeats (7).  There 
are specific side-chain interactions in the parallel β-helices, where an asparagine ladder 
forms H-bonds with itself or main chain amides to stabilize the tight turn of the beta-helix 
(17).  The asparagine residue in the suppressor mutant strain could be altering the 
structure of the protein and affecting the function of LpxA. However, LpxA exhibits 
unusually high stability due to the natural nanotube formed by the left-handed parallel β-
helix and does not unfold completely until the protein reaches temperatures as high as 
525 K (7). The requirement for such high temperatures precluded a melting curve 
assessment for LpxA.  Figure 11A shows the circular dichroism (CD) spectra of LpxA 
wild type using three concentrations ranging from 125 µg ml-1 to 65 µg ml-1.  At all 
concentrations the large maximum near 194 nm and minimum near 208 nm and 220 nm 
correspond with the secondary structure of LpxA representing CD spectra for α-helices, 
left-handed β-helices, and β-turns. The molar ellipticity values for all concentrations of 
wild type were the same while the values for LpxA T36N displayed much less secondary 
structure (Fig. 11B). LpxA T36N was loaded at 65 µg ml-1, but spectra were present for 
only about 37 µg ml-1 (Fig. 11B).  The CD spectrum and molar ellipticity values for 
LpxA T36N suggests that 56% of the protein is not folded into the correct secondary 
structure and is different from wild type LpxA.  
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To determine if the T36N mutation in LpxA altered enzyme activity, we used the 
newly developed continuous fluorescent enzyme assay for LpxA, which measures the 
time-dependent turnover of LpxA catalyzed acyl group transfer (Fig. 11C) (14). The 
assay monitors the rate of holo-ACP production by detecting fluorescent ThioGlo 
1(methyl 10-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-9-methoxy-3-oxo-3H-
benzo[f]chromene-2-carboxylate) that conjugates to ACP once the acyl group is 
transferred to LpxA.  Control reactions in which individual components were omitted 
showed little increase in fluorescence, showing that the production of holo-ACP was 
being measured. Initial velocities were calculated using linear regression analysis during 
the first two minutes of the assay (Table 2).  The initial rate of LpxA T36N activity was 
33.7% lower than the initial rate of wild type LpxA from F. tularensis suggesting the 
missense T36N mutation influences the enzyme activity of LpxA (Fig. 11C).  In addition, 
we observed significant decreases in LpxA T36N enzyme activity when compared to 
wild type LpxA after freezing the protein at -80 °C for as short as 5 minutes, supporting 
the hypothesis that the LpxA T36N mutation reduces protein stability and also decreases 
enzyme activity (Fig. 11D).  The initial rate of LpxA activity for wild type was only 
reduced by 7.4% when frozen at -80 °C, while the initial rate of LpxA T36N activity 
dropped by 88.5% (Table 2). 
These data demonstrate that the suppressor LpxA T36N is less stable and less 
active than wild type LpxA.  In addition, the induced expression of lpxA in the absence of 
ripA is detrimental to bacterial growth.  Together, these findings support the conclusion 
that the amount of LpxA protein is modulated by F. tularensis in a RipA dependent 
manner, and this control is important for adaptation to the intracellular environment. 
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Discussion 
 
The main goal of this study was to ascribe biological function to RipA, a key 
factor for F. tularensis intracellular growth, by isolating, mapping and characterizing an 
extragenic mutant S102.  S102 and 4 other independently derived extragenic mutations 
mapped to lpxA or glmU.  Both enzymes (LpxA and GlmU) are essential components of 
the lipid A biosynthesis pathway.  By taking a multidisciplinary approach, combining 
genetics and biochemistry, we determined RipA influences LpxA stability and LpxA 
specificity for longer acyl chain in F. tularensis.  What remains to be determined is the 
role RipA plays during intracellular growth, and how LpxA and RipA prime the bacteria 
to survive and withstand the host defenses that usually kill invading pathogens. 
Understanding RipA function provides an important insight into the specific mechanisms 
used by F. tularensis to modulate LpxA—the first enzyme in the lipid A biosynthesis 
pathway.   
The suppressor mutation in S102 made LpxA less stable, and the induced 
expression of wild type lpxA in the absence of ripA inhibited bacterial growth, supporting 
the conclusion that the interaction between RipA and LpxA is critical for controlling the 
first step in the lipid A synthesis pathway of F. tularensis. The tight regulation of the 
lipid A biosynthesis pathway may be important for adapting the membrane to withstand 
host environmental stresses.  A decrease in the activity of LpxA may stimulate the 
phospholipid biosynthetic pathway to divert the pool of hydroxyacyl-ACP more towards 
the synthesis of phosphatidylethanolamine. Homoviscous adaptation is critical for 
bacteria to respond to environmental changes, such as in temperature, osmolality, salinity 
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and pH (41).  Phosphatidylethanolamine and phosphatidylglycerol are the two major 
phospholipids present in F. tularensis contributing to 21% of the dry weight of the 
bacteria, which is high relative to other bacteria, and may allow F. tularensis to resist a 
diverse array of host defenses (2).  Recycling of the phospholipids and sugars that are 
used as intermediates in the synthesis of outer membrane components is critical for 
bacterial bilayer stability during peak infection, and is a tightly regulated process.  During 
intracellular growth, when long chain fatty acids are in short supply it may be critical to 
control the lipid A synthesis pathway so phospholipid synthesis can continue. For 
example, LpxC (the second step in lipid A biosynthesis) is proteolyticly regulated by 
FtsH to control the activity (8). The phospholipid acyl chains determine the viscosity of 
the membrane; with unsaturated chains providing more membrane fluidity and long 
saturated chains provide more rigidity (41). F. tularensis lipid A and phospholipids are 
composed of much longer fatty acid chains than seen in E.coli,  which could in part help 
F. tularensis adapt to the intracellular environment.  We show that RipA influences LpxA 
acyl chain specificity, increasing the amount of longer C18:0 fatty acids when compared 
to the amount of C16:0 fatty acids, which may provide more rigidity to the F. tularensis 
membrane and perhaps provide more bilayer stability.  This increased rigidity of the 
membrane may protect F. tularensis from cytoplasmic stresses such as pH changes, 
which is critical for pathogenesis. This hypothesis would be in agreement with the 
elevated transcription and translation of ripA at neutral pH coinciding with F. tularensis 
leaving the acidified vacuole and entering the neutral cytoplasm (10).  
LPS is the major glycolipid molecule present on the cell surface of most Gram-
negative bacteria that constitutes the interface between the environment and the interior 
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of the bacterial cell.  LPS is made up of a hydrophobic domain known as lipid A 
(endotoxin), a non-repeating core oligosaccharide, and a distal polysaccharide (O-
antigen). The O-antigen sugars are not required for growth in the laboratory, but help 
bacteria resist antibiotics, the complement pathway, and other environmental stresses 
(31).  Lipid A is referred to as endotoxin in Gram-negative bacteria because it induces a 
massive cytokine response and production of nitric oxide when recognized by host cell 
TLR4/MD2 receptors (29). Escherichia coli lipid A is a hexa-acylated disaccharide of 
glucosamine that is phosphorylated at both 1’ and 4’ positions and is easily recognized by 
the host cell and stimulates a robust inflammatory response (38). Several pathogens, 
including F. tularensis, have evolved ways to alter their lipid A to avoid host detection by 
removing phosphate groups and acyl chains (5, 15, 37).  Specifically, F. tularensis 
expresses an enzyme LpxF that removes the 4’ phosphate and the 3’ hydroxyacyl to make 
a tetra-acylated disaccharide of glucosamine with a 1’ phosphate (35, 36).  F. tularensis 
lipid A is also unique when compared to other Gram-negative bacteria because the 
majority of lipid A is not attached to the O-antigen sugars of LPS and is referred to as 
free lipid A (37). The resulting lipid A molecule is not recognized by TLR4 and thus does 
not provoke a significant host inflammatory response (34). The ability to prevent host 
innate immune detection of lipid A is a key component in F. tularensis pathogenesis (26).  
In addition to immune evasion, LPS plays an important positive role in the assembly of 
many outer membrane proteins, and the molecular nature and biochemical basis of this 
process remains poorly understood (18).  We have only just begun to appreciate the 
complexity of this process and the genetic analysis presented here may provide important 
clues in understanding the biogenesis of the outer leaflet in the outer membrane. The O-
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antigen sugars help bacteria resist antibiotics, the complement pathway, and other 
environmental stresses such as nitric oxides (31). LPS is also important for host cell 
attachment. It is unusual for F. tularensis to have the majority of the lipid A free of O-
antigen. What role free lipid A plays in the pathogenesis of F. tularensis is not fully 
understood, but may provide a means for F. tularensis to regulate the flux and usage of 
critical substrates such as UDP-GlcNAc needed for peptidoglycan synthesis and other 
cell envelope components. F. tularensis has evolved a number of strategies to modify the 
components of the cell envelope to adapt to intracellular environments.   
In conclusion, we have identified a new protein involved in controlling LpxA acyl 
chain specificity and ultimately lipid A synthesis, which may be an important player in 
membrane remodeling during host cell infections.  However, the precise changes in F. 
tularensis membrane composition during intracellular growth need to be further 
characterized.  
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Figures 
 
Figure 4.1. Extragenic suppressor enrichment in J774A.1 macrophage like cells 
Gentamicin protection assays were performed with a multiplicity of infection (MOI) of 
100 using wild type F. tularensis, and the ∆ripA strain.  The infection was extended to 36 
hours to allow time for extragenic suppressor mutations to arise in the ∆ripA strain under 
selective pressure.  All surviving colonies were collected from the ∆ripA mutant at 36 
hours and were used to infect another flask of J774A.1 macrophages at an MOI of 100. 
Individual colonies recovered from the second infection were saved for suppressor 
analysis. 
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Figure 4.2. Extragenic suppressor mutations map to lpxA and glmU 
Four of the five independently derived extragenic suppressor mutations mapped to lpxA.  
lpxA is centrally located in an essential operon containing five genes.  The amino acid 
substitutions in LpxA were mainly located along the left-handed helix of the short 
parallel β-sheet. LpxA contains hexapeptide repeats that is a signature of an 
acetyltransferase enzyme (shown in gray). One extragenic suppressor mutation mapped 
to glmU, which is also centrally located in an essential operon containing 4 genes. The 
amino acid substitution mapped within the uridyltransferase domain located close to the 
N-terminus.  LpxA and GlmU are both involved in membrane synthesis, and both 
proteins contain hexapeptide transferase signature domains.  
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Figure 4.3. The biosynthetic pathway of LpxA and GlmU 
UDP-N-acetylglucosamine (UDP-GlcNAc) is synthesized from fructose-6-phosphate 
with the last two sequential steps synthesized by the bifunctional acetyltransferase and 
uridyltransferase, GlmU.  The substrate UDP-glucosamine is either used by LpxA in 
conjunction with acyl-ACP in a reversible reaction to make a precursor molecule of lipid 
A, or is used by MurA to make a precursor molecule of the cell wall.   
N-acetyl-D-glucosamine-1-phosphate 
UDP-GlcNAc 
UTP 
diphosphate 
GlmU 
LpxA MurA 
Lipid A 
(LPS) 
Peptidoglycan 
(Cell Wall) 
Phosphoenolpyruvate 
Phosphate 
UPD-N-acetylglucosamine-enolpyruvate UDP-3-O-[(3R)-3-hydroxyacyl]-N-acetylgulcosamine 
(3R)-3-hydroxyacyl[acp] 
holo-[acp] 
RipA 
Fructose-6-phosphate 
 121 
 
 
Figure 4.4. The S102 extragenic suppressor mutant phenotype and repair in 
J774A.1 and TC-1 cells 
Intracellular replication of wild type F. tularensis LVS, ∆ripA, S102 (T36N), and the 
strain containing the repaired S102 extragenic suppressor mutation (LpxA N36 à T) was 
assessed within J774A.1 macrophages (A) and TC-1 epithelial cells (B) using the 
gentamicin protection assay.  Each graph is the mean of three independent experiments 
done in triplicate, and the error bars represent the standard deviation.  Statistical 
significance was determined using Student’s t tests comparing LpxA T36N to ∆ripA or to 
LpxA N36 à T36. *, P < 0.05; **, P < 0.001; ***, P  < 0.0001. 
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Figure 4.5. LpxA and RipA co-immunoprecipitate 
Western blot of immune precipitated proteins from whole cell lysates of F. tularensis. 
Left two western blots demonstrate LpxA-HA C-terminal tagged protein pulls out RipA 
when probed with primary antibodies to anti-HA and anti-N-terminal RipAaa1-19.  Right 
two western blots demonstrate that RipA-HA C-terminal tagged protein pulls out LpxA-
V5 protein. Western blots on the right were probed with primary antibodies to anti-HA 
and anti-V5.  This figure is a representative of at least three independent experiments. 
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Figure 4.6. LpxA localizes to the inner membrane 
Membrane fractionation separating the soluble (Sol), inner membrane (IN), and outer 
membrane (OM) fractions using ultracentrifugation and Sarkosyl extractions.  Fractions 
from wild type LVS with lpxA-HA in trans, and the ∆ripA strain with lpxA-HA in trans 
were probed with the N-terminal RipAaa1-19 antibody for an inner membrane control, 
the IglC antibody for the soluble fraction control (a small fraction of IglC was also 
present in the inner membrane fraction), and LPS antibody for the outer membrane 
control.  The monoclonal anti-HA antibody was used to probe for LpxA-HA. This figure 
is a representative of three independent experiments. 
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Figure 4.7. Membrane and LPS composition of suppressor S102 
 (A)Thin layer chromatography on purified membrane fractions from LVS, ∆ripA, and 
S102 using the Bligh and Dyer method (8). The plate was developed in the solvent 
chloroform, methanol, water, and acetic acid (25:15:4:2, v/v/v/v) and sprayed with 10% 
sulfuric acid in ethanol and charred at 100°C for 20 minutes. (B) Thin layer 
chromatography on purified membrane fractions from J774A.1 macrophages and 
J774A.1 infection with LVS, or ∆ripA using the same Bligh and Dyer method (C) LPS 
western blots on whole cell lysates from LVS, ∆ripA, and S102.  The blot was probed 
with Francisella tularensis, LPS antibody.  All experiments shown here are 
representatives, and were repeated at least three times. 
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Figure 4.8. Mass spectrometry on lipid A and membrane fractions 
Lipid A samples were analyzed using a matrix-assisted laser desorption ionization 
Fourier transform mass spectrometer (MALDI- FTMS). Spectra were obtained in a 
positive-ion mode.  (A) Wild type LVS, (B) ∆ripA, and (C) S102 all have a peak at m/z 
1549 and m/z 1521, which corresponds with the intact lipid A molecule with a 1’ 
phosphate and a 3’ stearoyl or palmitoyl acyl chain, respectively. Purified membrane 
samples were analyzed using electrospray ionization mass spectrometer ESI/MS in 
negative ion mode.  (D) Wild type LVS, (E) ∆ripA, and (F) S102 all have a peak at m/z 
1504 and m/z 1476, which also correspond with lipid A containing either a 3’ stearoyl 
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acyl chain (3-OH C18:0) or a palmitoyl acyl chain on the 3’ position of glucosamine (3-
OH C16:O), respectively. (G) Relative abundance of stearoyl (C18:0) to palmitoyl 
(C16:0) acyl chain for wild type LVS, ∆ripA, and S102. Mass spectrometry was repeated 
at least three times and one representative experiment is shown. Statistical significance 
for acyl chain specificity was calculated using Student’s t tests with unequal variance 
comparing the wild type ratio to ∆ripA or to S102 ratios. *, P < 0.05; ***, P  < 0.00001. 
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Figure 4.9. RipA is necessary for stability of LpxA 
 (A) Relative protein concentrations were determined on mid log phase cultures treated 
with 1.75 mg ml-1 chloramphenicol for an hour to stop protein translation.  The relative 
abundance of LpxA protein was quantified using Image J with IglB as a loading control 
for equal protein from three independent experiments.  Statistical significance was 
determined by comparing LpxA-HA adjusted relative protein values for wild type to each 
of the respective mutants. *, P < 0.05; **, P < 0.005. (B) Representative western blot 
probed for LpxA-HA and IglB protein loaded with equal protein. (C) Transcript levels of 
lpxA in wild type F. tularensis and the ∆ripA strain measured by qRT-PCR.  Data 
represent the relative transcript of lpxA normalized to gyrA from three independent 
experiments done in triplicate the relative transcripts were not statistically different.    
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Figure 4.10. Induced expression of lpxA stops ∆ripA Growth 
(A) Terminal OD600 at 24 hours of strains grown in CDM with or without 100 ng ml-1 of 
anhydrotetracycline (ATc).   LVS, ∆ripA, LVS containing lpxA in trans, and ∆ripA 
containing lpxA in trans.  ATc was used to induce expression of desired genes under the 
control of the rpsLp-tetR system (9). (B) Representative growth curve in CDM with 
induced expression of lpxA or ripA using 100 ng ml-1 of ATc. (C) Terminal OD600 at 24 
hours of S102 and S102 with ripA in trans, under the control of the repsLp-tetR system. 
(D) Representative growth curve in CDM where ripA expression was induced with 100 
ng ml-1 of ATc. The growth curves were repeated at least three times and statistical 
significance was determined using Student’s t tests *, P < 0.01; **, P < 0.001.   
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Figure 4.11. Circular dichroism spectra and enzyme assay with LpxA and LpxA T36N 
(A) Circular dichroism spectra for wild type LpxA at 125 µg ml-1, 100µg ml-1, and 65 µg ml-1 
(dotted lines), and LpxA T36N at 65 µg ml-1 (solid line).  (B) Molar ellipticity calculated from the 
CD spectra (C) Graphs of the complete LpxA reaction with wild type F. tularensis LpxA-His 
(dark green), LpxA-His T36N (dotted blue), and control reactions without, either nucleotide 
(purple), acyl-ACP (light green), or acyltransferase (black). (D) Graphs of the complete LpxA 
reaction after LpxA samples were frozen at -80°C. Wild type F. tularensis LpxA-His (dark 
green), LpxA-His T36N (dotted blue), and control reactions without, either nucleotide (purple), 
acyl-ACP (light green), or acyltransferase (black). The complete LpxA mixture contained 20mM 
Hepes (pH 8.0), 40 µM 3-hydroxypalmitoyl-ACP, 4 mM UDP-GlcNAc, 10 nM F. tularensis 
LpxA-His6 (added 5 minutes after ThioGlo) in a final volume of 100ul.  The reaction was 
incubated at 25°C, and its progress was monitored continuously at λex = 379 nm and λem = 513 
nm for 10 minutes at 15 second intervals.  Control reactions were run in a similar fashion with the 
omission of substrate or enzyme as indicated. Each graph is a representative of three experiments.   
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Tables 
 
Table 4.1. Whole genome sequencing results for suppressor S102 
 
Table 1. Polymorphisms detected by whole genome sequencing 
Gene Name Amino Acid Location Polymorphism verified 
FTL_0146 ABC transporter ATP 
binding protein 
R341L 152667 
1023bp from start 
wt, ΔripA, and S102 
FTL_0539 
(lpxA) 
UDP-N-
acetylglucosamine 
acyltransferase 
T36N 522331 
107 bp from start 
Unique to S102 
FTL_0717 
(rne) 
Ribonuclease E K38T 709489 
114 bp from start 
ΔripA, and S102 
FTL_1388  
(nadB) 
L-aspartate oxidase A93T 1317802 
278bp from start 
wt, ΔripA, and S102 
 
 
Table 4.2. Initial rate of LpxA-catalyzed acyl group transfer 
 
 
Name Initial rate (µM / sec) Statistical Significance 
LpxA wt 0.6648 ± 0.179 *, P < 0.05 
LpxA T36N 0.4408 ± 0.103 
LpxA wt frozen 0.6155 ± 0.263 ***, P < 0.0001 
LpxA T36N frozen 0.0509 ± 0.0196 
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Table 4.3. Bacterial Strains, Plasmids, and Primers 
 
Strain, 
Plasmid, or 
Primer  
Genotype, Phenotype, or Sequence  Source  
Bacterial 
Strains  
  
E. coli 
DH10B 
E. coli F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1endA1 araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ-  
Invitrogen  
E. coli Top10 E. coli F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 
recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG 
λ-  
Invitrogen  
E. coli DH5 
α 
E. coli φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rK-, mK+) phoA supE44 thi-1 gyrA96 relA1 λ- 
Invitrogen 
E. coli 
BL21(DE3) 
pLysS 
E.coli F-, ompT, hsdSB (rB-, mB-), dcm, gal, λ(DE3), pLysS, Cmr Promega 
F. holarctica 
LVS 
Francisella tularensis subsp. holarctica LVS (taxid:376619) CDC  
∆ripA Francisella tularensis subsp. holarctica LVS (9) 
RipA-HA Francisella tularensis subsp. holarctica LVS with RipA-HA 
chromosomally integrated  
(25) 
SKI12  E.coli BL21(DE3) pLysS with LpxA-His6 from F. tularensis LVS This work  
SKI13  E.coli BL21(DE3) pLysS with LpxA-His6 D144N from F. tularensis 
LVS S101 
This work  
SKI14 E.coli BL21(DE3) pLysS with LpxA-His6 T36N from F. tularensis 
LVS S102 
This work 
SKI15 E.coli BL21(DE3) pLysS with RipA-His6 from F. tularensis LVS This work 
SKI16 Francisella tularensis subsp. holarctica LVS with LpxA T36N This work 
SKI17 Francisella tularensis subsp. holarctica LVS with LpxA N36àT This work 
SKI18 Francisella tularensis subsp. holarctica LVS containing pSKI07 This work 
SKI19 Francisella tularensis subsp. holarctica LVS ∆ripA containing 
pSKI07 
This work 
SKI20 Francisella tularensis subsp. holarctica LVS containing pSKI08 This work 
SKI21 Francisella tularensis subsp. holarctica LVS ∆ripA containing 
pSKI08 
This work 
SKI22 Francisella tularensis subsp. holarctica LVS containing pSKI09 This work 
SKI23 Francisella tularensis subsp. holarctica LVS containing pEDL20 (23) 
SKI24 Francisella tularensis subsp. holarctica LVS ∆ripA containing (23) 
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pEDL20 
SKI25 Francisella tularensis subsp. holarctica LVS ∆ripA containing 
pSKI09 
This work 
SKI26 Francisella tularensis subsp. holarctica LVS with RipA-HA 
chromosomally integrated with pSKI10 
This work 
SKI27 Francisella tularensis subsp. holarctica LVS with pSKI10 This work 
Plasmids    
pSKI05 pET23a+lpxA-His6 from F. tularensis LVS AmpR This work 
pSKI06 pET23a+lpxA-His6 T36N from F. tularensis LVS S102 AmpR This work 
pSKI07 pMP822 with LpxA-HA HygR  blaB promoter This work 
pSKI08 pMP822 with LpxA-HA T36N HygR  blaB promoter This work 
pSKI09 FTRp-lpxA, rpsLp-tetR, HygR This work 
pSKI10 FTRp-lpxA-V5, rpsLp-tetR, HygR This work 
pSKI11 pMP812 with wt F. tularensis lpxA This work 
pEDL20 FTRp-ripA, rpsLp-tetR, HygR (20) 
pET23a+ N-terminal T7-Tag / C-terminal His-Tag with T7 promoter  (14) 
pMP812 sacB suicide vector, KanR, SucS (21) 
pMP590 sacB suicide vector, KmR, SucS (23) 
pMP822 E.coli-F.tularensis shuttle vector, HygR blaB promoter (22) 
pMP831  E.coli-F. tularensis shuttle vector, HygR  (21) 
pEDL50  Conjugative sacB suicide vector, HygR, SucS  (20) 
Primers 5’à3’  
Sequencing Validation  
FTL_0146F ggatgagcctttttctgcac This work 
FTL_0146R gcataacgagcccagtcaat This work 
FTL_0717F ggcgaagaaacaagaattgc This work 
FTL_0717R atgacgatagaaccgccaga This work 
FTL_1388F gcaggtgtagttgctgctattg This work 
FTL_1388R atcatcgcactgccattacc This work 
FTL_0453F tatcagcagcagcaacttgg This work 
FTL_0453R ccaactattgcaccttcacg This work 
FTL1914F atccggcgaagatttcatta This work 
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FTL1914R tgaggtaaccaagcaatttcg This work 
FTL_0539F tgttgagaaagctggtggtg This work 
FTL_0539R ttcgcgaagtaccaatcaca This work 
Chromosomal Gene Disruption and Vector Cloning 
LpxA F ggcggtccgctaatcgtgatacatagtttggcagtagtacatgag This work 
LpxA-HA R  cccctcgagttatccaccaccagcataatctggaacatcataaggatagccacctcttagtata
cctcttcgcgaagtac 
This work 
LpxA-V5 R gggacccgggttatccagtagaatctagtcctagtagtgggtttggtattggttttcctcctctta
gtatacctcttcgcgaagtac 
This work 
LpxA F 
pET23 
cagcatatgctaatcgtgatacatagtttggcagtagtacatgag This work 
LpxA R 
pET23 
cccctcgagtcttagtatacctcttcgcgaagtacc This work 
Real Time PCR  
gyrA RT F ctatacgctagtagatggacaaggtaactt This work 
gyrA RT R ctatacgctagtagatggacaaggtaactt This work 
lpxA LVS F gtcgtggatttacgcctgaagag This work 
lpxA LVS R tcttcttttgccatcgctttg This work 
Underlined text indicates restriction sites 
Bold and underlined text indicates His-tag, HA-tag, or V5 tag 
 
 
Table 4.4 Zero Coverage Regions Detected by Whole Genome Sequencing 
Zero Coverage Regions Detected 
  
Gene Name   Location 
 
    Size start stop 
FTL_0678 isftu1 315 665342 665657 
FTL_0678 isftu1 215 665722 665937 
FTL_0678 isftu1 11 666002 666013 
FTL_0678 isftu1 79 666074 666153 
FTL_0969 isftu1 2595 937366 939961 
FTL_0969 isftu1 151 938026 938177 
FTL_1127 isftu1 881 1072296 1073177 
FTL_1195 isftu1 150 1143319 1143469 
FTL_1195 isftu1 215 1143534 1143749 
FTL_1446 isftu1 211 1372642 1372853 
FTL_1446 isftu1 432 1372918 1373350 
FTL_1462 isftu1 390 1386695 1387085 
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FTL_1462 isftu1 429 1387150 1387579 
FTL_1463 isftu2 159 1387646 1387805 
FTL_1463 isftu2 499 1387862 1388361 
FTL_1471 isftu1 794 1395471 1396265 
FTL_1505 isftu1 389 1437352 1437741 
FTL_1505 isftu1 434 1437806 1438240 
FTL_1516 isftu2 162 1446331 1446493 
FTL_1516 isftu2 535 1446562 1447097 
FTL_1572 isftu2 600 1500255 1500855 
FTL_1572 isftu2 130 1500922 1501052 
FTL_1610 isftu1 323 1538210 1538533 
FTL_1610 isftu1 506 1538519 1539025 
FTL_1627 isftu1 150 1556619 1556769 
FTL_1627 isftu1 216 1556834 1557050 
FTL_1627 isftu1 390 1557115 1557505 
FTL_1630 isftu1 888 1560158 1561046 
FTL_1643 isftu1 151 1573322 1573473 
FTL_1643 isftu1 219 1573538 1573757 
FTL_1643 isftu1 391 1573818 1574209 
FTL_1680 isftu2 345 1614000 1614345 
FTL_1687 isftu1 434 1620255 1620689 
FTL_1687 isftu1 311 1620754 1621065 
FTL_1718 isftu1 395 1649522 1649917 
FTL_1718 isftu1 434 1649974 1650408 
FTL_1757 isftu1 435 1691942 1692377 
FTL_1757 isftu1 389 1692442 1692831 
FTL_1815 isftu1 392 1748889 1749281 
FTL_1815 isftu1 435 1749342 1749777 
FTL_1851 isftu2 716 1782910 1783626 
FTL_1885 isftu1 313 1818680 1818993 
FTL_1885 isftu1 434 1819054 1819488 
FTL_1891 isftu1 434 1822911 1823345 
FTL_1891 isftu1 389 1823410 1823799 
FTL_1894 transposase (IS4) 429 1825412 1825841 
FTL_1914 ripA 535 1847061 1847596 
FTL_1925 isftu1 390 1857283 1857673 
FTL_1925 isftu1 289 1857738 1858027 
FTL_1925 isftu1 76 1858094 1858170 
FTL_1926 isftu2 158 1858699 1858857 
FTL_1944 isftu1 75 1873330 1873405 
FTL_1944 isftu1 9 1873472 1873481 
FTL_1944 isftu1 219 1873542 1873761 
FTL_1944 isftu1 390 1873826 1874216 
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Chapter 5  
 
PanG, A New Ketopantoate Reductase Involved in Pantothenate Synthesis12 
 
Overview 
 
Pantothenate, commonly referred to as vitamin B5, is an essential molecule in the 
metabolism of living organisms and forms the core of coenzyme A.  Unlike humans, 
some bacteria and plants are capable of de novo biosynthesis of pantothenate making this 
pathway a potential target for drug development.  Francisella tularensis subspecies 
tularensis Schu S4 is a zoonotic bacterial pathogen that is able to synthesize 
pantothenate, but is lacking the known ketopantoate reductase (KPR) genes, panE and 
ilvC, found in the canonical Escherichia coli pathway. Described herein is a gene 
encoding a novel KPR, for which we propose the name panG (FTT1388) that is 
conserved in all sequenced Francisella species and is the sole KPR in Schu S4.  
                                                
1 Reprinted with permission from: Cheryl N. Miller, Eric D. LoVullo, Todd M. Kijek, 
James R. Fuller, Jason C. Brunton, Shaun P. Steele, Sharon A. Taft-Benz, Anthony R. 
Richardson, and Thomas H. Kawula. PanG, a new ketopantoate reductase involved in 
pantothenate synthesis. J. Bacteriol. 2013, 195(5):965 DOI: 10,1128/JB.01740-12. 
 
2 Attributions: Cheryl Miller performed all the experiments in this chapter with the 
following exceptions. Eric LoVullo helped developing the project and helped create the 
KPR double deletions in F. novicida and E. coli (Figure 2). Eric LoVullo also created the 
plasmids pEDL70 and pEDL71 for the complementation experiments. Todd Kijek and 
James Fuller initially started the project on pantothenate by repairing the LVS panD 
mutation (Figure 7).  
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Homologs of this KPR are present in other pathogenic bacteria such as Enterococcus 
faecalis, Coxiella burnetii, and Clostridium difficile.   Both the homologous gene from E. 
faecalis V583 (EF1861) and the E. coli panE functionally complemented Francisella 
novicida lacking any KPR.  Furthermore, panG from F. novicida can complement an 
E.coli KPR double mutant. A Schu S4 ∆panG strain is a pantothenate auxotroph and was 
genetically and chemically complemented with panG in trans or with the addition of 
pantolactone. There was no virulence defect in the Schu S4 ∆panG strain as compared to 
wild type in a mouse model of pneumonic tularemia. In summary, we characterized the 
pantothenate pathway in Francisella novicida and tularensis and identified an unknown 
and previously uncharacterized KPR that can convert 2-dehydropantoate to pantoate, 
PanG.   
Introduction 
 
Coenzyme A (CoA) is a ubiquitous cofactor found in all domains of life and plays a 
central role in carbon and energy metabolism. Pantothenate forms the core of CoA; 
however animals and some microorganisms lack the ability to synthesize pantothenate.  
The pantothenate biosynthetic pathway is present in some plants, fungi, bacteria and 
archaea making the pathway a strong candidate for the discovery of novel antibiotics 
(22).  The pantothenate biosynthesis pathway was first genetically and chemically 
defined in Escherichia coli and Salmonella enterica serovar Typhimurium and is 
composed of four enzymes that use the precursors 2-oxoisovalerate and L-aspartic acid to 
make pantothenate (9, 27) (Fig. 1A).  In one branch of the pathway aspartate-1-
decarboxylase, PanD, converts L-aspartate to β-alanine and in a separate branch two 
enzymes PanB, a ketopantoate hydroxymethyltransferase, and PanE, a ketopantoate 
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reductase (KPR), convert 2-oxoisovalerate to pantoate (8).  The acetohydroxy acid 
isomerase, IlvC, has also been shown to function as a KPR in E. coli and S. Typhimurium 
converting 2-dehydropantoate to pantoate, similar to PanE (11, 36). In some species, e.g. 
Corynebacterium glutamicum, IlvC is the sole KPR (29).  In the final step of the 
pantothenate synthesis pathway, pantoate and β-alanine are ligated by the pantothenate 
synthase, PanC, to form pantothenate (6).  The published genomes of Francisella species 
contain panB, panC, and panD.  No homolog of E. coli PanE exists in the sequenced 
Francisella genomes and the most virulent strain of F. tularensis Schu S4 contains a 
frameshift mutation in ilvC suggesting a gap in the pantothenate biosynthetic pathway. 
Combining the known nutritional requirements of Francisella species with the sequenced 
genomes revealed that several strains require exogenous pantothenate for growth (30).   
Interestingly, the most virulent strain Schu S4 lacks a recognizable KPR and is a 
pantothenate prototroph, while LVS has a KPR but is clearly auxotrophic (4, 21).  The 
genetic basis for differences in the requirement for pantothenate among Francisella 
strains is not known.   
Francisella belongs to the γ-proteobacteria and includes a number of species that 
share greater than 95% genomic similarity but differ in their ability to cause the disease 
tularemia in humans (5, 37).  Of all the species, Francisella tularensis subsp. tularensis is 
the most virulent exhibiting the highest morbidity and mortality, while also having a very 
low infectious dose of less than 10 bacteria (21, 39). F. tularensis subsp. holarctica is 
also highly infectious for humans but clinical disease associated with this bacterium is 
typically mild (42). The live vaccine strain (LVS) was derived from a F. tularensis subsp. 
holarctica strain and is attenuated in humans.  Francisella novicida is rarely associated 
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with human disease. As a facultative intracellular pathogen, Francisella must acquire the 
nutrients needed to support growth while within host cells. Several genetic screens for 
replication defective mutants have implicated biosynthetic pathways as contributing 
factors to the pathogenesis of Francisella species (34).  Interruption in genes involved in 
purine, aromatic amino acids, and biotin biosynthesis results in attenuation of F. 
tularensis within a mouse model of tularemia (31-33, 44). Collectively, these studies 
highlight the contribution of de novo biosynthetic pathways to the ability of F. tularensis 
to survive within the host environment.  Using F. novicida, a genome wide mutant screen 
identified two genes contained in the putative pantothenate operon that are required for 
pulmonary and systemic infections in mice. Inactivation of FTN_1351 (panG) or FTN-
1355 (coaX) resulted in mutant strains impaired in their ability to proliferate in the organs 
of infected mice (20). Furthermore, transcriptional profiling of F. tularensis revealed a 
dramatic increase in expression of the F. tularensis homologs of panB, panC and panD, 
as well as the homologs of FTN_1351 (panG) and FTN_1355 (coaX) in strains grown 
within bone marrow derived macrophages. This suggests that pantothenate biosynthesis 
may play a role in adaptation of Francisella to its intracellular niche (46).  The 
requirement for de novo synthesis of pantothenate in virulence was demonstrated in a 
different intracellular pathogen, Mycobacterium tuberculosis where a double mutant in 
panC and panD was attenuated in both BALB/c and SCID mouse models of infection 
(38).   Collectively the published data suggests that pantothenate biosynthesis may 
contribute to virulence of Francisella and the disparity in the requirement for 
pantothenate among Francisella strains led us to investigate the genetic basis for 
pantothenate biosynthesis in several species of Francisella.   
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Materials And Methods 
 
Bacterial strains and cell culture 
 
Escherichia coli strains (Table 1) were grown at 37◦C in Luria-Bertani (LB) broth, on LB 
agar, or in M9 minimal media supplemented with 1 µg/ml thiamine, 3.4 mM valine, 3 
mM isoleucine, and 3 mM leucine.  Unless otherwise noted all F. tularensis strains 
(Table 1) were grown at 37◦C on chocolate agar (25 g BHI l-1, 10µg hemoglobin l-1, 15g 
agar l-1) supplemented with 1% IsoVitalex (Becton-Dickson) or in Chamberlain’s 
Defined Medium (CDM) (4).  When necessary Hygromicin B (Hyg; Roche Applied 
Science) was used at 200 µg ml-1, sucrose was used at 5% for E.coli or 10% for F. 
tularensis (w/v), Ampicillin (Amp; Roche Applied Science) was used at 100 µg ml-1, L-
arabinose (Sigma-Aldrich) was used at 10 mM, and Kanamycin (Km; Sigma-Aldrich) 
was used at 50 µg ml-1 for E. coli and 10 µg ml-1 for F. tularensis. 
Growth Assays 
 
Growth assays for F. tularensis and F. novicida were performed at 37◦C while shaking in 
an Infinite M200 or M200 pro (Tecan) in 96 well microtiter plates with absorbance 
(OD600) monitored every fifteen minutes.  Bacterial strains grown overnight on chocolate 
agar were resuspended in PBS to a Klett reading of 100 (approximately 1 X109 CFU/ml).  
Resuspended cultures were diluted 1:20 into test media.  The test media consisted of 
CDM, or CDM without calcium pantothenate (Sigma-Aldrich).  Genetic 
complementation in trans was evaluated in CDM lacking pantothenate.   Chemical 
complementation was evaluated in CDM lacking pantothenate and supplemented with 
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100 µM pantolactone (Sigma-Aldrich), which can act in place of pantoate (43) or 100 
µM β-alanine (Sigma-Aldrich).     
Construction of a double mutant using Flp/Frt recombination in F. novicida 
To create the ilvC::Tnflp/panG::Tn mutant (“flp” signifies a cured Km cassette) we 
performed Flp-mediated recombination of ilvC::Tn bearing the T20 insertion by 
introducing pFFlp-hyg, a temperature-sensitive plasmid, by electroporation and isolated 
Km sensitive colonies grown at 30◦C (14). Removal of the Km cassette left an 80 base 
pair insertion with the expected single FRT site remaining. Once the Km resistance 
marker was excised pFFlp-hyg was cured by growing the culture overnight at 37◦C.  The 
panG mutation was introduced by transformation of genomic DNA from the panG::Tn 
strain into the ilvC::Tnflp mutant and selecting for Km resistant colonies, creating the 
double mutant (14).  For genetic complementation mutant strains were transformed with 
their respective plasmids (25).  Plasmids were first transformed with the addition of 1 µl 
of TypeOne Restriction Inhibitor (Epicentre) into a restriction mutant FTN_1698::Tnflp 
strain (14). 
Construction of the E.coli double mutant ilvC::flp/panE::kan using FLP/FRT 
recombination and λ-Red recombineering 
 
Using λ-Red recombineering the double mutant ilvC::flp/panE::kan mutant (“flp” 
signifies a cured Km cassette) was created in E. coli by first introducing pFlp2 into 
ilvC::kan (JW3747-2) by electroporation and isolated Km sensitive colonies (2, 10). 
Removal of the kanamycin cassette left the signature single FRT site of FLP/FRT 
recombination creating ilvC::flp. Once the Km resistance marker was excised pFlp2 was 
cured by growing the culture overnight and plating on LB with 5% sucrose minus NaCl 
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and the resulting colonies were screened for Amp sensitivity.  Next the λ-Red 
recombineering plasmid, pKD46, was introduced into the ilvC::flp strain by 
electroporation (17).  When the absorbance of ilvC::flp with pKD46 reached 0.1 OD600, 
10mM of L-arabinose was added to induce expression of the λ-Red recombineering 
proteins: Gam, Bet and Exo. The panE::kan mutation was introduced by transformation 
into the ilvC::flp mutant using PCR fragments generated from genomic DNA of 
panE::kan (JV0415-1) and colonies were selected for Km resistance. 
F. novicida Coenzyme A levels  
 
F. novicida was grown overnight on chocolate agar plates at 37◦C then resuspended to an 
absorbance of 0.2 OD600 in 50ml of CDM lacking pantothenate and incubated for 5 hours.  
The cells were pelleted at 10,000 x g for 5 minutes at 4◦C and then resuspended in 0.5ml 
of cold PBS and snap frozen in liquid nitrogen.  The cells were thawed and bead beaten 2 
times for 30 seconds at 4◦C using lysing matrix B tubes (MP Biomedicals).  Cell debris 
was removed by centrifuging at 14,000 x g for 2 minutes.  Protein concentration was 
determined by BCA assay for each sample.  To deproteinize the lysates 100µl of cold 1N 
perchloric acid was added to each sample and centrifuged at 14,000 x g at 4◦C for 2 
minutes to pellet precipitated protein.  To neutralize the supernatant 30µl of cold 3M 
potassium bicarbonate was added to the samples.  The concentrations of CoA were 
determined for each sample using PicoProbeTM Acetyl CoA Assay Kit (BioVision).  The 
manufacturer’s protocol was followed except the CoA quenching solution was not used, 
thereby allowing us to determine total concentration of CoA in each sample. 
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Replacing LVS panD (panDLVS) with F. novicida panD (panDU112) 
 
The putative panD (FTN_1354) allele was PCR amplified from F. novicida genomic 
DNA. The amplified DNA was subcloned into the TOPO pCRII vector (Invitrogen) for 
propagation and maintenance.  The BamHI-NotI fragment containing the F. novicida 
panD allele was ligated into the sacB suicide vector pMP590 and electroporated into 
LVS.  Allelic exchange was performed as previously described (26).   
Deletion of FTT1388 (panG) in Schu S4 
 
The putative panG (FTT1388) allele plus 300bp of DNA flanking each end was PCR 
amplified from F. tularensis Schu S4 genomic DNA.  The amplified fragment was cut 
with BamHI and NotI then ligated into the sacB suicide vector, pEDL50 (24).  Using 
splice junction PCR FTT1388 (panG) was eliminated from the plasmid creating a product 
with AatII restriction sites on either end.  The PCR product was digested with AatII and 
ligated, forming pSKI01. Conjugation and allelic exchange were then performed to 
introduce the clean in frame deletion of panG into F. tularensis Schu S4 as previously 
described (18, 24).   
Mouse infection 
 
Groups of six-week-old C57BL/6 mice were anesthetized and inoculated intranasally 
with 50 CFU of Schu S4 or Schu S4 ∆panG (FTT1388). Mice were euthanized on days 1 
and 3 post-infection and lungs, livers, and spleens were aseptically removed and 
homogenized into 2ml of sterile PBS using a Biojector (BIOSPEC Products, Inc.).  
Bacterial CFU for each organ were enumerated by plating serial dilutions of tissue 
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homogenates onto chocolate agar. The infection experiments were approved and 
performed according to the animal care and use guidelines established by IACUC.  
Results 
 
Organization of the Francisella pantothenate biosynthesis pathway 
 
The advances in whole genome sequencing have made identification of metabolic 
pathways through the use of sequence homology common.  However, little experimental 
evidence is associated with these annotations and gaps exist in many annotated metabolic 
pathways including F. tularensis and F. novicida.  Bioinformatics analysis suggests the 
pantothenate biosynthesis pathway in F. novicida is much like E. coli, putatively using 
PanB, PanD, PanC, and IlvC to convert L-aspartate and 2-oxoisovalerate into 
pantothenate (Fig. 1A). Using F. novicida blastp (NCBI) generated Expect values of 
7e10-69 for PanB, 6e10-58 for PanC, 3e10-20 for PanD, and 8e10-22 for IlvC relative to the 
characterized E. coli K12 enzymes (1).  Interestingly, no homolog of E. coli PanE was 
identified in any of the 36 sequenced Francisella genomes.  In addition the ilvC gene in 
F. tularensis Schu S4 contains a frameshift mutation, which creates a premature stop 
codon after amino acid 74 suggesting a gap in the pantothenate biosynthetic pathway. 
LVS also has a truncation in the panD gene shortening the encoded protein from 111 
amino acids to 91 amino acids. 
Unlike E. coli, the panB, panC, and panD genes of Francisella species are organized into 
a predicted operon (Fig. 1B and C), which is conserved in all the sequenced Francisella 
strains (13). In addition to panBCD, this putative operon contains additional predicted 
Open Reading Frames (ORF) both 5’ and 3’ of panBCD (Fig. 1C).  There is an annotated 
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ORF immediately 5’ of panBCD that encodes an uncharacterized conserved protein 
(panG) containing a domain of unknown function, DUF2520 (28).  The ORF 3’ of 
panBCD encodes a putative type III pantothenate kinase (CoaX), which catalyzes the first 
dedicated step in CoA synthesis from pantothenate (3, 47).  Francisella tularensis also 
contains another coaX homolog, FTT0112, which is not part of the putative operon. 
The Francisella panBCD genes are required for growth in the absence of pantothenate 
 
We used the F. novicida comprehensive two-allele transposon mutant library to assess 
the functionality of individual components of the pantothenate biosynthesis pathway (15). 
The pantothenate biosynthetic pathway in F. novicida was characterized by 
complementing auxotrophic mutants with metabolic intermediates of pantothenate 
biosynthesis.   
FTN_1352 (PanB) is a ketopantoate hydroxymethyl transferase that catalyzes the 
conversion of 2-oxoisovalerate to 2-dehydropantoate (Fig. 1A).  Functional inactivation 
of panB results in mutant strains deficient in 2-dehydropantoate and loss of pantothenate 
synthesis.  The panB::Tn exhibited limited growth in CDM lacking pantothenate and 
growth of this mutant was restored by supplementation with pantolactone (an alternative 
substrate to pantoate) (Fig. 2A) thereby bypassing the PanB/IlvC branch (43).   
Supplementation with β-alanine alone was not sufficient to support growth of this mutant 
(Fig. 2A) demonstrating that FTN_1352 functions in the PanB/IlvC branch of the 
pathway and is consistent with the annotation of FTN_1352 as panB.   
FTN_1353 (PanC) encodes pantothenate synthase, which catalyzes the formation of 
pantothenate from L-pantoate and β-alanine (Fig. 1A).  Inactivation of panC results in a 
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strain that requires the addition of pantothenate for growth and neither supplementation 
with pantolactone nor β-alanine rescued growth. This indicates that the FTN_1353 
transposon mutation interrupts the pantothenate biosynthesis pathway downstream of 
both the PanD and PanB/IlvC branches, consistent with the phenotype of a pantothenate 
synthase mutant (Fig. 2B).   
FTN_1354 (PanD) is a L-aspartate α-decarboxylase that forms β-alanine from L-
aspartate (Fig. 1A) and inactivation of panD results in a strain that is auxotrophic for β-
alanine.  Consistent with this phenotype panD::Tn exhibited growth defects in CDM 
lacking pantothenate and was rescued by the addition of β-alanine.  Supplementation 
with pantolactone failed to restore growth of panD::Tn (Fig. 2C). These results 
demonstrate that inactivation of FTN_1354 results in a loss of β-alanine synthesis and are 
consistent with the prediction that FTN_1354 is a functional PanD (8).   
FTN_1040 (IlvC) is known to function as an acetohydroxy acid isomerase essential for 
branch chain amino acid synthesis and can also function as a KPR in E. coli and S. 
Typhimurium (35). As the only recognized enzyme with KPR activity within F. novicida 
genome, we were surprised to find that the ilvC::Tn transposon mutant in F. novicida did 
not require pantothenate for growth (Fig. 2D).  This result suggested that there was 
another unrecognized enzyme with sufficient KPR activity to support pantothenate 
biosynthesis within F. novicida ilvC::Tn.  
FTN_1351 (panG) is annotated as an uncharacterized conserved gene and is part of the 
putative pantothenate operon, so we tested the panG::Tn pantothenate growth 
requirement.  Under each condition panG::Tn grew suggesting that either PanG may not 
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be involved in pantothenate synthesis or it is functionally redundant with IlvC in KPR 
activity (Fig. 2E).   
To determine if IlvC in F. novicida is a functional acetohydroxy acid isomerase we grew 
wild type F. novicida U112 and ilvC::Tn in CDM with and without branch chain amino 
acids (Fig. 2F).  Only wild type U112 could grow in CDM without branch chain amino 
acids supporting our hypothesis that IlvC is functioning as an acetohydroxy acid 
isomerase in F. novicida.   
A new class of ketopantoate reductase found in a number or pathogenic organisms 
 
Ketopantoate reductases (KPR) have a dinucleotide-binding domain called a Rossmann-
fold that consists of a βαβ pocket to accommodate the coenzyme NADPH (23).  Within 
the Rossmann-fold is a consensus sequence GXGXXG, which appears at the border 
between the first beta sheet and the alpha helix (16).  In E. coli the PanE N-terminal 
Rossmann-fold domain and the C-terminal alpha-helical domain form a cleft, and at that 
cleft is a conserved-essential residue Lys176 that forms the hydrogen bond with C2 
hydroxyl of pantoate (6).  Pantoate also forms additional interactions with conserved 
residues Ser244, Asn98, and Asn180 (6).  PanE and IlvC each have an N-terminal 
NADB_Rossmann superfamily domain (28).  IlvC is an acetohydroxy acid isomerase, 
which can also function as a KPR and requires two cofactors NADPH and Mg2+ for the 
reduction of 2-dehydropantoate (40).   
Bioinformatic analysis of PanG (FTN_1351) gave little insight into its function.  The 
comparison of the sequence to PanE and other known KPR revealed no significant 
matches (11, 41).  Phylogenetic analysis indicated that PanG is in a distinct group 
separate from annotated KPRs using the Jukes-Cantor genetic distance model (Fig. 3). 
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There is no Rossmann domain identified in the C-terminal region of FTN_1351 and the 
GXGXXG motif is not present (16). The C-terminal region of FTN_1351 has a domain 
of unknown function, DUF2520 (E-value of 1.5e10-6), that often accompanies an N-
terminal Rossmann domain suggesting the protein could function as an uncharacterized 
KPR (28). We made a double mutant, ilvC::Tnflp/panG::Tn, in F. novicida to determine 
if FTN_1351 protein could function as a KPR.  The double mutant did not grow in media 
lacking pantothenate (Fig. 4A).  Growth of the double mutant was restored when 
complemented in trans with panG expressed under its native promoter, with ilvC driven 
by the Francisella blaB promoter or when the media was supplemented with 
pantolactone (Fig. 4A and B). This result confirms that IlvC is active in the F. novicida 
pantothenate metabolic pathway and that FTN_1351 is a novel KPR, which we named 
panG. Homologs of PanG are also found in other pathogenic bacteria including 
Enterococcus faecalis, Coxiella burnetii, and Clostridium difficile. Blastp analysis of F. 
tularensis Schu S4 PanG (FTT1388) revealed that this protein has significant homology 
with  Enterococcus faecalis V583 (EF1861) ( Expect value = 2e10-11 ), Coxiella burnetii 
(CBU1660)( Expect value = 2e10-7), and Clostridium difficile (CD630-15140) ( Expect 
value = 8e10-6 ) (1). In E. faecalis and C. difficile the panG genes are organized similarly 
in putative pantothenate operons (Fig. 1B).  Expression of the E. faecalis V583 gene in F. 
novicida ilvC::Tnflp/panG::Tn  restored growth of this mutant strain to near wild type 
levels in CDM lacking pantothenate, confirming genetically that EF1861 is a functional 
KPR (Fig. 4C).  PanE an analog KPR from E. coli (EC 1.1.1.169) is not present in any 
sequenced genome of Francisella, and expression of this gene restored growth of F. 
novicida ilvC::Tnflp/panG::Tn in media lacking pantothenate (Fig. 4D).  Expression of 
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the F. novicida panG gene in the E.coli KPR double mutant, ilvC::flp/panE::kan, restored 
growth in M9 minimal media lacking pantothenate, confirming genetically that PanG is a 
functional KPR in E.coli  (Fig. 4E). 
Francisella novicida Coenzyme A Levels 
 
Coenzyme A is made from pantothenate, cysteine, and adenosine and is an essential 
cofactor in the first step of the TCA cycle.  To determine the contribution of PanG and 
IlvC in the production of pantothenate synthesis and subsequent CoA synthesis we 
measured the concentration of CoA after five hours of pantothenate depletion in wild 
type F. novicida, ilvC::Tn, panG::Tn, and ilvC::Tnflp/panG::Tn.  CoA levels were not 
significantly different between wild type and ilvC::Tn suggesting that PanG can fulfill the 
requirement for KPR activity in F. novicida (Fig. 5).  The CoA levels of the panG::Tn 
mutant strain were less than half of wild type levels and similar to the 
ilvC::Tnflp/panG::Tn double mutant suggesting that PanG is responsible for the majority 
of KPR activity in F. novicida (Fig. 5).   
Francisella tularensis LVS is a β-alanine auxotroph 
 
Early studies revealed varying nutritional requirements of Francisella strains for 
pantothenate that appeared to correlate with virulence in mice (4, 30). We assessed the 
requirement for pantothenate with three different strains of Francisella: F. tularensis 
Schu S4, F. tularensis LVS, and F. novicida U112.  Each strain grew logarithmically in 
complete CDM (Fig. 6A-D).  F. tularensis Schu S4 and F. novicida U112 grow 
logarithmically under each dropout condition suggesting both strains have complete 
pantothenate biosynthesis pathways (Fig. 6).  However, F. tularensis LVS failed to grow 
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in media without pantothenate indicating that LVS is a pantothenate auxotroph.  This 
result is in agreement with the observations of Chamberlain (4).  Additionally, we 
observed that growth of LVS could be restored by the addition of β-alanine indicating 
that LVS lacks PanD activity (Fig. 6D).  Comparison of the nucleotide sequences of the 
putative panGBCD genes among Francisella species revealed that F. tularensis LVS 
contains a base substitution in the annotated panD gene.  This substitution creates a Q92 
Ochre stop, resulting in a truncation of PanD by 20 amino acids.  To determine if LVS β-
alanine auxotrophy is due to a non-functional panD, we replaced panDLVS with the 
functional panDU112 via allelic exchange.  As predicted, F. tularensis LVS harboring the 
panDU112 allele grew similarly in CDM with or without added pantothenate (Fig. 7). This 
demonstrates that the observed pantothenate auxotrophy of LVS results from a lack of 
PanD activity.  This truncation in PanD is unique to LVS, we questioned whether the lack 
of PanD activity contributed to the attenuated phenotype of this strain. However, repair of 
panD activity in F. tularensis LVS panDU112 did not confer a competitive advantage 
relative to F. tularensis LVS panDLVS in a mouse model of pneumonic tularemia (data 
not shown).  Thus, the LVS panD mutant allele does not contribute to the attenuated 
phenotype of this strain.   
Francisella tularensis Schu S4 ∆panG is a pantothenate auxotroph 
 
The ∆panG (FTT1388) strain in Schu S4 requires pantothenate for growth, and can be 
rescued with the addition of pantolactone in CDM lacking pantothenate or with panG 
expressed in trans.  Schu S4 does not have a functional IlvC protein, at least in regards to 
its KPR activity, due to a frameshift mutation, making PanG the sole KPR. The ∆panG 
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strain can be complemented in trans with the panG gene from F. novicida driven by the 
F. novicida native promoter (Fig. 8B).  Given that F. novicida panG (FTN_1351) was 
identified in a screen to be required for virulence in a mouse model of infection (20) and 
F. tularensis panG, panB, panC, panD and coaX genes were highly upregulated within 
bone marrow derived macrophages, suggested that pantothenate production and 
ultimately CoA synthesis may play a role in adaptation of Francisella to its intracellular 
niche (46). We wanted to determine if ∆panG was important for infection in mice.  With 
an intranasal inoculum of 50 CFU we saw no difference in lung, liver or spleen burdens 
when comparing ∆panG to wild type Schu S4 at one or three days post inoculation (Fig. 
8C-E).  
Discussion 
 
Pantothenate forms the core of Coenzyme A and is a precursor to acyl carrier protein 
(ACP) making it essential in both energy and lipid metabolism.  We characterized the 
genes that function in pantothenate biosynthesis in Francisella using genetic and 
chemical complementation approaches. These genes are organized into a putative operon, 
which also included a hypothetical protein, PanG (FTN_1351), that we discovered is a 
novel KPR responsible for converting 2-dehydropantoate to pantoate.  PanG (FTN_1351) 
does not have the known conserved Rossmann-domain that is typically associated with 
KPRs.  However, PanG does contain a C-terminal DUF2520, which usually accompanies 
an N-terminal Rossmann-like domain.  PanG rescued growth of an E. coli KPR double 
mutant in the absence of pantothenate and the panG homolog from E. faecalis V583 
(EF1861) complemented KPR function in the F. novicida double mutant.  EF1861 also 
contains a predicted C-terminal DUF2520 domain in addition to a predicted N-terminal 
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Rossmann-like domain.  The panG genetic data (FTN_1351 and EF1861) suggest the 
DUF2520 domain is involved in KPR activity.  Further biochemical characterization of 
PanG needs to be done to determine structural binding motifs and enzymatic activity.  
Normally KPR proteins bind cofactors such as NAD or NADP; more work needs to be 
done to characterize what cofactor, is required for PanG KPR activity.  There is no 
GXGXXG motif in PanG, which is responsible for NADP-binding in E. coli, however 
amino acids 11-16 are GXGXXA, which is found in mitochondrial flavoenzymes that 
bind NADP (16).  Using secondary structure predictions of PanG, the GXGXXA 
consensus sequence starts right at the junction of a β-sheet and an α-helix that would be 
compatible with a KPR βαβ fold-forming sequence (7).    
Functional complementation assays demonstrated that expression of panB, panC and 
panD were each required for growth of F. novicida in media devoid of pantothenate.  In 
regard to KPR activity, only an ilvC::Tnflp/panG::Tn double mutant of F. novicida 
created a pantothenate auxotroph, demonstrating that PanG is functionally redundant with 
the acetohydroxy acid isomerase, IlvC. Both the panG homolog from E. faecalis V583 
and the known panE gene encoding a KPR from E. coli DH10B could functionally 
complement the F. novicida KPR double mutant ilvC::Tnflp/panG::Tn.  CoA levels were 
not significantly different between wild type and ilvC::Tn after five hours of pantothenate 
depletion demonstrating that PanG can fulfill the requirement for KPR activity in F. 
novicida.  CoA levels in both the panG::Tn mutant strain and the ilvC::Tnflp/panG::Tn 
double mutant were less than half the concentration of wild type suggesting PanG is 
responsible for the majority of KPR activity in F. novicida.  We also found that the LVS 
strain is a β-alanine auxotroph resulting from a base substitution in panD causing an 
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amino acid substitution shortening the aspartate-1-decarboxylase.  While the lack of 
PanD activity appears unique to the LVS strain, it does not contribute to the attenuation 
of this strain in mice.  In addition, the Schu S4 frameshift in ilvC produced a 
nonfunctional protein, in regards to KPR activity.  We demonstrated that PanG is the sole 
KPR in Schu S4 since creating an in frame panG deletion resulted in a pantothenate 
auxotroph.  However, the Schu S4 ∆panG strain did not have a demonstrable virulence 
defect in a mouse model of pneumonic tularemia. It is not clear where or what molecule 
this mutant acquired from the host to satisfy its pantothenate requirement. Given that 
mice have a blood plasma pantothenate level of 20µM, while humans only have 2-4µM, 
it is possible that a F. tularensis pantothenate synthesis mutant could be attenuated in 
humans but not mice (45). It is possible that mice have excess pantothenate in their blood 
stream considering their diet is supplemented with pantothenate in addition to that 
naturally acquired from their gut flora.  E. coli can produce and secrete 15 times more 
pantothenate than required for CoA biosynthesis, and ruminants obtain sufficient 
quantities of pantothenate from their gut microorganisms (12, 19).  Virtually all bacteria, 
including F. tularensis, can take up pantothenate, but F. tularensis does not have an 
annotated panF homolog responsible for sodium-cotransport of pantothenate (22).  It 
appears F. tularensis is able to obtain pantothenate, a CoA precursor (such as 
phosphopantheine), or CoA from the host and is likely storing sufficient quantities of 
pantothenate to support logarithmic growth for several rounds of replication while inside 
cells where pantothenate may be limited.  Pantothenate is immediately phosphorylated 
once taken up by host cells and could affect F. tularensis ability to acquire pantothenate. 
Further work will be needed to determine how F. tularensis acquires pantothenate or 
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other substituents of CoA from the host.  It may be a valuable endeavor to look further 
down in the CoA pathway for potential drug targets for Francisella tularensis, starting 
with the putative type III pantothenate kinases (FTT1392 and FTT0112), which is the 
first committed step in CoA biosynthesis. 
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Figures 
 
 
 
Figure 5.1. The biosynthetic pathway in Francisella species and the putative 
pantothenate operon. 
 (A.) The pantothenate biosynthetic pathway consists of two converging arms.  PanB the 
ketopantoate hydroxymethyltransferase converts 2-oxoisovalerate with tetrahydrofolate 
to form 2-dehydropantoate. The substrate 2-dehydropantoate is then converted to (R)-
pantoate by a number of enzymes including IlvC and PanG that are both capable of 
ketopantoate reductase (KPR) activity.  On the other branch of the pathway PanD, an 
aspartate-1-decarboxylase, converts L-aspartic acid to β-alanine. The pathway converges 
with PanC, the pantothenate synthase that ligates (R)-pantoate with β-alanine to form 
pantothenate. Molecules were made in PubChem Compound on NCBI and the pathway 
was constructed using KEGG metabolic pathway 00770 as a reference 
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http://www.genome.jp/kegg-bin/show_pathway?FTN_00770. (B.) The genomic 
organization of the putative pantothenate operon is conserved among sequenced 
Francisella strains containing the genes panGBCD and the pantothenate kinase coaX. 
(C.) Synteny diagram of the putative operon in F. novicida, F. tularensis LVS, F. 
tularensis Schu S4, E. faecalis V583, and C. difficile 630 (13). 
  
 160 
 
 
Figure 5.2. Functional complementation of panB::Tn, panC:Tn, panD::Tn, ilvC::Tn, and 
panG::Tn. 
Functional complementation of the pantothenate biosynthetic genes in F. novicida transposon 
mutant strains grown in 96 well microtiter plates with absorbance (OD600) monitored every fifteen 
minutes in CDM lacking pantothenate (grey) either supplemented with β-alanine (black dotted 
line), pantolactone (grey dotted line), or calcium pantothenate (black). (A.) panB::Tn (B.) 
panC::Tn (C.) panD::Tn, (D.) ilvC::Tn, and (E.) panG::Tn.  (F.) F. novicida U112 and ilvC::Tn 
growth in CDM with and without branch chain amino acids. U112 in CDM (black), ilvC::Tn in 
CDM (grey), U112 in CDM without branch chain amino acids (black dotted line), and ilvC::Tn in 
CDM without branch chain amino acids (grey dotted line). Each growth curve was repeated a 
minimum of three times and the graph represents the mean of three replicate experiments. 
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Figure 5.3. Phylogenetic tree of known ketopantoate reductase proteins and PanG. 
The phylogenetic tree of known KPR proteins and PanG was generated using Geneious 
Pro 5.5.6 Tree Builder with the cost matrix set to identity and Jukes-Cantor as the genetic 
distance model with no outgroups.  All IlvC, and PanE proteins are annotated on PubMed 
to be involved in pantothenate synthesis, while all PanG proteins are annotated as 
hypothetical proteins.  Enterococcus faecalis V583 PanG is annotated as a hypothetical 
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protein EF1861, Clostridium difficile 630 PanG is annotated as a hypothetical protein 
CD630-15140, Coxiella burnetii RSA 493 PanG is annotated as a hypothetical protein 
CBU_1660, Clostridium botulinum BKT015925 PanG is annotated as a hypothetical 
protein CbC4_0183, and Desulfotomaculum nigrificans DSM 574 PanG is annotated as a 
hypothetical protein DUF2520 protein.  
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Figure 5.4. Genetic complementation of the F. novicida, and E. coli KPR double 
mutant with panG. 
Genetic complementation of the F. novicida ilvC::Tnflp/panG::Tn double mutant with F. 
novicida FTN_1351 panG gene, F. novicida ilvC gene, E. faecalis V583 (EF1861) panG 
gene, E. coli panE and genetic complementation of E.coli ilvC::flp/panE::kan double 
mutant with F. novicida panG.  Functional complementation experiments were carried 
out by growing Francisella in CDM lacking pantothenate in 96 well microtiter plates and 
measuring the absorbance (OD600) every fifteen minutes for 30 hours. Competent F. 
novicida were transformed with DNA (A.) pSKI01 encoding F. novicida panG 
(FTN_1351) driven by its native promoter, (B.) pSKI04 encoding ilvC from F. novicida 
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driven by F. tularensis blaB promoter, (C.) pEDL71 encoding panG from E. faecalis 
driven by F. tularensis blaB promoter, or (D.) pEDL70 encoding panE from E. coli 
driven by F. tularensis blaB promoter.  ilvC::Tn grown in CDM lacking pantothenate 
containing an empty control vector pMP822/pMP831 (black), the double mutant 
ilvC::Tnflp/panG::Tn containing an empty control vector (grey), ilvC::Tnflp/panG::Tn 
containing the respective complementing plasmid (black dotted line),and 
ilvC::Tnflp/panG::Tn grown in CDM supplemented with pantolactone (grey dotted line). 
(E.) E.coli double mutant ilvC::flp/panE::kan complemented with pSKI01 encoding F. 
novicida panG driven by its native promoter.  ilvC::kan grown in M9 media lacking 
pantothenate containing an empty control vector (black), the double mutant 
ilvC::flp/panE::kan containing an empty control vector (grey), ilvC::flp/panE::kan 
containing the respective complementing plasmid (black dotted line),and 
ilvC::flp/panE::kan grown in M9 supplemented with pantolactone (grey dotted line). 
Each growth curve was repeated three times and the graph represents the mean of three 
replicate experiments. 
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Figure 5.5. F. novicida Coenzyme A levels. 
CoA concentrations were measured from 50ml cultures of wild type F. novicida, 
ilvC::Tn, panG::Tn, and ilvC::Tnflp/panG::Tn after 5 hours of pantothenate depletion.  
All strains were grown to the same OD600 and were normalized to total protein.  The CoA 
levels represented are the mean ± SD for three independent experiments. Statistical 
significance was determined by comparing the mutant values to wild type F. novicida. 
***, P < 0.0001; ** P < 0.001.  
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Figure 5.6. F. tularensis Schu S4, F. tularensis LVS, F. novicida growth in 
pantothenate drop out media. 
Growth curves of F. tularensis subspecies tularensis Schu S4 (black), F. tularensis 
subspecies holarctica LVS (black dotted line) and F. novicida U112 (grey) were 
monitored in (A.) CDM, (B.) CDM lacking pantothenate, (C.) CDM lacking pantothenate 
supplemented with pantolactone, or (D.) CDM lacking pantothenate supplemented with 
β-alanine.  Each strain was grown in triplicate in 96 well microtiter plates with 
absorbance (OD600) monitored every fifteen minutes over 40 hours. Each graph 
represents the mean of three replicate experiments.   
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Figure 5.7. Repair of F. tularensis LVS β-alanine auxotrophy. 
Growth curves of LVS (grey) and LVS with the native panDLVS replaced with panDU112 
from F. novicida U112 (black). Each strain was monitored in (A.) CDM, (B.) CDM 
lacking pantothenate.  Both strains were grown in 96 well microtiter plates and (OD600) 
determined every fifteen minutes for 24 hours. Each graph represents the mean (OD600) 
of three replicate experiments.    
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Figure 5.8. F. tularensis subspecies tularensis Schu S4 ΔpanG growth and virulence 
phenotype. 
 (A.) Chemical complementation of Schu S4 ∆panG grown in CDM (black), CDM 
lacking pantothenate (black dotted line), CDM lacking pantothenate supplemented with 
β-alanine (grey), and CDM lacking pantothenate supplemented with pantolactone (grey 
dotted line).  (B.) Genetic complementation of F. tularensis subspecies tularensis Schu 
S4 ∆panG with F. novicida panG gene expressed by the native promoter in the shuttle 
vector pMP831. Growth curve of F. tularensis subspecies tularensis Schu S4 (black), F. 
tularensis subspecies tularensis Schu S4 ∆panG with pMP831 (empty control vector) 
(grey), and F. tularensis subspecies tularensis Schu S4 ∆panG complemented with 
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pSKI01 (black dotted line).  All growth curves were done in triplicate monitoring 
absorbance (OD600) in a 96 well microtiter dish.  Graphs represent the mean absorbance 
at OD600. (C-E.) Recovery of Schu S4 or Schu S4 ∆panG mutant in mice following i.n. 
inoculation.  C57BL/6 mice were infected intranasally with either wild type Schu S4 
(black circles) or Schu S4 ∆panG (grey triangles) at a lethal dose of 50 CFU. Mice were 
euthanized on days 1 and 3 post infection and (C.) lung burdens, (D.) liver burdens and 
(E.) spleens burdens were determined and graphed.  Each symbol represents data from a 
single mouse.  There were no significant differences in recovery of mutant versus wild 
type organisms from any organ at any time point as determined by the nonparametric 
Mann-Whitney test. 
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Tables 
 
Table 5.1. Bacterial strains and plasmids 
 
Strain or Plasmid  Genotype or Phenotype  Source  
Bacterial Strains    
E. coli DH10B E. coli F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1endA1 araD139 Δ(ara leu) 
7697 galU galK rpsL nupG λ-  
Invitrogen  
E. coli Top10 E. coli F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacΧ74 recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL 
(StrR) endA1 nupG λ-  
Invitrogen  
E. coli panE::kan 
JW0415-1 
E. coli ∆(araD-araB)567, ∆lacZ4787(::rrnB-3), 
∆panE782::kan,λ-, rph-1,∆(rhaD-rhaB)568, hsdR514 
Keio 
Collection 
E. coli ilvC::kan 
JW3747-2 
E. coli ∆(araD-araB)567, ∆lacZ4787(::rrnB-3), λ-, rph-1, 
∆ilvC725::kan, ∆(rhaD-rhaB)568, hsdR514 
Keio 
Collection 
F. novicida U112  Francisella tularensis subsp. novicida U112 (taxid:401614)  ATCC  
F. holarctica LVS Francisella tularensis subsp. holarctica LVS (taxid:376619) CDC  
F. tularensis Schu S4 Francisella tularensis subsp. tularensis SCHU S4 
(taxid:177416)  
BEI 
Resources  
E. faecalis  V583  Lance 
Thurlow  
panB::Tn  
 
tnfn1_pw060328p05q156 T20 (ISFn2/FRT)  (FTN_1352) Gallagher, et 
al. 2007 
panC::Tn  tnfn1_pw060328p03q178 T20 (ISFn2/FRT)  (FTN_1353) Gallagher, et 
al. 2007 
panD::Tn  tnfn1_pw060323p04q175 <Kan-2> (FTN_1354) Gallagher, et 
al. 2007 
panG::Tn  tnfn1_pw060420p03q142 T20 (ISFn2/FRT)  (FTN_1351) Gallagher, et 
al. 2007  
ilvC::Tn  tnfn1_pw060420p04q122 T20 (ISFn2/FRT) (FTN_1040) Gallagher, et 
al. 2007 
FTN_1698::Tnflp tnfn1_pw06032p08q164 (“flp” signifies a cured kanamycin 
cassette) 
This work 
ilvC::Tnflp/panG::Tn  tnfn1_pw060420p04q122flp/tnfn1_pw060420p03q142 
(“flp” signifies a cured kanamycin cassette)  
This work  
SKI01  F. tularensis Schu S4 ∆panG  This work  
SKI02  F. novicida U112 ilvC::Tnflp/panG::Tn with pEDL70  This work  
SKI03  F. novicida U112 ilvC::Tnflp/panG::Tn with pEDL71  This work  
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SKI04  F. novicida U112 ilvC::Tnflp/panG::Tn with pSKI01  This work 
SKI05  F. tularensis Schu S4 ∆panG with pSKI01  This work 
SKI06  F. tularensis Schu S4 ∆panG with pMP831 empty vector 
control  
This work  
SKI07  F. novicida U112 ilvC::Tnflp/panG::Tn with pMP831 
empty vector control  
This work  
SKI08  F. holarctica LVS with panD from F. novicida U112 This work  
SKI09 E. coli ilvC::flp/panE::kan  (JW0415-1 and JW3747-2) This work 
SKI10 E. coli ilvC::flp/panE::kan  (JW0415-1 and JW3747-2) with 
pSKI01 
This work 
SKI11 E. coli ilvC::flp/panE::kan  (JW0415-1 and JW3747-2) with 
pSKI04 
This work 
Plasmids    
pFFLP-hyg  Encodes flp under Francisella groEL promoter for 
recombination of FRT sites, TempSens, HygR 
Gallagher, et 
al. 2008 
pKD46 λ-Red recombineering plasmid GenBank: J02459.1 
TempSens, AmpR 
Datsenko, et 
al. 2000 
pFlp2 Encodes flp recombinase for recombination of FRT sites, 
AmpR, SucS 
Hoang, et al. 
1998 
pEDL70  pMP822.panE, HygR  This work  
pEDL71  pMP822.EF1861, HygR  This work  
pSKI01  pMP831.panG  FTN_1351, HygR  This work  
pSKI02 pEDL50 with ∆panG Schu S4 construct, KmR, SucS This work 
pSKI03 pMP590 with panDU112 (FTN_1354), KmR, SucS This work 
pSKI04 pMP822.ilvC, HygR This work 
pMP590 sacB suicide vector, KmR, SucS LoVullo, et al. 
2006 
pMP822 E.coli-F.tularensis shuttle vector, HygR blaB promoter LoVullo, et al. 
2009 
pMP831  E.coli-F. tularensis shuttle vector, HygR  LoVullo, et al. 
2009  
pEDL50  Conjugative sacB suicide vector, HygR, SucS  LoVullo, et al. 
2012  
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Chapter 6 	  
 
Discussion, Conclusions, And Future Directions 
 
Substantial progress has been made identifying virulence factors in F. tularensis 
while I conducted my graduate research. During the last five years a total of 765 journal 
articles have been published on the species F. tularensis alone.  Highlighted below are 
some of the key findings that were instrumental to understanding F. tularensis and the 
disease tularemia. 
Progress has been made in characterizing the Francisella pathogenicity island 
(FPI) in the most virulent strain F. tularensis subsp. tularensis with the creation of 
several double deletion mutants.  Interestingly, the phenotype of the double deletion of 
pdpC was different when compared to the same mutant in F. novicida (12, 13).  Further 
characterization of the secreted components of the FPI in F. tularensis LVS showed 
fundamental differences when compared to F. novicida, where IglE, IglC, VgrG, IglI, 
PdpE, PdpA, IglJ and IglF were all detected to be secreted in F. tularensis, while only 
IglE, IglC, PdpA and PdpE were detected to be secreted in F. novicida (6).  A basic 
understanding of the biochemical interactions that form the secretion system is needed. 
One example of a thorough characterization of two interacting components within the 
pathogenicity island was done with IglA and IglB (5).  
Colin Manoil’s group was able to assign function to many proteins that were 
previously unknown and uncharacterized using the comprehensive transposon mutant 
library in F. novicida under a variety of stress and nutritional conditions (10).  Their 
 178 
 
screen identified a new phosphofructokinase, an unusual proline biosynthetic pathway, 
and a novel antibiotic resistance mechanism, all of which differ from those present in 
model species (10).  
With current advancements in technology we are now able to see dissemination in 
real time of Francisella species in mice using a microPET scanner monitoring 
radiolabeled 64Cu F. novicida (15).  Ojeda’s work has shown that the pulmonary route is 
associated with rapid septicemia, and that the cecum is a novel site of colonization of 
Francisella novicida in mice.  
Francisella noatunesis is a recently identified species that is a serious pathogen of 
Atlantic cod (Gadus morhua), causing significant losses to the Norwegian aquaculture 
industry (18).  The genome sequence for Francisella noatunesis was just published in 
2012, which will allow scientists the opportunity to identify new potential drug targets 
and characterize the unique properties of this species of Francisella (18). A reservoir 
outside the fish host has yet to be identified for F. noatunesis.  
LPS modification has been known to be a common strategy employed by bacterial 
pathogens to avoid innate immunity.  Recently a two-component Kdo (3-deoxy-D-
manno-octulosonic acid) hydrolase was identified that catalysis the removal of a side 
chain Kdo sugar from LPS precursors in F. tularensis, which is essential for preventing 
host proinflammatory cytokine production in a TLR2 dependent manner (16). 
Earlier in 2009, researchers identified a heat stable bacterial component 
responsible for suppressing dendritic cell response to different Toll-like receptor agonists 
(7). This component is one example of a mechanism used by F. tularensis to control the 
host environment for optimal bacterial growth. Recently, Weiss et al, and we showed that 
the lipid composition of F. tularensis changes in response to the host cell environment 
 179 
 
when compared to culture grown bacteria (Chapter 5) (2).  The exact compositional 
changes have not been identified and further work needs to be done to characterize the 
new lipids that help F. tularensis adapt to the hostile host environment. The FabI enoyl-
acyl carrier protein reductase gene was identified to be essential to bacterial viability 
during infection and could be responsible for some of the lipid composition differences 
seen during intracellular growth (11).   
The host immune response is suppressed between 2 and 6 hours after F. tularensis 
infection indicating there may be unknown mechanism used by F. tularensis to suppress 
the immune response (4). Identifying these potential effectors will be key to 
understanding the control mechanisms used by F. tularensis to manipulate the host 
environment for optimal bacterial growth. DnaK is a recently identified protein that 
interacts with the host plasma alkaline phosphatase and inhibits its activity, which may be 
one mechanism used by F. tularensis to control the inflammatory response and create an 
advantageous environment in the host for bacterial growth (1).  
A recent study examined immune responses in BALB/c mice vaccinated with 
mutant strains of F. tularensis that elicited varying degrees of protection against systemic 
and aerosol challenges with the wild type strain (17).  They established correlates of 
protection in animal models that can relate to human vaccines, and identified that the 
ΔclpB mutant elicits superior protection compared to the live vaccine strain (17).  Our 
laboratory demonstrated that the F. tularensis clpB mutant altered host immunity and 
induced the expression of two proinflammatory cytokines, IFN-gamma and IL-17 (3). 
We have only recently appreciated the role autophagy plays in F. tularensis 
growth and virulence inside host cells.  Autophagy was thought to be a mechanism 
involved in breakdown of cellular components and clearance of invading pathogens. 
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Cells clear the replication deficient mutant, ΔdipA, in F. tularensis in an autophagy 
dependent manner (8). Only recently has autophagy been shown to have a positive role 
for a few pathogens, including Brucella abortus (19). Earlier transcriptional analysis of 
host cells infected with F. tularensis provided evidence that F. tularensis affects 
expression of many genes involved in autophagy (9).  Our lab recently published work 
demonstrating that ATG5 independent autophagy provides amino acids for F. tularensis 
to support intracellular growth (in press). The mechanisms and potential effectors used by 
F. tularensis to manipulate the host and acquire nutrients form autophagosomes remains 
a tantalizing avenue to explore. 
 In this dissertation we identify a F. novicida specific virulence factor, IclR, which 
is a transcriptional regulator responsible for controlling the expression of genes that are 
lost or disrupted in the more virulent F. tularensis strains (Chapter 2).  Future studies 
with IclR include characterization of the specific IclR regulated genes responsible for the 
virulence differences in F. novicida and F. tularensis, and determining how these 
evolutionary changes impact pathogenesis of the F. tularensis.  
We developed the first anhydrotetracycline inducible and repressible system for 
F. tularensis to control gene expression (Chapter 3) (14).  Regulated expression systems 
are instrumental tools for identifying the unique mechanism used by F. tularensis to 
control gene expression and biosynthetic pathways.  Using this tool we determined the 
induced expression of lpxA was detrimental for growth of F. tularensis lacking the ripA 
locus, while the wild type strain containing ripA was unaffected by the production of 
lpxA (Chapter 4).  With this genetic tool we can continue to assign function to more 
genes in Francisella. 
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We identified the function of a key virulence factor, RipA by isolating, mapping 
and characterizing an extragenic mutant, S102 (Chapter 4).  S102 and 4 other 
independently derived extragenic mutations mapped to lpxA or glmU.  Both enzymes 
(LpxA and GlmU) are essential components of the lipid A biosynthesis pathway.  We 
determined RipA influences LpxA stability and LpxA specificity for C18:0 compared to 
C16:0 acyl chain in F. tularensis. What remains to be determined is the role RipA plays 
during intracellular growth, and how LpxA and RipA may modify the bacterial 
membrane to adapt to the host environment.  Understanding RipA function provides an 
important insight into the specific mechanisms used by F. tularensis to modulate LpxA—
the first enzyme in the lipid A biosynthesis pathway.   
RipA homologs are also found in several randomly distributed prokaryotic 
species, and include mainly non-pathogenic organisms.  To date there are only four 
pathogenic bacteria known to have RipA homologs, and the role these homologs play in 
virulence is unknown.  It is likely that RipA is a conserved virulence factor unique to 
Francisella. RipA homologs are present in Gram-positive bacteria that do not make lipid 
A.  If RipA is important for modulating LpxA, the enzyme responsible for the first step in 
lipid A biosynthesis, why is RipA present in organisms that do not make lipid A? Future 
complementation studies performed with the RipA homologs from other prokaryotes 
expressed in F. tularensis ΔripA would help determine if Francisella has evolved a 
unique virulence mechanism distinct from other prokaryotes.  The complementation 
studies may also identify another function for RipA that has broader application to 
include more Gram-positive organisms.  
The original immunoprecipitation experiments performed by James Fuller with 
RipA identified multiple putative RipA-interactors, including LpxA.  Interestingly, IclR 
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was also identified to be a RipA interacting protein, however we were unable to identify a 
role RipA played in IclR transcription regulation in F. tularensis (unpublished results 
Brittany Mortensen). It may be interesting to determine if RipA helps regulates gene 
expression in other prokaryotic organisms containing IclR transcriptional regulators.   
In chapter 4 we characterized one extragenic suppressor mutant of ΔripA that 
restored growth inside host cells, S102, but there remain 4 other independently derived 
extragenic suppressor mutants that need to be characterized.  One extragenic suppressor 
mutation mapped to glmU.  We repaired the mutation within glmU and demonstrated that 
the mutation was responsible for the suppressor phenotype (unpublished results). We 
performed immunoprecipitation reactions with GlmU and RipA, however no interaction 
was identified (unpublished results).  We measured protein concentrations of GlmU in 
the absence and presence of RipA and found no differences in concentrations 
(unpublished results).  We induced expression of glmU in the wild type strain and the 
ΔripA strain to determine if RipA is important for modulating GlmU activity, however 
we did not see any growth defects as seen with lpxA induced in the ΔripA strain 
(unpublished results).  The connection between GlmU and RipA remains an enigma.  It 
seems likely that RipA binds and modulates LpxA activity, while GlmU is only indirectly 
involved with RipA considering GlmU performs the two sequential steps prior to LpxA 
in the lipid A synthesis pathway. 
In addition to identifying RipA function, we also identified a novel ketopantoate 
reductase (KPR), PanG, involved in vitamin B5 synthesis that converts 2-dehydropantoate 
to pantoate (Chapter 5). As a facultative intracellular pathogen, F. tularensis must acquire 
or synthesize the nutrients needed to support growth while within host cells. The genes 
involved in vitamin B5 biosynthesis are very highly expressed in F. tularensis during 
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infection, supporting that they may contribute to the pathogenesis of F. tularensis (20).  
We experimentally validated the annotation of the vitamin B5 synthesis pathway in F. 
tularensis and identified a gap in the pathway of the most virulent strain F. tularensis 
Schu S4. Homologs of this novel KPR are also found in other pathogenic bacteria such as 
Clostridium difficile, Coxiella burnetii, and Enterococcus faecalis, demonstrating broad 
implication for our understanding of bacterial vitamin B5 synthesis. 
The culmination of this work has provided new genetic tools that aided in the 
characterization of two novel proteins, one involved in lipid A synthesis and the other 
involved in vitamin B5 synthesis. 
This research identifying function of novel proteins in Francisella tularensis has 
led to the following finding: 
1) Francisella tularensis and F. novicida have a distinctly different set of virulence 
factors owing to the fact that the IclR transcriptional regulator is important for the 
pathogenesis in F. novicida, while dispensable for F. tularensis pathogenesis due 
to reductive evolution of the more virulent strain.  
2) Developing the anhydrotetracycline inducible expression system for F. tularensis 
has been a powerful tool used to characterizing RipA function. 
3) By mapping extragenic suppressor mutations of ΔripA we determined the 
function of RipA in F. tularensis.  The location of the suppressor mutations 
mapped to two genes, lpxA and glmU, both involved in lipid A biosynthesis.  
RipA modulates the activity and amount of LpxA in F. tularensis and could be a 
unique virulence mechanism specific to Francisella species to adapting to the 
host environment.  
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4) We identified a novel ketopantoate reductase (KPR), PanG, involved in vitamin 
B5 synthesis. Homologs of PanG are also found in three other pathogenic bacteria 
such as Clostridium difficile, Coxiella burnetii, and Enterococcus faecalis, 
demonstrating broad implication for our understanding of bacterial vitamin B5 
synthesis.   
 
In this study we identified the function of novel proteins in Francisella tularensis, 
one of the six classified Category A Select Agents, which is a pathogen that has evolved 
unique strategies to survive in a broad range of hosts.  We believe that the most important 
goal of research in the F. tularensis field should focus on characterizing the genes with 
unknown function important for infection and pathogenesis, and we have used this 
motivation for the research and findings we reported in this dissertation.   
Within the last decade, numerous screens have been developed to identify 
virulence factors of F. tularensis, and now is the time to assign novel function to the 
many virulence factors that remain unknown. 
  
 185 
 
References 
 
1. Arulanandam, B. P., S. L. Chetty, J. J. Yu, S. Leonard, K. Klose, J. Seshu, A. 
Cap, J. J. Valdes, and J. P. Chambers. 2012. Francisella DnaK inhibits tissue-
nonspecific alkaline phosphatase. The Journal of biological chemistry 287:37185-
37194. 
 
2. Barker, J. H., J. W. Kaufman, D. S. Zhang, and J. P. Weiss. 2013. Metabolic 
labeling to characterize the overall composition of Francisella Lipid A and LPS 
grown in broth and in human phagocytes. Innate Immun. 
 
3. Barrigan, L. M., S. Tuladhar, J. C. Brunton, M. D. Woolard, C. J. Chen, D. 
Saini, R. Frothingham, G. D. Sempowski, T. H. Kawula, and J. A. Frelinger. 
2013. Infection with Francisella tularensis LVS clpB leads to an altered yet 
protective immune response. Infect Immun 81:2028-2042. 
 
4. Bradburne, C. E., A. B. Verhoeven, G. C. Manyam, S. A. Chaudhry, E. L. 
Chang, D. C. Thach, C. L. Bailey, and M. L. van Hoek. 2013. Temporal 
transcriptional response during infection of type II alveolar epithelial cells with 
Francisella tularensis live vaccine strain (LVS) supports a general host 
suppression and bacterial uptake by macropinocytosis. The Journal of biological 
chemistry 288:10780-10791. 
 
5. Broms, J. E., M. Lavander, and A. Sjostedt. 2009. A conserved alpha-helix 
essential for a type VI secretion-like system of Francisella tularensis. Journal of 
bacteriology 191:2431-2446. 
 
6. Broms, J. E., L. Meyer, K. Sun, M. Lavander, and A. Sjostedt. 2012. Unique 
substrates secreted by the type VI secretion system of Francisella tularensis 
during intramacrophage infection. PLoS One 7:e50473. 
 
7. Chase, J. C., J. Celli, and C. M. Bosio. 2009. Direct and indirect impairment of 
human dendritic cell function by virulent Francisella tularensis Schu S4. Infect 
Immun 77:180-195. 
 
8. Chong, A., T. D. Wehrly, R. Child, B. Hansen, S. Hwang, H. W. Virgin, and 
J. Celli. 2012. Cytosolic clearance of replication-deficient mutants reveals 
Francisella tularensis interactions with the autophagic pathway. Autophagy 
8:1342-1356. 
 
9. Cremer, T. J., A. Amer, S. Tridandapani, and J. P. Butchar. 2009. Francisella 
tularensis regulates autophagy-related host cell signaling pathways. Autophagy 
5:125-128. 
 
10. Enstrom, M., K. Held, B. Ramage, M. Brittnacher, L. Gallagher, and C. 
Manoil. 2012. Genotype-phenotype associations in a nonmodel prokaryote. mBio 
3. 
 186 
 
 
11. Kingry, L. C., J. E. Cummings, K. W. Brookman, G. R. Bommineni, P. J. 
Tonge, and R. A. Slayden. 2013. The Francisella tularensis FabI enoyl-acyl 
carrier protein reductase gene is essential to bacterial viability and is expressed 
during infection. Journal of bacteriology 195:351-358. 
 
12. Lindgren, M., K. Eneslatt, J. E. Broms, and A. Sjostedt. 2013. Importance of 
PdpC, IglC, IglI, and IglG for modulation of a host cell death pathway induced by 
Francisella tularensis. Infect Immun 81:2076-2084. 
 
13. Long, M. E., S. R. Lindemann, J. A. Rasmussen, B. D. Jones, and L. A. Allen. 
2013. Disruption of Francisella tularensis Schu S4 iglI, iglJ, and pdpC genes 
results in attenuation for growth in human macrophages and in vivo virulence in 
mice and reveals a unique phenotype for pdpC. Infect Immun 81:850-861. 
 
14. Lovullo, E. D., C. N. Miller, M. S. Pavelka, Jr., and T. H. Kawula. 2012. 
TetR-based Gene Regulation Systems for Francisella tularensis. Applied and 
environmental microbiology. 
 
15. Ojeda, S. S., Z. J. Wang, C. A. Mares, T. A. Chang, Q. Li, E. G. Morris, P. A. 
Jerabek, and J. M. Teale. 2008. Rapid dissemination of Francisella tularensis 
and the effect of route of infection. BMC microbiology 8:215. 
 
16. Okan, N. A., S. Chalabaev, T. H. Kim, A. Fink, R. A. Ross, and D. L. Kasper. 
2013. Kdo hydrolase is required for Francisella tularensis virulence and evasion 
of TLR2-mediated innate immunity. mBio 4:e00638-00612. 
 
17. Ryden, P., S. Twine, H. Shen, G. Harris, W. Chen, A. Sjostedt, and W. 
Conlan. 2013. Correlates of protection following vaccination of mice with gene 
deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 
that elicit varying degrees of immunity to systemic and respiratory challenge with 
wild type bacteria. Mol Immunol 54:58-67. 
 
18. Sridhar, S., A. Sharma, H. Kongshaug, F. Nilsen, and I. Jonassen. 2012. 
Whole genome sequencing of the fish pathogen Francisella noatunensis subsp. 
orientalis Toba04 gives novel insights into Francisella evolution and 
pathogenecity. BMC Genomics 13:598. 
 
19. Starr, T., R. Child, T. D. Wehrly, B. Hansen, S. Hwang, C. Lopez-Otin, H. 
W. Virgin, and J. Celli. 2012. Selective subversion of autophagy complexes 
facilitates completion of the Brucella intracellular cycle. Cell host & microbe 
11:33-45. 
 
20. Wehrly, T. D., A. Chong, K. Virtaneva, D. E. Sturdevant, R. Child, J. A. 
Edwards, D. Brouwer, V. Nair, E. R. Fischer, L. Wicke, A. J. Curda, J. J. 
Kupko, 3rd, C. Martens, D. D. Crane, C. M. Bosio, S. F. Porcella, and J. 
Celli. 2009. Intracellular biology and virulence determinants of Francisella 
 187 
 
tularensis revealed by transcriptional profiling inside macrophages. Cell 
Microbiol 11:1128-1150. 
 
 
